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ABSTRACT
Overexpression of the plasminogen activation system has been found to play an
important role in the progression of a number of forms of cancer. Plasminogen is
activated to plasmin via the actions of the serine proteases urokinase plasminogen
activator (uPA) and tissue plasminogen activator (tPA).Whilst cell surface bound
plasminogen is protected from direct inhibition, uPA and tPA are inhibited by
plasminogen activator inhibitor type-1 (PAI-1) and type-2 (PAI-2). PAI-1 and PAI-2
belong to the serpin protein superfamily (SerpinE1 and SerpinB2, respectively)
which, despite significant variations in primary sequence fold into a well conserved
structure consisting of three β–sheets and nine α-helices. PAI-2 is unique among the
serpins in containing a 33-amino acid interhelical loop between α-helices C and D
(the CD-loop), which is commonly removed in recombinant PAI-2 production. Upon
inhibition of cell bound uPA (or tPA), plasminogen activator:inhibitor complexes are
endocytosed by members of the low-density lipoprotein receptor (LDLR) family.
Tumour overexpression of uPA and PAI-1 correlates with poor prognosis and
increased metastatic potential. Conversely, tumour expression of PAI-2 (in
combination with uPA) is associated with favourable outcome and relapse free
survival. Previous work has suggested that the distinct binding interactions of PAI-1
and PAI-2, due to the presence of a high-affinity LDLR binding motif in PAI-1 that is
absent in PAI-2, may underlie differential downstream cellular behaviours.
The aims of this thesis were to: (1) Determine the impact that removal of the CD-loop
of PAI-2 had on uPA inhibition and clearance and confirm that this PAI-2 form (PAI2 ∆CD-loop) could be utilised in the further aims of this study; (2) characterise the
molecular basis underlying the differential interactions of PAI-1 and PAI-2, both
individually and in complex with uPA, with receptors of the LDLR family; and (3)

XIV

examine the functional consequences resulting from the complementation of LDLR
binding in PAI-2, specifically the initiation of promitogenic signalling and cell
proliferation.
Removal of the CD-loop of PAI-2 was shown to have no impact on the inhibition of
both solution phase and cell surface uPA or on the rate of clearance of uPA from the
surface of MCF-7 cells. Additionally, uPA:PAI-2 ∆CD-loop had similar binding
kinetics (KD ~ 5 nM) for the very low-density lipoprotein receptor (VLDLR) to that
previous published for uPA:PAI-2 complexes. Furthermore, PAI-2 ∆CD-loop
expressed and purified in the system described here gave both higher yield and purity
than wild-type PAI-2 expressed and purified under identical conditions.
Introduction of the LDLR minimal binding motif present in the α-helix D of PAI-1 in
PAI-2 via site-directed mutagenesis enabled high affinity binding to VLDLR. The
binding of this mutant, PAI-2YK in complex with uPA was remarkably similar to that
of uPA:PAI-1 in both mechanism and affinity (heterogeneous analyte, KD values of
1.35 nM & 70.1 nM). Interestingly, mutation of an additional residue adjacent to the
LDLR binding motif was required for high affinity binding of PAI-2 to low-density
lipoprotein receptor related protein-1 (LRP1).
Complementation of the LDLR binding motif in PAI-2 had profound impacts on the
downstream functionality of PAI-2. Specifically, the LDLR-binding PAI-2 forms
enhanced uPA endocytosis on both VLDLR and LRP1 expressing cell lines,
demonstrating that LDLR affinity is the critical determinant in the rate of uPA
internalisation. Furthermore, treatment of MCF-7 cells with PAI-2 YK sustained ERK
activation, and increased proliferation in a manner indistinguishable from the effects
of PAI-1.
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The findings presented in this thesis clearly demonstrate that introduction of an
otherwise absent LDLR minimal binding motif in PAI-2 increases affinity of
uPA:PAI-2 complex for LDLRs to mimic that of uPA:PAI-1. This has a profound
impact on the downstream function of PAI-2 via sustained activation of cell signalling
pathways and subsequent proliferative effects. This has clear relevance to
understanding the paradoxical disease outcomes associated with overexpression of
these proteins in cancer.
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CHAPTER 1
LITERATURE REVIEW

1

1.1 INTRODUCTION TO CANCER
Cancer is a genetic disease caused by the sequential acquisition of chromosomal
mutations leading to uncontrolled cell growth and proliferation. In Australia alone,
cancer is responsible for approximately 40,000 deaths per annum (29% of total
deaths) (Australian Institute of Health and Welfare & Australasian Association of
Cancer Registries, 2010). Tumour progression is categorised by an interrelated set of
six key physiological events: evasion of apoptosis, self-sufficiency of growth signals,
insensitivity to anti-growth signals, limitless replicative potential, sustained
angiogenesis (the formation of blood vessels in the tumour) and tissue invasion and
metastasis (the formation of secondary tumours) (Bertram 2000; Hanahan and
Weinberg 2000; Bergers and Benjamin 2003). A tumour is only classified as
malignant upon acquisition of the final trait. The order in which these characteristics
develop varies between the over one hundred distinct types of cancer that have been
identified (Hanahan and Weinberg 2000). However, the ability of a cancer to invade
and metastasise is the primary determinant of cancer prognosis (Duffy et al. 1999;
Brabletz et al. 2005), with mestastases accounting for 90% of cancer deaths (Sporn
1996).

This review will focus on the roles of the plasminogen activation system in invasion
and metastasis with an emphasis on the inhibition of this system at the cell surface by
plasminogen activator inhibitors type-1 (PAI-1, SerpinE1) and type-2 (PAI-2,
SerpinB2). The non-proteolytic roles of PAI-1 and PAI-2 in the plasminogen
activation system will then be examined, in order to further the understanding on the
apparent contrasting roles of PAI-1 and PAI-2 in tumour progression. Finally, the
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current hypotheses and models believed to underlie this functional divergence will be
discussed.

1.1.1 INVASION AND METASTASIS
Metastasis is the spread of cancer from its primary site to sites elsewhere in the body
and occurs at some stage during the course of most forms of human cancer (Hanahan
and Weinberg 2000). For metastasis to occur successfully, malignant cells have to
detach from the biologically heterogeneous primary tumour (Fidler 2002), invade a
blood or lymphatic vessel, travel via circulation to a site distant from the primary
tumour and establish a new cellular colony (Rusoslahti 1996; Choong and
Nadesapillai 2003) (Figure 1.1). This colony may be within an organ or tissue,
requiring escape from the blood or lymphatic vessel and subsequent invasion
(Tryggvason et al. 1987; Mignatti and Rifkin 1993), or within the vessel itself (Fidler
2002). There is increasing evidence that tumour associated cells, such as fibroblasts
and immune cells, play an important role in invasion and metastasis, engaging in
cellular cross talk via exchanging of proteases and cytokines with cancer cells (Wever
and Mareel 2003; Kalluri and Zeisberg 2006; Mareel and Madani 2006; Steidl et al.
2010; Turner and Grose 2010). In order to develop into a secondary tumour, the
invading cell must recruit and co-operate with the right combination of stromal cells
in the new environment (Danø et al. 2005). There is also evidence that metastases are
partly controlled by messages in the microenvironment of the organs to which they
spread (Couzin 2003). Tumour invasion is facilitated by diminished expression of
cellular adhesion molecules (CAMs) and the breakdown of the underlying basement
membrane (BM) and extracellular matrix (ECM) (Liotta 1984; Andreasen et al. 1997).
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Figure 1.1: The metastatic process in cancer. Metastatic cancer cells are able to
colonise tissues distant to the primary tumour. (A) Mutagenesis leads to aberrant cell
proliferation resulting in formation of a tumour mass. (B) Invasive cells must break
away from the primary tumour, breakdown the extracellular matrix (ECM) and the
basement membrane in order to reach blood or lymph vessels. (C) These cells then
enter circulation in a process called intravasation. (D & E) Leaving circulation,
extravasation requires breakdown of the basement membrane and ECM at the
secondary site (F) for the formation of metastases. Adapted from Alberts et al. (2008).
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CAMs provide not only a physical anchor between cells and the surrounding stroma
(Rusoslahti 1996), but adjacent cells that are connected by E-cadherin bridges also
convey mutual anti-growth signals (Christofori and Semb 1999). Overcoming Ecadherin mediated cell adhesion has been demonstrated to be a rate-limiting step in
the conversion of a benign to an invasive phenotype in epithelial cancer (Christofori
and Semb 1999).

The ECM consists of collagens, glycoproteins (such as laminin, fibronectin, entactin
and nidogen), proteoglycans and glycosaminoglycans as a mesh surrounding
connective tissue (Mignatti and Rifkin 1993). The BM, which is comprised of layers
of ECM, separates epithelial or endothelial cells from underlying connective tissue
and blood vessels (Mignatti and Rifkin 1993). Penetration of the BM allows the entry
of metastatic cancer cells into the circulatory system (intravasation), with their
subsequent escape into tissues (extravastion) requiring BM degradation at the
secondary site. This degradation is accomplished by the concerted action of several
proteases, including the serine protease plasmin and a number of matrix
metalloproteases (MMPs). Plasmin is generated from the zymogen precursor
plasminogen via the actions of the plasminogen activation system. As such, this
system is important in the context of tumour progression and metastasis.

1.2 THE PLASMINOGEN ACTIVATION SYSTEM
1.2.1 GENERAL OVERVIEW
The plasminogen activation system (Figure 1.2) is a multi-component regulatory
system that, under normal conditions, functions in the clearance of blood clots and
matrix degradation during tissue remodeling processes. However, unregulated
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plasminogen activation is implicated in key events in malignant tumour progression,
specifically solid tumour growth, invasion and metastatic spread (Andreasen et al.
1997; Ranson et al. 1998; Scherrer et al. 1999; Schmitt et al. 2000; Choong and
Nadesapillai 2003; Ranson and Andronicos 2003; Duffy 2004; Danø et al. 2005;
McMahon and Kwaan 2008; Kwaan and McMahon 2009). Initiation of the
plasminogen activation system is facilitated by the serine proteases urokinase-type
plasminogen activator (uPA) and tissue-type plasminogen activator (tPA), resulting in
the conversion of the zymogen plasminogen to the active, serine protease plasmin
(Figure 1.2). Activation of plasminogen involves proteolytic cleavage of the peptide
bond Arg561 – Val562 (Violand and Castellino 1976; Ponting et al. 1992; Syrovets and
Simmet 2004). Plasmin is able to digest the majority of proteins present in the ECM –
laminin, fibronectin, fibrin, vitronectin, proteoglycans and collagen (Mignatti and
Rifkin 1993; Andreasen et al. 1997; Andreasen et al. 2000). Additionally, plasmin can
activate MMPs and other proteases that can also degrade ECM proteins (Castellino
and Ploplis 2005). Plasmin is also able to activate transforming growth factor-β (TGFβ) and trigger the release of fibroblast growth factor-2 (FGF2) (Rifkin 1997) which
have the potential to enhance tumour progression (Duffy 2004).

Generally, uPA is agreed to be the enzyme of most relevance to tumour biology
(Andreasen et al. 1997; Andreasen et al. 2000; Weigelt et al. 2005; McMahon and
Kwaan 2008) with the primary role of tPA in the generation of plasmin for
fibrinolysis in blood vessels (Andreasen et al. 2000; McMahon and Kwaan 2008).
However, tPA has been found to play an important role in some forms of cancer such
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Figure 1.2: The urokinase plasminogen activation system. The activation of
plasminogen to plasmin is catalysed by the urokinase-type plasminogen activator
(uPA) which is bound to the specific uPA receptor (uPAR). In turn, plasmin converts
the zymogen pro-uPA to the active form of the enzyme. Additional enzymes such as
cathespins can also activate pro-uPA. Plasmin mediates extracellular matrix (ECM)
degradation by both direct proteolysis and indirectly via the activation of matrix
metalloproteases (MMPs) and growth factor release. Whilst circulating plasmin can
be inactivated by a number of inhibitors, such as α2-antiplasmin (α2-AP), cell surface
plasmin is protected from inhibition. Plasminogen activator inhibitors (PAI) can
indirectly inhibit plasminogen activation by irreversibly inhibiting cell surface bound
uPA. Adapted from Croucher et al. (2008).
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as melanoma and neuroblastoma (Rijken and Collen 1981; Nielsen et al. 1982; Bizik
et al. 1990). As a matter of completeness, tPA will be discussed briefly before an indepth examination of the role of uPA in cancer.

1.2.2 tPA
tPA is a 562 amino acid serine protease secreted from numerous cell types. Unlike
uPA, the 72 kDa glycosylated single chain tPA (sc-tPA) form is active, with enhanced
catalytic activity in the two chain form. Sc-tPA is converted to two chain tPA (tc-tPA)
via cleavage of the Arg310 – Ile311 bond by plasmin, tissue kallikrein or factor Xa. The
basic structure of tPA is comprised of an N-terminal finger domain, an EGF-like
domain, two kringle domains and a serine protease domain. The primary biological
function of tPA, thrombosis and fibrinolysis, is mediated via the ability of tPA to bind
to fibrin with high affinity. Both the single and double chain forms of tPA display
enhanced enzymatic activity for plasminogen (~ 2 fold) when bound to fibrin
(Hoylaerts et al. 1982). Similar to this, binding of tPA to heparin also results in an
increase in plasminogen activation (Liang et al. 2000).

In addition to interacting with fibrin, tPA is also able to bind to monocyte,
macrophage, endothelial and human tumour cell lines via lysine dependent
interactions and activate cell-surface associated plasminogen (Ljungner et al. 1983;
Felez et al. 1991; Noorman et al. 1995; Lobov et al. 2008; Lee et al. 2010). tPA has
been demonstrated to interact with annexin II (p36), the annexin II heterotetramer
(AIIt) (comprised of two subunits of p36 and two of p11), the low-density lipoprotein
receptor-related protein-1 (LRP1), LRP-1B, the very low-density lipoprotein receptor
(VLDLR), laminin, cytokeratin-8 and the mannose receptor (Biessen et al. 1997;
8

Goldfinger et al. 2000; Gonias et al. 2001; Liu et al. 2001; Strickland et al. 2002; Ling
et al. 2004; Lee et al. 2010). Expression of annexin II and tPA in breast cancer cells
has been demonstrated to mediate cell motility and correlate to tumour
neovascularisation (Sharma et al. 2010). The role of tPA in cancer may lay primarily
in the effects mediated by tumour associated cells, with tPA activity upregulated in
breast cancer associated fibroblasts (Sadlonova et al. 2009) and in normal tissues
adjacent to gastrointestinal carcinomas (Scicolone et al. 2006). Additionally,
Borgfeldt et al. (2003) found that high levels of tPA in the plasma were associated
with shorter patient survival in ovarian cancer.

1.2.3 uPA AND uPAR
uPA is translated as a single chain 53 kDa precursor, pro-uPA (Duffy 2004) (Figure
1.3A). Plasmin-mediated cleavage of the Lys158 – Ile159 bond of pro-uPA generates
active two-chain uPA. The two chains are covalently linked via the disulfide bridge
Cys148-Cys279 (Duffy 2004). Receptor (uPAR, CD88) binding potentiates the
activation of pro-uPA and results in the initiation of a pro-enzyme activation feedback
loop, resulting in amplification of plasmin production (Behrendt 2004; Danø et al.
2005). Both pro-uPA and uPA are able to bind to uPAR, which is crucial for efficient
cell-associated plasminogen activation (Ellis et al. 1999; Ranson and Andronicos
2003; Stillfried et al. 2007). In addition to plasmin, pro-uPA can also be activated by
matriptase, hepsin, kallikreins and cathepsins (Kobayashi et al. 1991; List et al. 2000;
Kilpatrick et al. 2006; Moran et al. 2006) (Figure 1.2). The two chains of uPA consist
of 4 distinct regions: an epidermal growth factor domain (residues 1-49); a kringle
domain (50-131) and an interdomain linker region (132-158) in the A chain and the
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Figure 1.3: Structures of uPA and uPAR. The A-chain of uPA contains an
epidermal growth factor domain (yellow), a kringle domain (green) and an
interdomain linker region (blue). The protease domain (red) is present in the B chain.
Activation of pro-uPA to active two chain uPA (high molecular weight uPA, HMWuPA) occurs via cleavage if the Lys158-Ile159 bond. Low molecular weight uPA
(LMW-uPA) retains the proteolytic activity of uPA, but is unable to bind to uPAR.
(B) Ribbon structure of the serine protease domain (residues 159 – 404) of uPA
shown in detail. (C) The growth factor (residues 7 – 43) and kringle (residues 50 –
131) domains of uPA (grey) in complex with uPAR (domains are indicated).
Structures are coloured from N-termius (blue) to C-terminus (red). Constructed using
PDB coordinates 1GJ8 (Katz et al. 2001), 2FD6 (Huai et al. 2006) and the PyMOL
molecular graphics system (DeLano 2002).
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serine protease domain comprising the whole of the B-chain (159-411) (Figure 1.3A)
(Petersen et al. 2001). Low molecular weight uPA (LMW-uPA), which is Nterminally truncated at Lys136, retains the catalytic activity of native uPA but is unable
to

bind

to

uPAR

(Bansal

and

Roychoudhury

2006)

and

is

produced by autocatalytic conversion of active uPA. The high affinity binding (KD
~0.2 nM) (Lin et al. 2010) of (pro)uPA to uPAR consists of the growth factor domain
of uPA inserting into a deep binding cavity (~ 14 Å) in uPAR (Huai et al. 2006)
(Figure 1.3C). This binding is mediated by residues in the epidermal growth factor
domain of uPA (Lys23, Tyr24, Phe25 and Ile28) (Lin et al. 2010). The ligation of uPA to
uPAR results in the cleavage of the Arg83- Ala84 and Arg89-Ser90 bonds in the linker
region between domains 1 and 2 of uPAR and is thought to iniate major
conformational changes in uPAR which have a dramatic influence on the functionality
of this receptor (Blasi 1999; Rasch et al. 2008; Smith and Marshall 2010).

In general, uPAR is expressed at relatively low levels in normal tissues (Behrendt
2004), but is overexpressed by many cancer cell lines (Schmitt et al. 2000). uPAR is
also highly expressed on the surface of activated macrophages and various other
leukocytes. The low concentration of uPA in plasma and the fact that the majority of
circulating uPA is found bound to the inhibitor plasminogen activator inhibitor type-1
(PAI-1) suggests that autocrine and paracrine releases of uPA are mostly responsible
for plasminogen activation (Ranson and Andronicos 2003).

As discussed, initiation of uPA facilitated activation of plasminogen at the cell surface
requires binding of uPA to its receptor uPAR (Andreasen et al. 1997), with bound
uPA regulated by plasminogen activator inhibitors (Figure 1.2). Acceleration of the
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activation of plasmin is believed to occur via the co-localisation of plasminogen
receptors and uPAR at the cell surface (Mignatti and Rifkin 1993; Félez 1998; Ranson
and Andronicos 2003; Behrendt 2004) (Figure 1.2). Additionally, as mentioned
previously, receptor bound plasmin/ogen is protected from inhibition by circulating
plasmin inactivators (Hall et al. 1991).

Inappropriate activation of the plasminogen activation system in cancer, and hence
increased metastatic potential, occurs via upregulated expression of components of the
urokinase plasminogen activation system on the cell surface (Andreasen et al. 1997;
Duffy et al. 1999; Schmitt et al. 2000). As such, uPA/uPAR overexpression is a
feature of a number of cancers including acute leukemias, breast, gastric, colorectal,
esophageal, renal, lung, brain, urinary tract, endometrial, thyroid and ovarian cancers
(Duffy et al. 1999; Scherrer et al. 1999; Schmitt et al. 2000; Tecimer et al. 2001; Look
et al. 2002; Weigelt et al. 2005; Ulisse et al. 2006; Mengele et al. 2010) and has also
been linked to poor patient outcome (Knoop et al. 1998; Foekens et al. 2000; Choong
and Nadesapillai 2003; Duffy 2004; Ohba et al. 2005; Schmitt et al. 2010).

uPAR plays a critical role in pericellular proteolysis but has also been identified as
possessing a number of other important physiological roles: cell adhesion and
motility; growth promoting activity; mitogenic activity in normal and tumour cells;
chemotactic activity as demonstrated in neutrophils, endothelial cells and
keratinocytes; signal transduction; ligand internalisation and functional interplay with
integrins (Ehart et al. 1998; May et al. 1998; Mazar 2008; Blasi and Sidenius 2010).
uPAR is also able to compete with integrins for vitronectin present in the ECM
(Behrendt and Stephens 1998), impacting on cell adhesion and motility (Kjoller
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2002). It has been determined that vitronectin binding at the leading edge of the cell
promotes cell migration, whilst binding at the trailing edge of the cell inhibits
migration (Andreasen et al. 1997; Behrendt and Stephens 1998). Many studies using
different cell lines have shown that uPA and uPAR are overexpressed at the leading
cell edge of malignant cancer cells (Estreicher et al. 1990; Mazzieri and Blasi 2005;
Raghu et al. 2010). Thus, the uPA system plays a key role in tumour progression and
metastasis through involvement in cellular adhesion and chemotaxis/migration (i.e.,
through non-proteolytic functions) in addition to proteolytic degradation (Ranson and
Andronicos 2003; Blasi and Sidenius 2010).

1.2.4 INHIBITORS
Due to the far-reaching and potentially damaging effects of plasmin, regulation of the
plasminogen activation system is crucial for normal non-invasive cell function. The
inhibition of inappropriate extracellular proteolysis is recognised as a valid treatment
for cancer. Physiological regulation of the plasminogen activation system may be
facilitated by either direct inhibitors of plasminogen/plasmin (α2-antiplasmin and α2macroglobulin) or specific plasminogen activator inhibitors [PAI-1, plasminogen
activator inhibitor type-2 (PAI-2), protein C inhibitor and protease nexin-1] (Behrendt
2004).

Both PAI-1 and PAI-2 efficiently inhibit uPA in solution and at the cell surface
(Astedt et al. 1987; Ellis et al. 1990; Al-Ejeh et al. 2004) through the formation of
covalent, irreversible enzyme:substrate complexes. As the focus of this review is the
biological role of PAI-2 relative to that of PAI-1, the functional aspects of α2antiplasmin, α2-macroglobulin, protease nexin-1 and protein C inhibitor will not be
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discussed further. For reviews on these inhibitors the reader is referred to Kruithof
(1988), Geiger et al. (1996), Stassen et al. (2004) and Arnout et al. (2006),
respectively.

1.3 PLASMINOGEN ACTIVATOR INHIBITORS
1.3.1 OVERVIEW OF SERPINS
PAI-1 and PAI-2 belong to a superfamily of proteins known as the serpins (serine
protease inhibitors) (Silverman et al. 2001). The majority of serpins serve as
regulators of serine or cystine protease activity in such diverse roles as complement
activation, inflammation, coagulation, fibrinolysis, carcinogenesis, angiogenesis and
apoptosis (Irving et al. 2000). The physiological importance of serpins is highlighted
by their presence in all major forms of life (Bacteria, Archaea, Eukarya and Viridae)
(Irving et al. 2000; Roberts et al. 2004). Members of the serpin superfamily are
organised into sixteen clades, designated A through P based on their structure,
sequence and function (Silverman et al. 2001). Despite considerable variations in
primary peptide sequence (Huber and Carrel 1989), members of the serpin family
generally fold into a well-conserved tertiary structure consisting of 3 β-sheets, 8-9 αhelices and a reactive centre loop (RCL). Most serpins contain 350-500 amino acids
(Silverman and Lomas 2004), with variations due to amino- or carboxyl- terminal
extensions or by glycosylation in the case of extracellular serpins (Potempa et al.
1994).

Whilst a number of the characterised serpins have no known inhibitory function, the
remainder, including both PAI-1 and PAI-2, display an inhibitory activity that
Silverman and Lomas (2004) described as ‘a unique, irreversible suicide substrate-like
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mechanism of inhibition’, occurring via a branched pathway (Silverman et al. 2001).
The serpin inhibitory mechanism is facilitated by the ability of serpins to undergo
structural rearrangements. These differing conformations are largely dependent on the
positioning of the RCL. In the active ‘native/stressed’ conformation (Figure 1.4A) the
RCL is exposed and intact. Cleavage of the RCL at the active site (denoted P1-P1’)
and insertion into β-sheet A, forming a fully anti-parallel β-sheet, yields the cleaved
‘relaxed’ conformation (Figure 1.4B). The transition from the ‘stressed’ to ‘relaxed’
state represents a lowering in the thermodynamic state of the serpin molecule. The
latent conformation (Figure 1.4C), which is inactive, is formed by the partial insertion
of the RCL into β-sheet A without the cleavage of the P1-P1’ bond. The initial step of
inhibition involves the reversible formation of a noncovalent Michaelis-like enzymesubstrate complex (Figure 1.5B) through interactions with residues flanking the P1P1’ bond (Silverman et al. 2001). The target protease attacks the P1-P1’ bond,
triggering covalent bonding between the target protease and the backbone carbonyl of
the P1 residue and cleavage of the P1-P1’ peptide bond to form an acyl-enzyme
intermediate (Petersen et al. 2001). From this point, the complex can proceed via the
non-inhibitory pathway, resulting in release of active protease and an RCL-cleaved
serpin (Gettins 2002) (Figure 1.5D), or the inhibitory pathway (Figure 1.5C),
depending on serpin identity (Stratikos and Gettins 1999). In the inhibitory pathway,
the RCL fully inserts into β-sheet A, translocating the P1 covalently linked protease a
distance of more than 70 Ǻ (Fa et al. 2000) to the opposite end of the serpin. The
protease is thereby inactivated by deformation against the base of the serpin
(Huntington et al. 2000).
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Figure 1.4: General conformations of serpins. Serpins exist in three main ‘normal’
states. The native ‘stressed’ conformation (A) is required for inhibitory activity.
Cleavage of the P1-P1’ bond within the RCL and full insertion of the reactive centre
loop (RCL) into β-sheet A yields the cleaved ‘relaxed’ conformation (B), the most
thermodynamically stable state for inhibitory serpins. In the ‘latent’ confirmation (C),
the RCL inserts into β-sheet A without P1-P1’ cleavage. Adapted from Gettins
(2002).
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Figure 1.5: The inhibitory mechanism of serpins. The ability to undergo major conformational changes is central to the inhibitory
mechanism of serpins. The native conformation (A) is required for inhibitory activity. The first step in the inhibitory mechanism is the
reversible formation of the noncovalent Michaelis-like complex (B). From this point the reaction can traverse either the inhibitory or noninhibitory pathway. The inhibitory pathway results in the formation of a covalent complex (C) with the active site of the protease
inactivated via distortion against the base of the serpin. The non-inhibitory pathway results in cleavage of the serpin and release of the
active protease (D). Adapted Law et al. (2006).
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1.3.2 PLASMINOGEN ACTIVATOR INHIBITOR TYPE 2 (PAI-2, SERPINB2)
PAI-2 is a 415 amino acid clade B serpin that is present in two forms in the human
body, an extracellular 60 kDa glycosylated form and a non-glycosylated 47 kDa form
found both intra- and extracellularly (Genton et al. 1987; Wohlwend et al. 1987). PAI2 is an efficient inhibitor of both uPA (second order rate constant = 2.1 × 106 M-1s-1)
and tc-tPA (second order rate constant = 5.3 × 105 M-1s-1), but does not efficiently
inhibit sc-tPA (second order rate constant = 4.6 × 103 M-1s-1) (Thorsen et al. 1988).
Whilst PAI-2 levels in plasma are normally too low to be detected, in certain
conditions, such as pregnancy and some myelomonocytic leukemias, PAI-2 is
consistently detected in plasma (Kawano et al. 1970; Astedt et al. 1987; von Heijne et
al. 1991; Brenner 2004). The main physiological producers of PAI-2 are activated
monocytes and macrophages (Wohlwend et al. 1987; Hamilton et al. 1993; Ritchie et
al. 1997), however additional cell types including eosinophils (Swartz et al. 2004),
keratinocytes (Robinson et al. 1997), microglia (Akiyama et al. 1993), endothelial and
epithelial cells (Kruithof et al. 1995) have also been demonstrated to produce PAI-2 in
vivo.

The identification of PAI-2 as a clade B serpin was due to its significant amino acid
homology with chicken ovalbumin (SerpinB14), the presence of an internal secretion
signal, shorter N- and C- termini than a prototypical serpin and a penultimate serine
residue (Kruithof et al. 1995). Whilst most clade B serpins have only an intracellular
distribution, this is not the case for PAI-2. However, the majority of expressed PAI-2
is not secreted (Dickinson et al. 1995) due to two mildly hydrophobic internal regions
that serve as an inefficient internal signal sequence (Belin et al. 1989; von Heijne et
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al. 1991). The secretion efficiency of PAI-2 can be significantly increased by fusing
the signal sequence of PAI-1 to the N-terminus of the PAI-2 encoding gene (Mikus et
al. 1993; Mikus and Ny 1996).

The tertiary structure of PAI-2 is that of a typical serpin, with 9 α-helices (A-I) and 3
β-sheets (A-C) (Figure 1.6). PAI-2 does not readily convert into the latent serpin
conformation. The gene encoding PAI-2 possesses an exon encoding a polypeptide
loop (the CD-loop) between the α-helices C and D. At 33 amino acids, the CD-loop
of PAI-2 is the longest among known serpins (Remold-O'Donnell 1993; Scott et al.
1999). The CD-loop is involved in transglutaminase mediated cross-linking to cellular
and ECM proteins (Jensen et al. 1996). The CD-loop regulates the ability of PAI-2 to
polymerise (Wilczynska et al. 2003), with PAI-2 the only known serpin to polymerise
spontaneously and reversibly under physiological conditions, via the formation of a
disulfide bond between Cys79 of the CD-loop and Cys161 at the bottom of helix F
(Mikus et al. 1993; Mikus and Ny 1996). Whilst mutations in other serpins, such as
α1-antitrypsin and neuroserpin result in protein polymerisation and are characteristic
of conformational diseases (Gooptu and Lomas 2009), no known pathology is
associated with PAI-2 polymerisation. The tertiary structure of PAI-2 has only been
resolved for a mutant lacking the CD-loop (Harrop et al. 1999) (Figure 1.6) and as
such, the precise conformation of the CD-loop is unknown. Using intramolecular
measurements, Lobov et al. (2004) triangulated the CD-loop to the side of the
molecule in monomeric PAI-2. In the polymerogenic form, the CD-loop folds under
the bottom of the molecule to facilitate formation of the Cys79-Cys161 disulfide bond
(Lobov et al. 2004).
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Figure 1.6: Structure of plasminogen activator inhibitor type-2. As a member of
the serpin family of proteins (clade B), PAI-2 contains 9 α-helices, 3 β-sheets and a
reactive centre loop (RCL). PAI-2 also possesses a CD-loop – a polypeptide chain
between α-helices C and D (putative position shown as a dotted line). The
conformation of the CD-loop has yet to be resolved and the structure shown is a CDloop and RCL deleted mutant. Structure is coloured from N-terminus (blue) to Cterminus (red). Constructed using PDB coordinates 1BY7 (Harrop et al. 1999) and the
PyMOL molecular graphics system (DeLano 2002).
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1.3.2.1 Expression of PAI-2
PAI-2 expression is acutely up-regulated in pregnancy, inflammation, infection and
other pathophysiological conditions. Isolation and characterisation of the PAI-2
promoter region has identified mechanisms by which transcription of PAI-2 mRNA
and/or protein levels can be up-regulated by a wide range of activating molecules
(Table 1.1). The PAI-2 promoter region contains a putative MAZ (Myc-associated
zinc finger protein) binding site (Almeida-Vega et al. 2009), an ASC-1 (activating
signal cointegrator-1) site (Almeida-Vega et al. 2009), two AP1-like binding sites
(Cousin et al. 1991), an AP2-like binding site (Cousin et al. 1991), CRE-like element
(Cousin et al. 1991; Park et al. 2005) and a NF-κB binding site (Mahony et al. 1999;
Park et al. 2005). Response elements to glucocorticoids (Schuster et al. 1993;
Schuster et al. 1994), retinoic acid (Schuster et al. 1993; Schuster et al. 1994) and
xenobiotics (Sutter et al. 1991) have also been localised to the 5’ promoter region of
PAI-2. In addition to the promoters described above, the PAI-2 gene contains at least
two repressor regions in the 5’ region of the PAI-2 gene (positions,1859-1100 and
259-219) (Antalis et al. 1996). The latter site also contains a binding site for an as yet
unidentified nuclear protein (Dear et al. 1996). A repressor motif termed PAUSE-1
(PAI-2 upstream silencer element-1, sequence: 5’-CTCTCTAGAGAG-3’) (Antalis et
al. 1996) is located at position -1832 and binds a specific, ~ 67 kDa binding factor
(Ogbourne and Antalis 2001). This region overlaps with the repressor described by
Dear et al. (1996), suggesting that these studies described the same repressor.

Full length PAI-2 mRNA is unstable, with a half-life of approximately one hour
(Maurer et al. 1999). The best characterised mRNA degradation components are AU-
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Table 1.1: The expression of PAI-2 mRNA and/or protein can be regulated by a
range of biological agents in a diverse set of cell types.
Agent
Pro-inflammatory
Cytokines
TNF-α

Expression
mRNA Protein

Cell Type

Cell Line

Ref.

↑

↑

Fibroblast

HT-1080

(Medcalf et al. 1988)

↑

ND

Fibroblast

HT1080

(Tierney and Medcalf 2001)

↑

↑

Fibroblast

PC

Melanocyte

SK-MEL-109

↑

ND

Myeloid

U-937, PC

(Gyetko et al. 1992)

↑

↑

Vascular SM

PC

(Jang et al. 2004)

↑

↑

Keratinocyte

PC

(Wang and Jensen 1998)

↑

↑

Monocyte

U-937, PC

(Gyetko et al. 1992)

ND

↑

ND

↑

↑

ND

↑

↑

IL-2

↑

ND

IL-13

↑

ND

G-CSF

↑

↑

Monocyte

PC

(Hamilton et al. 1993)

M-CSF

↑

↑

Monocyte

PC

(Hamilton et al. 1993)

Gastrin

↑

ND

AGS

(Varro et al. 2002)

Epidermal Growth
Factor (EGF)

↑

↑

Interferon-γ

IL-1β

Fibroblast RT4, RT112, DAG-1,
(Bladder)

T24, J82S, TCCsup

Fibroblast

PC

(BM)
Monocyte

PC

Fibroblast

PC

(Synovial)
Monocyte

PC

Epithelial

PC

(Bronchial)

(Pytel et al. 1990)

(Champelovier et al. 2003)

(Hannocks et al. 1992)
(Gyetko et al. 1993)
(Hamilton et al. 1993)
(Gyetko et al. 1993)
(Woodruff et al. 2007)

Steriods/Hormones

↑

ND

Epithelial
(Gastric)
Epithelial

A-431

(Epidermal)

(George et al. 1990)

Cumulus

PC

Granulosa-

PC

(Piquette et al. 1993)

luteal
Glucocorticoids

Pathogenic Stimuli
LPS

↓

↓

Fibroblast

HT-1080

(Medcalf et al. 1988)

↓

ND

Epithelial
(Bronchial)

PC

(Woodruff et al. 2007)

↑

↑

Monocyte

PC

(Schwartz and Bradshaw 1992)

↑

ND

Macrophage

RAW-267, PC

(Costelloe et al. 1999)

↑

ND

Monocyte

PC

(Suzuki et al. 2000)

↑

↑

Fibroblast

PC

(Xiao and Bartold 2004)
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Signalling mediators
cAMP

↑

ND

Calcium

↑

↑

↑

Myeloid

PL-21

Keratinocytes

PC, HaCaT

ND

Neurons

PC

(Zhang et al. 2009)

↑

ND

Keratinocyte

SCC-12F

(Sutter et al. 1991)

↑

ND

M13SV1

(Ahn et al. 2005)

Kainate

↑

ND

Neuronal

Whole tissue

(Sharon et al. 2002)

Okadaic acids

↑

ND

Fibroblast

HT-1080

Myeloid

U-937

Myeloid

U-937

(Dear and Medcalf 2000)

Macrophage

RAW-267, PC

(Costelloe et al. 1999)

U-937, THP-1, HL60,

(Genton et al. 1987; Schleuning

Toxins
Dioxin

Oxamflatin

↑

↑

Tumour promoting
agents
PMA

↑

ND

↑

↑

↑

ND

ND

↑

Factor VIIa

↑

ND

Thrombin

↑

↑

Other
Lipoprotein-a

↑

Retinoic acid

Vasculature
effectors and
regulators
Angiotensin II
D-Dimer

VLDL and LDL

Epithelial
(Breast)

Myeloid

(Niiya et al. 1994)
(Wang and Jensen 1998; Seo et
al. 2002)

(Medcalf 1992)

K-562 et al. 1987; Schuster et al. 1993)

Aortic SM

PC

(Feener et al. 1995)

Myeloid

NOMO-1

(Hamaguchi et al. 1991)

Keratinocytes

HaCaT

(Camerer et al. 2000)

Monocyte/

U-937, primary (Lundgren et al. 1994; Ritchie et

Macrophage

cultures

al. 1995)

↑

Monocyte

PC

(Buechler et al. 2001)

↑

↑

Myeloid

↑

ND

↑
ND

U-937, THP-1, HL60,
K562

(Schuster et al. 1993)

Keratinocytes

PC

(Braungart et al. 2001)

↑

Monocyte

PC

(Montemurro et al. 1999)

↑

Monocyte

PC

(Wada et al. 1994)

ND: Not Determined
PC: Primary Culture
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rich regions in the 3’ region of mRNAs. The 3’-untranslated region of PAI-2 mRNA
contains an AU-rich region which plays an important role in the degradation of PAI-2
mRNA (Maurer and Medcalf 1996). Disruption of the nonameric motif 5’UUAUUUAUU-3’ via mutagenesis led to an increase in PAI-2 mRNA and protein
expression levels (Maurer et al. 1999). Additionally, this motif is a binding site for
HuR, which has been associated with mRNA decay (Maurer et al. 1999).
Tristetraprolin, a CCCH tandem zinc finger protein that binds to ARE-containing
transcripts, also interacts with the AU-rich region of the 3’-UTR and mediates PAI-2
mRNA degradation (Yu et al. 2003). Exon 4 of PAI-2 also contains an mRNA
instability region, sharing homology with instability determinants of other mRNAs
(Tierney and Medcalf 2001).

1.3.2.2 Polymorphisms
Whilst SERPINB2-/- mice have been successfully generated and described (Dougherty
et al. 1999), no naturally occurring PAI-2 deficient humans have been reported.
Additionally, PAI-2 has not, as yet, been linked to any ‘serpinopathies’, that is,
diseases directly related to or caused by aberrant PAI-2 function. However, PAI-2
expression by trophoblasts during the very early stages of pregnancy (Astedt et al.
1998) suggests that mutations within the PAI-2 gene resulting in protein dysfunction
could be embryonic lethal in humans. Successful development of the SERPINB2-/mouse model can be explained by inter-species variability, whereby PAI-2 expression
is not detectable in littermates until late stage gestation (Ong et al. 2000) and therefore
does not appear to play a role in early murine fetal development or placental
homeostasis. Differences in PAI-2 expression between humans and mice during
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pregnancy indicate the unsuitability of this mouse model for human fetal development
studies.

Whilst no mutation within the PAI-2 gene resulting in dysfunction at the protein level
has been described, there are numerous studies showing correlation between disease
states and polymorphisms of the PAI-2 gene. Two isoforms of PAI-2 have been
described, with variations in three amino acids (Antalis et al. 1988; van den Berg et al.
1990). These variations occur at positions 120, 404 and 413 with Asn, Asn and Ser in
isoform A and Asp, Lys and Cys in isoform B. Each of these changes is the result of a
single base change in each codon (120, Aat/Gat; 404, aaC/aaG; 413, tCc/tGc),
however it appears that all three mutations are linked (ie. they are a haplotype) and do
not exist in isolation. Whilst the functional consequences of these residue changes are
unknown, a number of studies have associated PAI-2 genotype and disease. Form A
has been associated with lupus erythematosus and thrombic pneumonia in patients
with this condition (Palafox-Sanchez et al. 2009), anti-phospholipid syndrome
(Vazquez-Del Mercado et al. 2007) and mycocardial infarction (Buyru et al. 2003;
McCarthy et al. 2004), although Foy and Grant (1997) found no evidence of the link
between PAI-2 variants and mycocardial infarction. These disease states all relate to
disorders in haemostasis, highlighting a role for PAI-2 in this system. In addition,
Shioji et al. (2005) showed an association between the A form and prostate cancer.
PAI-2 B is linked to preterm birth in subjects later diagnosed with cerebral palsy
(Gibson et al. 2007) and poor overall survival in patients with non-small cell lung
cancer (Di Bernardo et al. 2009). Recently, Byrol et al. (2010) found that isoform B is
associated with dose-dependent proteasome inhibitor drug related peripheral
neuropathy in multiple myeloma patients.
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1.3.2.3 Intracellular roles
The distribution of PAI-2 within the nucleus, cytoplasm was well as the extracellular
environment suggests accessory functions independent of plasminogen activator
inhibitor activity as neither tPA or uPA are found in the intracellular environment and
no binding partner for intracellular PAI-2 as an inhibitory serpin has yet to be
identified. Intracellular PAI-2 has been associated with a variety of potential roles
such as signal transduction (Antalis et al. 1998), inhibition of apoptosis (Dickinson et
al. 1995), monocyte proliferation and differentiation (Yu et al. 2002). Zhou et al.
(2001) found that over expression of PAI-2 in keratinocytes resulted in sustained
cutaneous papilloma lesions compared to controls within a mouse model potentially
due to protection from apoptosis. Earlier studies reported that HT1080 fibrosarcoma
and HeLa epithelial cell lines transfected with PAI-2 were protected from TNF-α
induced apoptosis (Dickinson et al. 1995) with this function dependant on the CDloop (Dickinson et al. 1998). Additionally, PAI-2 was also reported to protect primary
culture human macrophages from Mycobacterium avium infection (Gan et al. 1995).
More recently, the hypothesis that PAI-2 protects against apoptosis by these
mechanisms has been questioned. Recently, Fish and Kruithof (2006) conducted a
thorough investigation of PAI-2 in the prevention of TNF-α induced apoptosis using
HeLa, Isreco-1 and HT1080 cell lines. Unlike earlier works, this study used a lentiviral transfection system which did not require clonal selection and subsequently
found that PAI-2 had no effect on apoptosis, concluding that previous transfection
methodology had most likely resulted in a clonal bias effect.

The tumour suppressor retinoblastoma protein (Rb) was previously identified as a
binding partner for PAI-2 (Darnell et al. 2003), stabilising Rb and thereby inhibiting
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apoptosis. Subsequent experiments reported suppression of human papilloma virus
(HPV) type-18 oncogenes (E6/E7) by PAI-2 through the stabilisation of Rb (Darnell
et al. 2005). However, Fish and Kruithof (2006) were unable to detect any difference
in Rb levels when comparing IS-1 and HT1080 cell lines transfected with PAI-2.
Furthermore, Schroder et al. (2010) were unable to find a correlation between PAI-2
and Rb expression when comparing the SERPINB2-/- mouse model to littermates and
Major et al. (2011) showed that PAI-2 did not bind to or regulate the expression of
Rb. As the studies describing the PAI-2 Rb interaction (Darnell et al. 2003; Darnell et
al. 2005) used the same HeLa cell lines stably transfected with PAI-2 as those used in
the early apoptosis studies (Dickinson et al. 1995), it appears likely that the reported
stabilisation of Rb by PAI-2 is also a product of clonal bias. The role of intracellular
PAI-2 thus remains poorly defined.

1.3.2.4 Extracellular roles
Secreted or released PAI-2 (the previously described 60 kDa or 47 kDa forms,
respectively) have been detected in various biological fluids including pregnancy
plasma, amniotic fluids and umbilical cord blood (Astedt et al. 1985; Lecander and
Astedt 1987; Booth et al. 1988; Astedt et al. 1998), gingival fluid (Kinnby 2002),
saliva (Virtanen et al. 2006), peritoneal fluid (Scott-Coombes et al. 1995), infectious
pleural effusions (Aleman et al. 2003), as well as in human tears (Csutak et al. 2008).
PAI-2 has also been detected in the plasma of patients with monocytic leukaemia (up
to 160 ng.mL-1) (Scherrer et al. 1991), severe sepsis (Robbie et al. 2000), in ascites
fluid and tumour vessel blood from patients with advanced ovarian cancer (up to 108
ng.mL-1) (Lecander et al. 1990), and in the plasma of hypergastrinemic patients
(Varro et al. 2002).

27

Extracellular PAI-2 may regulate plasminogen activation through inhibition of uPA
(and tPA) via the inhibitory serpin pathway. Al-Ejeh et al. (2004) found that cellsurface uPA:PAI-2 complex formation on breast and prostate cancer cells at 37ºC was
both efficient and rapid (inactivation rate constant [ki] of 0.32 – 0.47 min-1 and
inhibition constant [KI] of < 81 pM). The ability of PAI-2 to inhibit two chain is tPA
dependant on the type of tPA binding interaction to either cell surfaces or proteins.
For example, PAI-2 has been demonstrated to inhibit two chain tPA bound to various
cell types in vitro (Lee et al. 2010), tPA bound to purified annexin II heterotetramer
(Lobov et al. 2008) and poly-D-lysine-bound-tPA (Leung et al. 1987). However, as is
the case for PA1-1, fibrin-bound tPA is protected from inhibition by PAI-2 (Leung et
al. 1987).

Direct evidence of PA:PAI-2 complexes as indicative of protease inhibition in vivo is
lacking, though PAI-2 in the plasma is able to form inhibitory complexes with added
PAs. Kiso et al. (1991) identified placental derived PAI-2 cleaved at the P1-P1’
position, indicating that it had reacted with a target protease. Additionally, PAI-2 and
uPA have been shown to co-localize within syncytiotrophoblasts of the placenta
(Nakashima et al. 1996). Furthermore, PAI-2 and tPA exist as high molecular weight
SDS-stable complexes in the gingival crevicular fluid, suggesting inhibitory complex
formation (Brown et al. 1995). Using a monoclonal antibody (2H5), that specifically
recognises the ‘relaxed’ conformation of PAI-2 (as adopted in a protease:serpin
inhibitory complex (Saunders et al. 1998)), the presence of relaxed PAI-2 in gingival
epithelium has been shown (Lindberg et al. 2001), again suggesting inhibition of
plasminogen activators.
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1.3.3 PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1, SERPINE1)
PAI-1, the primary regulator of tPA and potentially uPA activity in human blood
(Agirbasli 2005; Dellas and Loskutoff 2005), is a 379 amino acid clade E serpin
secreted as a 60 kDa protein by platelets, monocytes, macrophages, endothelial cells
and smooth muscle cells (Gettins 2002; De Taeye et al. 2004). PAI-1 effectively
inhibits both uPA and tPA with second order rate constants of 2.5 × 107 M-1s-1 and 1 ×
107 M-1s-1, respectively (Thorsen et al. 1988). PAI-1 also inhibits pro-uPA, but with a
> 1000 fold reduction in the rate of inhibition compared to uPA (De Taeye et al.
2004). Unlike PAI-2, PAI-1 is able to efficiently inhibit sc-tPA (second order rate
constant = 5.5 × 106 M-1s-1) (Thorsen et al. 1988). The structure of PAI-1 conforms to
that of the general serpin architecture (Figure 1.7) and is remarkably similar to that of
PAI-2 despite significant variation (24.2% sequence homology) in peptide sequence
(Huber and Carrel 1989). The relationships between the structural domains of PAI-1
and functionality are well understood due to extensive characterisation (De Taeye et
al. 2004). Under physiological conditions, PAI-1 is relatively unstable and rapidly
converts to a latent form incapable of interacting with uPA (Lindahl et al. 1989;
Andreasen et al. 2000; Stout et al. 2000). However, the half-life of active PAI-1,
which is normally 1-2 hours, can be extended two to four-fold via binding to
vitronectin (Keijer et al. 1991; Padmanabhan and Sane 1995). This binding has been
shown, via site directed mutagenesis, to be dependent on residues Arg101 and Met110,
Leu116 and Gln123, which reside in α-helix E and strand 1 of β-sheet A of PAI-1
(Lawrence et al. 1994; Arroyo De Prada et al. 2002; Jensen et al. 2002; Einholm et al.
2003; Jensen et al. 2004). As vitronectin is an ECM component, PAI-1 thus can
modulate cellular adhesion and migration (Dellas and Loskutoff 2005).
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RCL

Figure 1.7: Structure of plasminogen activator inhibitor type-1. PAI-1 conforms
to the general structure of a serpin with 9 α-helices, 3 β-sheets and a reactive centre
loop (RCL). The structure shown is lacking the RCL and represents the cleaved form
of PAI-1. Structure is coloured from N-terminus (blue) to C-terminus (red).
Constructed using PDB coordinates 1A7C (Xue et al. 1998) and the PyMOL
molecular graphics system (DeLano 2002).
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As the primary physiological inhibitor of plasminogen activation (Agirbasli 2005;
Dellas and Loskutoff 2005), PAI-1 is an important regulator of the fibrinolytic
system, which serves to prevent intravascular thrombosis and is thought to participate
in the regulation of such processes as ovulation, embryogenesis and wound repair
(Duffy 2004). Whilst PAI-1 inhibits plasminogen activation at the cell surface, via
inactivation and clearance of uPA and tPA, it has also been found to play a critical
role in cancer development, being associated with tumor growth, invasion, metastasis
and angiogenesis (Webb et al. 2001; Degryse et al. 2004). The use of PAI-1 (along
with co-expression of uPA) has been suggested as a prognostic marker in cancer
diagnosis (Harris et al. 2007), with (somewhat paradoxically) high PAI-1 levels
associated with increased malignancy in gynaecological cancers, gliomas, sarcomas,
renal cell carcinoma and cancers of the breast, bladder and gastrointestinal tract
(Foekens et al. 2000; Stefansson et al. 2003; Bajou et al. 2004; Czekay and Loskutoff
2004; Degryse et al. 2004). This may be due to the effects of PAI-1 on proliferation
and migration which occur through involvement in non-proteolytic roles, the specifics
of which will be discussed in Section 1.4. It has been suggested that the cancer related
actions of PAI-1 appear to be dose-dependent, with physiological concentrations of
PAI-1 promoting tumour invasion and metastasis whilst supraphysiological levels of
PAI-1 inhibit tumour vascularisation (Bajou et al. 2004).

1.3.4 PROGNOSTIC VALUES OF PAI-1 AND PAI-2 IN CANCER
Whilst the inhibition of cell surface uPA activity by PAI-1 and PAI-2 in vitro serves
to decreases plasminogen activity, tumour overexpression of uPA, uPAR and PAI-1 is
associated with poor patient prognosis (Foekens et al. 2000; Choong and Nadesapillai
2003; Duffy 2004; Ohba et al. 2005) and increased metastatic potential (Duffy et al.
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1999; Scherrer et al. 1999; Schmitt et al. 2000; Look et al. 2002; Weigelt et al. 2005).
The significance of this relationship in expression and disease outcomes is further
highlighted by the recommendation of uPA/PAI-1 expression as a tumour marker in
breast cancer by the American Society of Clinical Oncology (Harris et al. 2007). In
contrast, high levels of PAI-2 expression in breast carcinomas is correlated with
increased, relapse-free survival (Sumiyoshi et al. 1992; Bouchet et al. 1994; Foekens
et al. 1995; Ishikawa et al. 1996; Duggan et al. 1997; Umeda et al. 1997; Bouchet et
al. 1999; Foekens et al. 2000; Borstnar et al. 2002; Borstnar et al. 2002; Spyratos et al.
2002; Duffy and Duggan 2004; Meijer-van Gelder et al. 2004), whilst low expression
has the opposite effect. Whilst relatively few studies have assessed the prognostic
value of PAI-2 expression in other cancer forms, there is a general trend between
PAI-2 expression and neutral or positive outcomes (Croucher et al. 2008).

Whilst definitive identification of uPA:PAI-2 complexes within tumour masses is
absent, the relationship between positive patient prognosis and high PAI-2 levels in
node negative breast cancer is only statistically relevant if uPA levels are also
elevated (Bouchet et al. 1999; Foekens et al. 2000). This suggests that the inhibitory
relationship between uPA and PAI-2 in the tumour microenvironment mediates this
functionality. Previous studies have hypothesised that PAI-2 may be the bona fide
uPA inhibitor in this context (Nakamura et al. 1992; Bouchet et al. 1994; Umeda et al.
1997; Nozaki et al. 1998; Bouchet et al. 1999; Zhao et al. 2003). Whilst it appears that
the sole function of extracellular PAI-2 is to inhibit and clear uPA (and tPA) activity,
the potential functions of PAI-1 are much more diverse as PAI-1 is also able to
compete for binding to the ECM protein vitronectin, thereby moderating cell
adhesion/deadhesion. Furthermore, PAI-1 has been demonstrated, upon binding to
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LDLRs to activate pro-mitogenic signalling pathways, resulting in cell proliferation
and migration (discussed in section 1.4.3). These additional physiological roles may
explain the paradoxical prognostic profiles of PAI-1 verses PAI-2 expression in
cancer.

1.4 NON-PROTEOLYTIC FUNCTIONS OF THE PLASMINOGEN
ACTIVATION SYSTEM
Subsequent to formation of the enzyme:substrate complex, uPA:PAI-1 and uPA:PAI2 are cleared from the cell surface via receptor mediated endocytosis and
subsequently degraded in lysosomes (Ploug et al. 1991; Al-Ejeh et al. 2004). This
endocytosis is dependent on cell surface uPA to uPAR association (Hussain et al.
1999; Strickland et al. 2002; Strickland and Ranganathan 2003; Al-Ejeh et al. 2004).
As uPAR is anchored to the plasma membrane by a glycosylphosphadityl inositol
(GPI) moiety (Ploug et al. 1991), endocytosis requires the participation of an
additional transmembrane receptor. Members of the LDLR superfamily have been
demonstrated to mediate the internalisation of uPA:PAI complexes (Kounnas et al.
1993; Argraves et al. 1995; Kasza et al. 1997; Strickland et al. 2002; Croucher et al.
2006; Croucher et al. 2007).

1.4.1 THE LDLR SUPERFAMILY
The LDLR superfamily contains (among other receptors), LDLR itself (low density
lipoporiten receptor), the low-density lipoprotein receptor-related protein-1 (LRP1),
megalin (LRP2) and the very low-density lipoprotein receptor (VLDLR). Members
of the LDLR superfamily are implicated in diverse physiological roles such as
lipoprotein metabolism, cell signaling in a variety of tissue types and regulation of
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extracellular proteolytic activity through an ability to bind to a variety of functionally
and sequentially diverse ligands (such as lipoproteins, MMPs, serpin:protease
complexes and cytotoxic species) (Strickland et al. 2002; Strickland and Ranganathan
2003; May et al. 2007).

LDLR-family members are composed of epidermal growth factor (EGF)-like repeats,
clusters of YWTD-containing repeats (believed to be arranged in β-propeller
domains), clusters of ligand type binding repeats, a single transmembrane domain and
a cytoplasmic domain (Strickland et al. 2002) (Figure 1.8). Binding to target proteins
occurs via electrostatic interactions mediated by negatively charged regions in the
ligand type binding repeats (Lillis et al. 2005), with this supported by the resolved
crystal structure of an LDLR-RAP (receptor associated protein) complex revealing
interactions between acidic residues in the receptor and basic regions in the ligand
(Fisher et al. 2006). Further, Jensen et al. (2006) proposed an LDLR minimal binding
motif for ligands consisting of two basic residues separated by 2-5 residues and Nterminal flanked by hydrophobic residues. The cytoplasmic domain of LDLR
members contains sequence motifs that are recognised by adaptor proteins, resulting
in clathrin coated pit-mediated internalisation (Chen et al. 1990). All LDLRs contain
at least one copy of the NPxY motif, but may contain other internalisation motifs. For
example, the YxxL in LRP1 serves as the dominant adapter protein recognition motif
rather than either of the two NPxY motifs (Li et al. 2000). Intracellular signal
transducing adapter proteins are also able to interact with the cytoplasmic domains of
LDLR members (Strickland and Ranganathan 2003; Lillis et al. 2005).
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Figure 1.8: Structural representations of the LDLR members LDLR, VLDLR
and LRP1. All LDLR members comprise of a transmembrane domain and at least
one ligand binding domain, EFG repat, YWTD β-propeller and cytoplasmic domain
containing at least one NxPY motif. Adapted from Rebeck et al. (2006).
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Subsequent to internalisation, the receptor and ligand are delivered to endosomes
where dissociation of the complex takes place. Typically, the receptor is returned to
the plasma membrane whilst the ligand is degraded (Hussain et al. 1999), with Brown
et al. (1997) suggesting that recycling can occur over 100 times before receptor
degradation. As LDLRs are localised in clatherin coats pits on the cell surface,
LDLRs are repetitively internalised and recycled to the cell surface regardless of
bound ligand. Release of the ligand from the receptor is moderated by the acidic pH
of the endosome. X-ray crystallography has revealed that, under acidic conditions, the
YWTD propeller domain of LDLR can act as an alternative ligand for the ligand
binding type repeats, displacing bound LDL (Innerarity 2002; Rudenko et al. 2002). It
is likely that a similar mechanism is involved in the release of other ligands from
LDLRs.

1.4.2 ENDOCYTOSIS OF uPA:PAI COMPLEXES
The internalisation of uPA:PAI-1 complexes by LDLRs is best characterised for the
receptors VLDLR and LRP1, although LRP2 (also known as megalin and gp330) and
sorLA (a member of the Vps10p-domian receptor family, but containing LDL ligand
binding repeat domains (Hermey 2009)) have also been shown to bind (and
presumable internalise) proteins of the plasminogen activation system (Table 1.2).
Whilst early studies seemed to suggest that PAI-2 is not internalised following
inhibition of uPAR-bound uPA (Ragno et al. 1995; Andreasen et al. 1997; Andreasen
et al. 2000; Schmitt et al. 2000), it is now clear that uPA:PAI-2 complexes are
internalised via LRP1 (Croucher et al. 2006) and VLDLR (Croucher et al. 2007) and
subsequently localised to endosomes and lysosomes (Al-Ejeh et al. 2004). Unlike
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Table 1.2: Reported affinities of plasminogen activation system components for
receptors of the low-density lipoprotein receptor family
Ligand
LRP1 KD (nM)
LRP2 KD (nM)
VLDLR KD (nM)

sorLA KD (nM)

1#

Pro-uPA

12
2*
45
16^
5

uPA

50
2*
60
3♦
100
13^
200
16^
7

18.4

8•

10.3

8•

-

5

16^

1#

3♦

100
14^
209 & 31.2

12

16^

23

16^

1#

PAI-1
PAI-2
PN-1

55
2*
93
5^
35
16^
24
13
No interaction
-

11

8•

-

No interaction
-

1#

uPA:PAI-1

0.4
2*
3
3♦
0.5
6•
1.4
15^
0.226
16^
2.1

uPA:PAI-2

36.2

uPA:PN-1

0.8

14^

51.8

14

-

6•

9•

0.8
8•
1.1

0.8
3♦
1.5
11•
14
12*
15
14^
84.8 & 1.51
15^
1.6

15^

0.48
16^
2.3

13^

-

4.68

15^

-

6•

-

0.14

6•

-

-

124

17^

-

-

23.0 & 139

-

131

1#

tPA

tPA:PAI-1

1130
5^
158
7^
323
17^
66.9
1#
3
5^
6.1
16^
12
17^
0.95 & 21.2

tPA:PAI-2
Plasminogen
References
1: Nykjaer et al. 1994
2: Kounnas et al. 1993
3: Heegaard et al. 1995
4: Degryse et al. 2004
5: Horn et al. 1997
6: Kasza et al. 1997
7: Samson et al. 2008
8: Stefansson et al. 1995
9: Moestrup et al. 1993
10:Kanalas and Makker 1991
11: Mikhailenko et al. 1999

66.1
-

17^

~225

12: Argraves et al. 1995
13: Croucher et al. 2006
14: Croucher et al. 2007
15: Skeldal et al. 2006
16: Gliemann et al. 2004
17. Lee et al. 2010

10*

17^

23

16^

17^

-

-

Experiment type
# Competition binding (NB. As such
these are EC50 values and not KD values)
* ELISA
^ Surface plasmon resonance (NB.
Where more than one KD value is
present, multiple binding sites are
present in the species)
• Solid phase binding assay – microtitre
125
plate ( I labelled ligand)
♦ Solid phase binding assay
electrophoretically immobilised analyte
125
( I labelled ligand)
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PAI-1 (Nykjaer et al. 1994), PAI-2 is unable to bind directly to LRP1 or VLDLR
(Croucher et al. 2006; Croucher et al. 2007).

The affinity of the uPA:PAI-1 and uPA:PAI-2 complexes for LDLR members are
significantly higher than that for uPA alone (Table 1.2), with this increased affinity
resulting in an increase in the rate of uPA clearance from the cell surface (Nykjær et
al. 1994; Croucher et al. 2006; Croucher et al. 2007). The binding of uPA:PAI-1 to
LDLR members is dependent on sites in the A-chain and serine protease domain of
uPA (Andreasen et al. 1994; Nykjær et al. 1994; Skeldal et al. 2006) and in the PAI-1
moiety of the complex (Horn et al. 1998; Rodenburg et al. 1998; Stefansson et al.
1998; Skeldal et al. 2006). Previous studies have identified a number of basic residues
in and around the α-helix D of PAI-1 that mediate the high affinity binding of the
PAI-1 moiety of the uPA:PAI-1 complex to LDLRs (Figure 1.9). In addition, the αhelix D of PAI-1 contains a proposed common binding motif for high affinity LDLR
family ligands consisting of two basic residues separated by 2-5 residues and Nterminally flanked by hydrophobic residues (Jensen et al. 2006) (Figure 1.9E). This
motif is not conserved within the α-helix D of PAI-2 (Figure 1.9E), with the first
hydrophobic/basic amino acid couple present, but the second pair replaced with serine
residues (Ser111, Ser112). Results obtained by Croucher et al. (2006) and Croucher et
al. (2007) suggest that the recognition sites in uPA:PAI-2 for both LRP1 and VLDLR
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A

C

B

D

E

PAI-1
PAI-2

69
88
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101
119

Figure 1.9: Structural comparison of the LDLR binding region of PAI-1 and the
corresponding region in PAI-2. (A, B) Structure of PAI-1 and PAI-2 showing
location of residues in α-helix D of PAI-1 implicated in the interaction with LDLRs
and the corresponding residues in PAI-2. (C, D) Comparison of surface potential
around the α-helix D region of PAI-1 and PAI-2, regions of positive electrostatic
potential are in blue, regions of negative potential in red and neutral regions in white.
(E) Alignment of α-helix D amino acid sequence from PAI-1 and PAI-2. The putative
minimal binding motif (Jensen et al. 2006) in PAI-1 is underlined with necessary
basic and hydrophobic residues highlighted in yellow and blue respectively. Adapted
from Croucher et al. (2007).
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lie solely within the uPA moiety of the complex, highlighting the importance of this
LDLR minimal binding motif. The increased affinity of uPA:PAI-2 relative to uPA
alone is thought to be due to changes to the structure of uPA upon complex formation.
Few crystal structures of serpin:protease complexes exist, and whilst Dementiev et al.
(2006) showed that no major structural changes occur in porcine pancreatic elastase
when in complex with α1-antitrypsin (SerpinA1), there are major structural
differences in uPA and porcine pancreatic elastase. This lack of an LDLR binding site
in the PAI-2 moiety of the uPA:PAI-2 complex results in reduced binding affinity for
LDLRs compared to uPA:PAI-1 (Table 1.2). Whilst these differences may seem
somewhat trivial, their impact on downstream functional effects is remarkable.

1.4.3 SIGNALLING PATHWAYS
Initially, it was thought that the function of the plasminogen activation system
components in cancer was restricted to roles in the degradation of tissue boundaries
(Duffy 2004). However, as previously mentioned, further studies have identified the
participation of plasminogen activator system components in cancer-related activities
such as cell adhesion and motility. Additionally, components of the plasminogen
activation system have been linked to the activation of pro-oncogenic cell signaling
and promotion of cell migration (Chapman 1997; Andreasen et al. 2000; Kjoller
2002).

Binding of uPA to uPAR at the cell surface of MCF-7 cells has been demonstrated to
result in transient extracellular signal-regulated kinase (ERK) phosphorylation
(Nguyen et al. 1999; Webb et al. 2001). The MAPK/ERK signalling pathway
regulates cell proliferation, differentiation, apoptosis and migration (Webb et al.
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2001). The phosphorylation/activation of FAK, p130Cas, Src and Rac have also been
reported to occur by uPA:uPAR mediated signal transduction (Kjoller 2002). The
activation of the above signalling pathways occur independent of LDLR-family
member association and are instead mediated via interactions with cell-surface
integrins (Resnati et al. 2002).

PAI-1 has been shown to promote cancer cell line development through the activation
of signalling pathways (Chapman 1997; Foekens et al. 2000; Webb et al. 2001; Duffy
and Duggan 2004; Ohba et al. 2005; Weigelt et al. 2005). Endocytosis of uPA:PAI-1
via VLDLR has been found to result in sustained ERK phosphorylation in MCF-7
(Webb et al. 2001) and SGC7901 (Di et al. 2010) cells, with this sustained activation
dependant on the high affinity interaction between the PAI-1 moiety of the complex
and VLDLR (Webb et al. 2001). The mechanism underlying this signalling response
is yet to be fully elucidated, and is likely mediated by a combination of described
models (Strickland et al. 2002). PAI-1 is also able to stimulate cell migration
independent of uPA, via activation of the Jak/Stat pathway (Degryse et al. 2004)

Endocytosis of uPA:PAI-2 does not result in sustained activation of signalling
pathways, as determined by decreased global tyrosine phosphorylation (Croucher et
al. 2007), but rather transient activation of ERK similar to that of uPA/uPAR
association (Croucher, unpublished observation). Furthermore, treatment of MCF-7
cells with uPA:PAI-2 did not result in increased cell proliferation (Croucher et al.
2007). The hypothesis that this difference in the moderation of mitogenic signalling
activity is dependent on the high affinity interaction between the PAI-1 moiety of the
complex and VLDLR is supported by the lack of ERK activation by uPA:PAI-1 R76E
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(uPA:PAI-1 R76E binds to LDLRs with decreased affinity, discussed further in
Chapter 3) and ability of RAP (which competes for LDLR binding) to block ERK
mediated cell proliferation. This difference in the activation of cell signalling
pathways may play an important role in the difference in biological activity of PAI-1
and PAI-2 in cancer.

1.5 POTENTIAL THERAPEUTIC VALUE OF PAI-2
The ability of PAI-2 to efficiently inhibit and clear uPA (Al-Ejeh et al. 2004), without
activating pro-invasive pathways in cancer cells like PAI-1 (Croucher et al. 2007) has
led to the development of PAI-2 as a basis for novel, targeted cancer therapies. High
plasma levels of PAI-2 are well tolerated, as in the third trimester of pregnancy PAI-2
levels can reach 250 ng.mL-1 in plasma (Kruithof et al. 1987; Hunt et al. 2009) with
no apparent associated health risks. In addition, PAI-2 cannot inhibit sc-tPA or fibrin
bound tPA (Leung et al. 1987), negating what could be problematic interplay in
fibrinolysis. Also, PAI-2 does not convert to the latent serpin conformation –
remaining active until reacting with uPA or being cleared from the bloodstream.
Conjugation of PAI-2 to bismuth-213 (an alpha-emitting radioisotope) has been used
to treat breast, prostate and melanoma cancer xenografts in animal models (Allen et
al. 2001; Li et al. 2002; Ranson et al. 2002; Allen et al. 2003; Stutchbury et al. 2007).
Suwa et al. (2008) found that treatment of mice bearing a human colon cancer
xenograft with an intraperationeal infusion of recombinant PAI-2 inhibited primary
tumour growth, decreased the frequency of metastasis and increased the apoptotic
index of tumours. Transfection with PAI-2 of uPA expressing cells in xenograft
models has also been demonstrated to inhibit or completely prevent metastasis (Laug
et al. 1993; Mueller et al. 1995; Praus et al. 1999). Vine et al. (2010) showed that 2’42

deoxy-5-fluorouridine (a pro-drug form of the common chemotherapeutic 5flurouracil) conjugated to PAI-2 was able to preferentially kill uPA/uPAR
overexpressing cell lines.

1.6 SUMMARY AND AIMS
PAI-1 and PAI-2 appear to play disparate roles in the progression of cancer. Whilst
both are able to inhibit uPA at the cell surface, thereby decreasing pericellular
plasminogen activation, PAI-1 is implicated in non-proteolytic roles stimulating cell
proliferation and migration. The molecular basis of the strong relationship between
breast cancer prognosis and expression of uPA and PAI-1 versus PAI-2 is unknown.
Croucher et al. (2008) proposed a model to explain the differential prognosis profiles
of PAI-1 and PAI-2 based on differing interactions with receptors in an extracellular
context. Whilst attempts have been made to relate the protective role of cancer in
PAI-2 to an intracellular role, as yet no clear mechanism has been described.

Characterisation of the interactions between uPA:PAI-2 and the endocytosis receptors
LRP1 and VLDLR has demonstrated clear differences in the way in which PAI-1 and
PAI-2 interact with these proteins (Croucher et al. 2006; Croucher et al. 2007). Whilst
it could be argued that on a biochemical basis these interactions differ only slightly,
the impact on downstream physiological function is striking. Further structural
characterisation of the interactions potentially underlying the differences in LDLRmediated cell signalling activities of PAI-1 and PAI-2 on carcinoma invasion and
metastasis may help explain the apparently paradoxical biomarker data for PAI1/PAI-2 in cancer. In addition, increased characterisation of the mechanism of
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internalisation of PAI-2 will help provide further rationale for the development of
PAI-2 based targeted therapies.

Given the lack of a definitive mechanism to explain the contrasting impact of PAI-1
and PAI-2 expression in cancer, the overall aim of this thesis was to elucidate the
molecular basis underlying the differences in LDLR binding between PAI-1 and PAI2 and examine the functional consequences of manipulating this interaction. Initially,
characterisation of an improved method for the purification and production of PAI-2
to be used further in this study will be described (Chapter 2). As this PAI-2 construct
lacks the interhelical CD-loop, the redundancy of this domain in the uPA-dependent
functionality and subsequent endocytosis of the uPA:PAI-2 complex will be
confirmed (Chapter 2). By comparing the residues previously implicated in the
interaction between PAI-1 and LDLRs with the corresponding residues in PAI-2, a
series of mutants will be made to introduce LDLR binding to PAI-2 (Chapter 3). The
impact of introducing LDLR binding to PAI-2 on downstream cellular functions
related to uPA internalisation will be characterised to fully detail the molecular basis
underlying the differential LDLR dependent differences of PAI-1 and PAI-2 in cancer
in vitro (Chapter 4).

44

CHAPTER 2
THE CD-LOOP OF PAI-2 (SERPINB2) IS
REDUNDANT IN THE TARGETING,
INHIBITION AND CLEARANCE OF CELL
SURFACE uPA ACTIVITY
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2.1 INTRODUCTION
As previously introduced in Chapter 1, PAI-2 is able to specifically target, inactivate
and clear cell surface uPA without interacting with components of the ECM or
modifying other cellular behaviours that may promote tumour cell behaviour (unlike
PAI-1) (Croucher et al. 2007; Croucher et al. 2008). This supports the use of
exogenous PAI-2 for uPA targeted cancer treatments. As discussed previously in
Section 1.5, promising results using bismuth-213 labelled PAI-2 have been obtained
in a number of in vitro, in vivo and preclinical evaluations which show clear cell
targeting specificity and tumour efficacy with minimal side effects in relevant animal
models (Li et al. 2002; Ranson et al. 2002; Allen et al. 2003; Allen et al. 2004; Qu et
al. 2005; Abbas Rizvi et al. 2006; Song et al. 2006; Song et al. 2007; Stutchbury et al.
2007).

To date, all work undertaken in developing PAI-2 based targeted therapies have used
full length, PAI-2 wild-type. However, it may be possible to utilise smaller, more
easily producible PAI-2 constructs without compromising the uPA inhibitory and
clearance functions of PAI-2. Previous studies have reported the purification of PAI-2
from placenta (Wun and Reich 1987), cultured human monocytes (Kruithof et al.
1986), transfected CHO cells (Mikus et al. 1993; Mikus and Ny 1996), baculovirus
infected insect larvae (Zhang et al. 1998) and from recombinant expression systems in
yeast (Steven et al. 1991; Gould et al. 2003) and Escherichia coli (Ye et al. 1987;
Antalis et al. 1988; Mikus et al. 1993; Jensen et al. 1994; Zhou et al. 1997;
Muehlenweg et al. 2000; Jankova et al. 2001; Wilczynska et al. 2003; Wilczynska et
al. 2003; Lobov et al. 2004; Di Giusto et al. 2005; Suwa et al. 2008). Methods of PAI2 expression in E. coli have generally utilised a one or two step purification
46

procedure, usually involving metal affinity chromatography and/or ion exchange
chromatography. The shift in the literature towards affinity tag based systems for the
production of recombinant PAI-2 constructs (Zhou et al. 1997; Muehlenweg et al.
2000; Wilczynska et al. 2003; Wilczynska et al. 2003; Lobov et al. 2004; Di Giusto et
al. 2005) allows for the purification of PAI-2 under milder, native conditions and
avoidance of denaturation/renaturation (Zhou et al. 1997) or extreme pH treatment
(Mikus et al. 1993) as used previously. The presence of an N-terminal 6 × his-tag has
previously been shown to have no significant impact on the uPA inhibitory activity of
PAI-2 (Wilczynska et al. 2003). Generally, his-tags are believed to have no effect on
overall protein structure (Carson et al. 2007).

An issue associated with the purification of recombinant PAI-2 wild-type is that the
CD-loop of PAI-2 is readily cleaved in both E. coli or mammalian expression systems
(Lobov et al. 2004). This results in two fractions of recombinant PAI-2 which retain
inhibitory activity but require additional purification steps such as ion-exchange
chromatography (Lobov et al. 2004) to achieve a homogenous protein population. Di
Giusto et al. (2005) showed that 6 × his-tagged PAI-2 lacking the CD-loop (termed
PAI-2 ∆CD-loop) can be purified with a one-step procedure and exhibited identical
soluble phase uPA inhibitory activity to that previously reported for full length PAI-2.
As discussed in Chapter 1, the functionality of the CD-loop has been described
primarily in an intracellular context (Croucher et al. 2008).

Altogether, this suggested that PAI-2 ∆CD-loop, being easy to produce and purify in
addition to retaining uPA inhibitory activity, could be used as an exogenous uPA
targeting substitute for PAI-2 wild-type in a therapeutic setting. Furthermore, the use
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of PAI-2 ∆CD-loop may be suitable to further characterise the uPA-dependent roles
of PAI-2 in vitro. This chapter compares the expression and purification of 6 × histagged wild type PAI-2 and PAI-2 ∆CD-loop and shows for the first time that the cell
bound uPA inhibitory activity and rapid clearance of uPA/uPAR by PAI-2 is not
compromised by the 6 × his-tagged form lacking the CD-loop.
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2.2 MATERIALS AND METHODS
2.2.1 MATERIALS
The expression vectors pET15b/PAI-2 wild-type and pET15b/PAI-2 ∆CD-loop (both
human type A PAI-2 cDNA) (Appendix II) were a kind gift from Prof. T Ny (Umea
University, Sweden); pQE9 vector and M15[pREP4] E. coli obtained from QIAGEN
(Hilden, Germany); Oligonucleotides from Geneworks (Adelaide, Australia); phorbyl
myristate

acetate

(PMA)

from

Sigma-Aldrich

(St.

Louis,

MO,

USA);

Alexa488 labelling kit, Alexa488 polyclonal antibody and BL21 Star (DE3) E. coli from
Invitrogen (Carlsbad, CA, USA); IPTG from Applichem (Darmstadt, Germany);
Monoclonal antibodies against human uPA (394) and human PAI-2 (3750), and high
molecular weight (HMW)-uPA from American Diagnostica Inc. (Stamford, CT,
USA); Ampicillin and kanamycin from Amresco (Solon, OH, USA); TALON metal
affinity resin from Clontech (Mountain View, CA, USA); BamHI restriction enzyme,
shrimp alkaline phosphatase and T4 DNA ligase from Fermentas (Vilnius, Lithuania);
CM5 BIAcore chip, PD-10 desalting columns and Hyperfilm ECL from GE
Healthcare (Princeton, NJ, USA); Recombinant VLDLR ligand binding region (V1-7)
was a gift from D Blaas (Medical University of Vienna, Austria); Z-Gly-Gly-ArgAMC from Merck (Darmstadt, Germany); Human recombinant non-histagged PAI-2
wild-type was from PAI-2 Pty Ltd (Sydney, Australia); Pfu HS Fusion II DNA
polymerase from Agilent Technologies (Santa Clara, CA, USA). Wizard SV Gel and
PCR Clean-Up System and Wizard Plus SV Minipreps DNA Purification kit were
from Promega (Madison, WI, USA). Precision Plus Protein Prestaind Standards and
PVDF membrane were from Bio-Rad (Hercules, CA, USA). SuperSignal West Pico
Chemiluminescence Substrate was from Pierce (Rockford, IL, USA).
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2.2.2

PREPARATION

OF

ELECTROCOMPETENT

E.

COLI

FOR

TRANSFORMATION

Electrocompetent Escherichia coli JM109, BL21 Star (DE3) and M15[pREP4] cells
were prepared as described by Sharma and Schimke (1996). E. coli were grown
overnight at 37°C with shaking in YENB medium (Appendix I). Cells were diluted
1:200 into 1 L of fresh YENB and grown at 37°C with shaking until mid-log phase
(OD600 ~ 0.6). Cells were harvested by centrifugation (4000 g for 10 min), washed
twice with 200 mL cold sterile MilliQ water, once with 50 mL of cold sterile 10%
glycerol and finally resuspended in 2 mL of cold sterile 10% glycerol. Prepared cells
were stored at -80°C for up to one year. Transformation was performed by
electroporation of competent cells. On ice, 1 µL of purified plasmid DNA (~100 ng)
was added to 40 µL of electrocompetent cells and electropulsed at 2.5 V, 200 Ω and
25 µFD using 0.2 cm MicroPulser cuvettes and a MicroPulser (BioRad, Hercules, CA,
USA). After transformation, 400 µL of SOC medium (Appendix I) was added, the
culture grown at 37°C with shaking for 1 h and then plated onto LB agar (Appendix I)
inoculated with the appropriate antibiotic(s). Where required, plasmids were extracted
from storage strains using a Wizard Plus SV Minipreps DNA Purification kit.

2.2.3 GENERATION OF pQE9/PAI-2 CONSTRUCTS
This work was previously conducted by Lakshitha Gunawardhana (B Biotech Hons,
University of Wollongong, Australia) and the methodology is included here, with his
permission, for the sake of completeness. PAI-2 wild-type and PAI-2 ∆CD-loop
cDNAs lacking the 3' untranslated region were amplified from pET15b using Pfu HS
Fusion

II

DNA

polymerase

and

the

GCGCGGATCCCTCGAGGATCTTTGTGTGGC-3'

following
(forward)

primers:
and

5'5'50

GCGCGGATCCTTAGGGTGAGGAAAATCTGCCG-3'

(reverse).

The

PCR

parameters used were: initial denaturing step 95ºC for 2 min, 30 cycles of denaturing
at 95ºC for 10 s, annealing at 55ºC for 20 s, extension at 72ºC for 1 min, followed by
a final extension step of 72ºC for 3 min. The PCR product was purified using agarose
gel electrophoresis and the WizardSV Gel and PCR Clean-Up System. Primers
contained BamHI sites to allow for ligation into pQE9. Both vector and insert were
digested with BamHI (37°C for 2 h), linear pQE9 de-phosphorylated using shrimp
alkaline phosphatise (as per manufacturer’s instructions) and the insert ligated into the
vector using T4 DNA ligase (as per manufacturer’s instructions). Successful insertion
and sequence integrity were confirmed using restriction digestion and DNA
sequencing.

2.2.4 DNA SEQUENCE ANALYSIS
DNA sequence analysis was used to confirm successful construction of of pQE9/PAI2 wild-type and pQE9/PAI-2 ∆CD-loop. Isolated plasmid DNA was sequenced using
an ABI Prism BigDye Primer Cycle Sequencing Kit (Applied-Biosystems, Sydney,
Australia), electrophoresed in an ABI PRISM 377 DNA sequencer (Perkin-Elmer,
Waltham, MA, USA) and analysed using BioEdit (Hall 1999). For each sequencing
reaction, 200 ng of DNA (in 1 µL), 0.5 µL BigDye, 2 µL 5 × sequencing buffer, 2
pmol of primer in 1 µL (Table 2.1, Figure 2.1) and 5.5 µL dH2O were placed in a
PCR thermocycler and set to the following program: 25 cycles, 96ºC for 30 s, 52ºC
for 15 s, 60ºC for 4 min. Excess dye terminators were removed from the sequencing
reactions via ethanol precipitation (Sambrook et al. 1989) and sequencing undertaken.
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Table 2.1: Oligonucleotides used for sequencing of pQE9/PAI-2 constructs. PAI-2
S4 is the reverse complement of PAI-2 S1. Location of primers on PAI-2 cDNA is
indicated in Figure 2.1
Primer name

Sequence

Direction

PAI-2 S1

5’-CACCGAAGACCAGATGG-3’

Forward

PAI-2 S2

5’-GTCAAGACTCAAACCAAAGG-3’

Forward

PAI-2 S3

5’-TTGCCGATGTGTCCACTG-3’

Forward

PAI-2 S4

5’-GCCATCTGGTCTTCGGTGC-3’

Reverse

pQE promoter

5’-CGGATAACAATTTCACACAG-3’

Forward

2.2.5 EXPRESSION AND PURIFICATION OF PAI-2
Purified pET15b/PAI-2 ∆CD-loop, pQE9/PAI-2 ∆CD-loop and pQE9/PAI-2 wildtype vectors were transformed into electrocompetent BL21 Star (DE3) and M15
[pREP4] cells, respectively as described in section 2.2.2. Cells were cultured
overnight at 37°C with shaking in LB containing 100 µg.mL-1 ampicillin and
25 µg.mL-1 kanamycin (only for M15[pREP4] cells). A 20 mL aliquot of this starter
culture was added to 1 L Z-broth (Appendix I) and grown to an OD600 of ~ 0.6.
Expression of PAI-2 ∆CD-loop was induced by the addition of 0.5 mM IPTG and the
culture incubated for a further 4 h. Cells were collected by centrifugation at 10,000 g
for 10 min. Pelleted cells were resuspended in 40 mL of ice-cold loading buffer
(Appendix I) and lysed using an EmulsiFlex-C5 homogeniser (Avestin, Ottawa,
Canada). Cell debris was then pelleted by centrifugation at 17,000 g for 30 min. The
supernatant was loaded onto equilibrated TALON metal affinity resin at a rate of 1
mL.min-1. Unbound proteins were removed using 10 column volumes of loading
buffer followed by 10 column volumes of wash buffer containing previously
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PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

PAI-2

10
20
30
40
50
60
70
80
90
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
ATGGAGGATCTTTGTGTGGCAAACACACTCTTTGCCCTCAATTTATTCAAGCATCTGGCAAAAGCAAGCCCCACCCAGAACCTCTTCCTC
M E D L C V A N T L F A L N L F K H L A K A S P T Q N L F L
100
110
120
130
140
150 S1/S4 160
170
180
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
TCCCCATGGAGCATCTCGTCCACCATGGCCATGGTCTACATGGGCTCCAGGGGCAGCACCGAAGACCAGATGGCCAAGGTGCTTCAGTTT
S P W S I S S T M A M V Y M G S R G S T E D Q M A K V L Q F
190
200
210
220
230
240
250
260
270
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
AATGAAGTGGGAGCCAATGCAGTTACCCCCATGACTCCAGAGAACTTTACCAGCTGTGGGTTCATGCAGCAGATCCAGAAGGGTAGTTAT
N E V G A N A V T P M T P E N F T S C G F M Q Q I Q K G S Y
280
290
300
310
320
330
340
350
360
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CCTGATGCGATTTTGCAGGCACAAGCTGCAGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT
P D A I L Q A Q A A D K I H S S F R S L S S A I N A S T G N
370
380
390
400
410
420
430
440
450
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
TATTTACTGGAAAGTGTCAATAAGCTGTTTGGTGAGAAGTCTGCGAGCTTCCGGGAAGAATATATTCGACTCTGTCAGAAATATTACTCC
Y L L E S V N K L F G E K S A S F R E E Y I R L C Q K Y Y S
460
470
480
490
500
510
520 S2 530
540
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
TCAGAACCCCAGGCAGTAGACTTCCTAGAATGTGCAGAAGAAGCTAGAAAAAAGATTAATTCCTGGGTCAAGACTCAAACCAAAGGCAAA
S E P Q A V D F L E C A E E A R K K I N S W V K T Q T K G K
550
560
570
580
590
600
610
620
630
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
ATCCCAAACTTGTTACCTGAAGGTTCTGTAGATGGGGATACCAGGATGGTCCTGGTGAATGCTGTCTACTTCAAAGGAAAGTGGAAAACT
I P N L L P E G S V D G D T R M V L V N A V Y F K G K W K T
640
650
660
670
680
690
700
710
720
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CCATTTGAGAAGAAACTAAATGGGCTTTATCCTTTCCGTGTAAACTCGGCTCAGCGCACACCTGTACAGATGATGTACTTGCGTGAAAAG
P F E K K L N G L Y P F R V N S A Q R T P V Q M M Y L R E K
730
740
750
760
770
780
790
800
810
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
CTAAACATTGGATACATAGAAGACCTAAAGGCTCAGATTCTAGAACTCCCATATGCTGGAGATGTTAGCATGTTCTTGTTGCTTCCAGAT
L N I G Y I E D L K A Q I L E L P Y A G D V S M F L L L P D
840
850
860
870
880
890
900
820 S3 830
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GAAATTGCCGATGTGTCCACTGGCTTGGAGCTGCTGGAAAGTGAAATAACCTATGACAAACTCAACAAGTGGACCAGCAAAGACAAAATG
E I A D V S T G L E L L E S E I T Y D K L N K W T S K D K M
910
920
930
940
950
960
970
980
990
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GCTGAAGATGAAGTTGAGGTATACATACCCCAGTTCAAATTAGAAGAGCATTATGAACTCAGATCCATTCTGAGAAGCATGGGCATGGAG
A E D E V E V Y I P Q F K L E E H Y E L R S I L R S M G M E
1000
1010
1020
1030
1040
1050
1060
1070
1080
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GACGCCTTCAACAAGGGACGGGCCAATTTCTCAGGGATGTCGGAGAGGAATGACCTGTTTCTTTCTGAAGTGTTCCACCAAGCCATGGTG
D A F N K G R A N F S G M S E R N D L F L S E V F H Q A M V
1090
1100
1110
1120
1130
1140
1150
1160
1170
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
GATGTGAATGAGGAGGGCACTGAAGCAGCCGCTGGCACAGGAGGTGTTATGACAGGGAGAACTGGACATGGAGGCCCACAGTTTGTGGCA
D V N E E G T E A A A G T G G V M T G R T G H G G P Q F V A
1180
1190
1200
1210
1220
1230
1240
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
GATCATCCTTTTCTTTTTCTTATTATGCATAAGATAACCAACTGCATTTTATTTTTCGGCAGATTTTCCTCACCCTAA
D H P F L F L I M H K I T N C I L F F G R F S S P *

Figure 2.1: Positions of oligonucleotide primers used to sequence PAI-2 cDNA (isoform A) as
described in Table 2.1. The ‘pQE promoter’ binds to a region in pQE9 as shown in Appendix I. The
region of the PAI-2 cDNA encoding for the CD-loop is underlined. The positions of amino acids that
differ between isoforms A and B are double underlined.
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optimised imidazole concentrations (Appendix I; 5 mM imidazole for PAI-2
expressed from pQE9, 15 mM for PAI-2 expressed from pET15b). Bound protein was
eluted from the column using elution buffer (Appendix I). Purification was analysed
using SDS-PAGE under reducing conditions and the successful isolation of PAI2 ∆CD-loop confirmed by western blotting using a monoclonal antibody against PAI2 (3750). Samples were buffer exchanged into PBS (Appendix I) using a PD-10
column to remove imidazole for subsequent experiments.

2.2.6 SDS-PAGE
SDS-PAGE was used to assess the performance of protein purification and expression
levels. Samples were diluted 1:4 with either 5 × reducing sample buffer (Appendix I)
or 5 × non-reducing sample buffer (Appendix I) and boiled for 3-5 min. The gel was
prepared using a Mini PROTEAN3 Cell system (BioRad, Hercules, CA, USA) using
4% stacking and 12% resolving acrylamide gels (Appendix I). Gels were
electrophoresed at 140 V for 2 h in 1 × SDS running buffer (Appendix I). Gels were
stained with coomassie rapid staining solution (Appendix I) and protein bands
resolved using firstly rapid destain (Appendix I) and then final destain solutions
(Appendix I). Standard curves were constructed using Precision Plus Protein
Prestained Standards to allow for estimation of protein size (Appendix III).

2.2.7 WESTERN BLOT ANALYSIS
Western blots were conducted using a Mini Trans-Blot Cell system (BioRad,
Hercules, CA, USA) and PVDF membrane. Prior to use, the membrane was activated
by soaking in methanol and equilibrated in transfer buffer (Appendix I). The blot was
assembled as per the manufacturers instructions with all components soaked in
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transfer buffer and run at 100 V for 1 h. Subsequent to protein transfer, the membrane
was blocked for 1 h at room temperature (RT) with 10% (w/v) powdered milk in
TBST (Appendix I). The membrane was incubated for 1 h at RT with a 1:500 dilution
of the primary antibody in 2% (w/v) powdered milk in TBST, re-blocked with 6%
(w/v) powdered milk in TBST and then incubated for 1 h at RT with a 1:5000 dilution
of the HRP-labelled secondary antibody in 2% (w/v) powdered milk in TBST.
Between each step, the membrane was washed with TBST and finally washed in TBS.
Labelled proteins were visualised using SuperSignal West Pico Chemiluminescence
Substrate and Hyperfilm ECL.

2.2.8 CATION-EXCHANGE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
(HPLC)
This work was performed by Dr Kara Perrow (University of Wollongong, Australia)
and is included with her permission. The purity of PAI-2 ∆CD-loop expressed and
purified from pQE9 was further determined by high performance liquid
chromatography using a BioSuite SP 10 µm, C × C (7.5 cm × 75 mm) cation
exchange semi-preparative column (Waters, Milford, MA, USA). The column was
pre-equilibrated with approximately 10 column volumes of 20 mM 2-(Nmorpholino)ethanesulfonic acid (MES, pH 5.0). PAI-2 ∆CD-loop (100 µL, ~1
mg.mL-1) was then loaded and eluted with a linear (curve 6) 0.5 M NaCl salt gradient
at 1 mL.min-1. The data was collected on a photodiode array at 280 nm and percent
purity determined using Empower Pro V2 (Waters, Milford, MA, USA) software.
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2.2.9 ELECTROSPRAY IONISATION MASS SPECTROMETRY (ESI-MS)
A positive ion mass spectrum of PAI-2 ∆CD-loop expressed and purified from pQE9
was acquired on a quadrupole time of flight spectrometer (Q-TOF-MS) (Micromass
Q-TOF Ultima, Waters, Milford, MA, USA) fitted with a Z-spray ionisation source. A
sample of freshly prepared protein in PBS (pH 7.4) was exchanged into 10 mM
ammonium acetate buffer (pH 6.8) containing 0.1% formic acid and made up to a
final concentration of 10 µM (Sample prepared by Dr Kara Perrow, University of
Wollongong, Australia). The protein was then injected into the Q-TOF Ultima mass
spectrometer (20 µL) and the mass spectrum acquired with a capillary voltage of 2.6
kV, cone voltage of 50 V, source block temperature of 40°C, and a resolution power
of 5000 Hz. Ceasium iodide was used for external calibration. The mass spectrum
data is presented as raw data, on an m/z scale. Mass was calculated using MassLynx
MS software (Waters, Milford, MA, USA).

2.2.10 TISSUE CULTURE CONDITIONS
The human breast epithelial adenocarcinoma cell line MCF-7 and the leukemic
monocyte lymphoma cell line U937 were routinely cultured in RPMI-1640
supplemented with 5% (v/v) heat-inactivated FCS (foetal calf serum). Cells were
incubated at 37°C in a humidified incubator with a 5% carbon dioxide/air atmosphere
and routinely passaged using trypsin/EDTA (MCF-7) or dilution (U937) as required.
Cells were routinely tested for absence of mycoplasma contamination.

56

2.2.11 uPA INHIBITORY ASSAYS
2.2.11.1 Formation of SDS-stable complexes
To ensure that PAI-2 ∆CD-loop retained uPA inhibitory activity, a 1:2 molar ratio of
HMW-uPA to PAI-2 ∆CD-loop was incubated at 37oC for 1 h. Complex formation
was then qualified by SDS-PAGE as previously described (Saunders et al. 2001).

2.2.11.2 Solution phase fluorogenic uPA activity assay
Several substrate and uPA concentrations were used to find the optimum range and to
set the gain on a Fluorostar Optima fluorescence plate reader (BMG Labtech,
Germany). PAI-2 ∆CD-loop or PAI-2 wild-type were diluted in reaction buffer
(Appendix I) and mixed with fluorogenic substrate, Z-Gly-Gly-Arg-AMC in 180 µL
reaction buffer. After a brief preincubation at 37°C, HMW-uPA (final concentration
0.675 nM) was added to start the reaction and fluorescence emission measured
immediately at 37°C. All assays were performed in triplicate and values corrected by
subtracting the background (reaction buffer plus substrate only).

2.2.11.3 Cell surface fluorogenic uPA activity assay
For cell based assays, PMA treated U937 cells (used to enhance the expression of
unoccupied uPAR (Picone et al. 1989)) were washed and preincubated with 50 nM
HMW-uPA in binding buffer (Appendix I) for 10 min to saturate uPAR. After 2
washes the cells were resuspended in binding buffer to give a final concentration of 5
× 105 cells.mL-1. To initiate the reaction 100 µL aliquots of the cell suspension were
transferred to a 96-well fluor plate containing 100 µL of 0.5 mM substrate +/- PAI-2
in binding buffer pre-equilibrated to 37°C (final concentrations, 0.25 mM substrate,
12.5 or 50 nM PAI-2) and fluorescence emission measured. All assays were
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performed in triplicate and values corrected by subtracting background fluorescence
[binding buffer plus substrate +/- PAI-2 (the presence of PAI-2 made no difference to
background levels)]. Differences in uPA activity were tested for significance using an
unpaired Student's t-test with p < 0.05 considered statistically significant.

2.2.12 SURFACE PLASMON RESONANCE
Surface plasmon resonance was used to determine the impact of the removal of the
CD-loop and presence of the 6 × his-tag on the affinity of uPA:PAI-2 complexes for
VLDLR, essentially as described by Croucher et al. (2007). VLDLR was immobilised
on a CM5 BIAcore chip, according to the manufacturer’s instructions (Appendix VI).
The

chip

was

activated

with

a

1:1

mixture

of

0.2

M N-ethyl-N'-(3-

dimethylaminopropyl)carbodi-imide and 0.05 M N-hydroxysuccimide. VLDLR was
coated onto the chip at 40 µg.mL-1 in 10 mM sodium acetate (pH 3) to a level of
~2,000 response units. Unoccupied binding sites were blocked using 1 M
ethanolamine (pH 8.5). Ligands were diluted into BIAcore running buffer (Appendix
I) before application to the BIAcore chip at 20 µL.min-1. Regeneration was achieved
using 100 mM H3PO4. For kinetic assays, data was analysed using BIAevaluation
software (Version 4), using a blank cell as the reference cell. Binding models were
selected based on the lowest χ2 value and analysis of residual plots.

2.2.13 ENDOCYTOSIS ASSAYS
Endocytosis assays were conducted essentially as previously described (Al-Ejeh et al.
2004; Croucher et al. 2006; Croucher et al. 2007), using the MCF-7 cell line. Cells
were grown for 48 h in 6 well plates to subconfluency, washed with phenol red free
hanks buffered salt solution (Appendix I) then incubated in binding buffer for 1 h at
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37°C to allow for receptor recycling. To confirm LDLR specificity, cells were
preincubated for 10 min with 200 nM RAP. Cells were incubated with 10 nM
uPA:Alexa488, both alone and previously complexed with either PAI-2 wild-type or
PAI-2 ∆CD-loop for 1 h at 37°C, to allow for internalisation. After this incubation
period, the cells were washed twice with ice cold binding buffer, harvested using 5
mM EDTA, washed again and resuspended in ice cold binding buffer containing
4 µg.mL-1 Alexa488 quenching polyclonal antibody. After 30 min the cells were
washed twice with ice-cold PBS and analysed by dual colour flow cytometry with
propidium iodide to exclude non-viable cells. Propidium iodide is membrane
impermeant, but displays increased fluorescence intensity when bound to DNA,
allowing cells fluorescing at 695 nm to be excluded from further analysis. Differences
in the amount of uPA internalised between treatments were tested for significance
using the unpaired Student's t-test with p < 0.05 considered statistically significant.
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2.3 RESULTS
2.3.1 EXPRESSION AND PURIFICATION OF PAI-2
Expression and purification of PAI-2 ∆CD-loop from both the pET15b and pQE9
vector systems yielded a product migrating as a major band at approximately 45 kDa
(Figure 2.2A). This corresponds to the expected molecular weight of PAI-2 ∆CD-loop
and its identity was confirmed via western blotting with a monoclonal antibody to
PAI-2 (Figure 2.2B). The PAI-2 ∆CD-loop from the pQE9 system contained less
impurities (seen as lower molecular weight bands; Figure 2.2A) compared to PAI2 ∆CD-loop from pET15b expressed and purified under similar conditions (Figure
2.2A, compare lanes 1 and 2). The abundance of PAI-2 ∆CD-loop expressed and
purified from the pQE9 versus the pET15b system was found to be ~95% pure
compared to ~74%, respectively, as measured by densitometry. The expression and
purification of PAI-2 ∆CD-loop using the pQE9 system regularly achieved yields
between 10 and 15 mg.L-1 of culture. PAI-2 wild-type expressed and purified using
the pQE9 system was less pure (Figure 2.2A, compare lanes 2 and 3) and of lower
yield (~5 mg.L-1) compared to PAI-2 ∆CD-loop. When visualised by SDS-PAGE
under reducing conditions, PAI-2 wild-type yielded two bands that were both
identified as PAI-2 via western blotting (Figure 2.2C). This agrees with the previous
finding that a portion of wild-type PAI-2 is cleaved in the CD-loop (Lobov et al.
2004), which would require further purification steps to obtain a homogenous protein
population. When analysed under non-reducing conditions, PAI-2 ∆CD-loop
displayed an additional band at ~74 kDa that was not present in the reduced sample
(Figure 2.3B). The purity of PAI-2 ∆CD-loop expressed in the pQE9 system was
confirmed via HPLC, with integration of the elution profile giving PAI-2 ∆CD-loop
an abundance of ~95% (Figure 2.3).
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Figure 2.2: SDS-PAGE and western blot analysis of highly enriched recombinant
PAI-2 proteins. A total protein amount of 10 µg from PAI-2 ∆CD-loop purified from
either pET15b (lane 1) or pQE9 (lane 2), or PAI-2 wild-type from pQE9 (lane 3) were
fractionated by a 12% SDS-PAGE under reducing conditions and stained with
coomassie blue to detect total protein (A). A sample of PAI-2 ∆CD-loop from pQE9
was also analysed under non-reducing conditions (B). Samples transferred to PVDF
membrane and probed with monoclonal PAI-2 antibody (3750) (C). The slight
difference in size between PAI-2∆CD-loop from pET15b and pQE9 is due to
differences in tag/linker length. * marks cleaved PAI-2 in wild-type population as
mentioned in text.
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Figure 2.3: Quantitative analysis of the purification of PAI-2 ∆CD-loop from pQE9. Protein (100 µL) was injected onto a cation
exchange column and eluted using a linear NaCl gradient (0–1 M) at 1 mL.min-1. PAI-2 ∆CD-loop was detected at 280 nm with a RT of
42.606 min. Integration of the peak corresponding to PAI-2 ∆CD-loop measured the purity at 94.5%. The green line indicates the relative
amount of buffer B (MES pH 5.0, 1 M NaCl) to buffer A (MES pH 5.0). Insert: Relative retention times and purity as calculated from
AUC using Empower Pro V2 (Waters, UK) software. RT = retention time.
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2.3.2 ELECTROSPRAY IONISATION MASS SPECTROMETRY (ESI-MS)
The ESI-MS spectrum of PAI-2 ∆CD-loop (Figure 2.4) shows a pattern of multiply
charged ions (13+ to 16+) in the m/z range of 2700–3500 consistent for the 45 kDa
monomeric species. The calculated molecular weight of 44496.72 Da is in agreement
with the theoretical monoisotopic molecular weight of 44480.16 Da. In addition, five
higher charge states (20+ to 24+) from m/z 3,700 – 4,500 representing an 89 kDa
dimeric species were also observed, this may correspond to the high molecular weight
bands observed when PAI-2 ∆CD-loop was analysed under non-reducing conditions
by SDS-PAGE (Figure 2.2B).

2.3.3 THE ABSENCE OF THE CD-LOOP DOES NOT AFFECT THE SOLUTION
PHASE OR CELL SURFACE UPA ACTIVITY INHIBITORY FUNCTION OF PAI-2

To ensure that PAI-2 ∆CD-loop retained uPA inhibitory activity, a 2-fold molar
excess of PAI-2 ∆CD-loop was incubated with uPA and analysed by SDS-PAGE
under reducing conditions (Figure 2.5A). A band at ~70 kDa was observed
corresponding to covalently complexed uPA:PAI-2 ∆CD-loop (whilst the expected
size of the uPA:PAI-2 complex is ~95 kDa, under reducing conditions the A-chain of
uPA is not present in the complex. Additionally, western blotting of this complex
formation using a monoclonal antibody to uPA showed no free uPA remained after
incubation (Figure 2.5B). PAI-2 ∆CD-loop and PAI-2 wild-type gave superimposable kinetic inhibition curves for HMW-uPA in solution (Figure 2.5C),
confirming that the absence of the CD-loop does not affect uPA inhibitory activity of
PAI-2. Di Giusto et al. (2005) showed that his-tagged PAI-2 ∆CD-loop had the same
second order rate constant for uPA inhibition in solution (2.40 × 106 M-1 s-1) as the
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Figure 2.4: A positive ion ESI-MS of PAI-2 ∆CD-loop from pQE9 in 10 mM ammonium acetate (pH 6.8) containing 0.1% formic
acid. The m/z spectrum shows a Gaussian-type distribution of multiply charged ions ranging from m/z 2700 – 4500. Charge states are
indicated. The monomeric (A) and dimeric (B) forms of the protein gave a measured molecular mass of 44496 Da (± 0.89) and 88961 Da
(± 0.84), respectively. Mass was calculated using MassLynx MS software (Waters) and caesium iodide was used for external calibration.
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Figure 2.5: PAI-2 ∆CD-loop efficiently inhibits both solution phase and cell bound uPA
activity. (A) PAI-2 ∆CD-loop is able to form SDS stable complexes with uPA. PAI-2 ∆CDloop was incubated in a 2:1 molar ratio with HMW-uPA for 30 min and analysed SDS-PAGE
under reducing conditions. (B) Western blot analysis of complex formation between uPA and
PAI-2 ∆CD-loop using a monoclonal antibody to the B-chain of uPA (~30 kDa), indicating
that no residual uPA remains in the sample. (C) Kinetic inhibition curves for PAI-2 wild-type
(dark red) versus PAI-2 ∆CD-loop (bright pink) against HMW-uPA in solution. The uPA
fluorogenic substrate was briefly pre-incubated with the PAI-2 forms or buffer alone (open
circles) and the assays initiated by the addition of HMW-uPA. Fluorescence units were
converted to a percentage of the maximal (uninhibited) uPA activity. Values shown are the
means of triplicate determinations. Errors (< 10%) are not shown for clarity of
presentation. (D) U937 cells were incubated with uPA fluorogenic substrate in the absence or
presence of PAI-2 wild-type (filled bars) or PAI-2 ∆CD-loop (open bars) for 1 h at 37°C.
Fluorescence units were converted to a percentage of the maximal (uninhibited) uPA activity.
Values shown are means ± SEM (n = 3). *p < 0.001 compared to inhibited samples for both
PAI-2 forms.
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published wild-type non-recombinant form. Moreover, we show that the inhibitory activity of
both variants was also identical towards cell surface receptor bound uPA as there were no
significant differences seen between the two PAI-2 forms (Figure 2.5D).

2.3.4 REMOVAL OF THE CD-LOOP DOES NOT AFFECT THE CLEARANCE OF UPA
FROM THE CELL SURFACE

Preliminary dot-blot analysis suggested that removal of the CD-loop of PAI-2 has no impact
on the interaction between the uPA:PAI-2 complex and members of the LDLR family
(Croucher et al. 2006). Surface plasmon resonance was thus used to measure the affinity of
uPA complexed with PAI-2∆CD-loop or PAI-2 wild-type for the endocytosis receptor
VLDLR (Figure 2.6). Both gave similar on (ka) and off (kd) rates and the affinity constant
(KD) of both uPA:PAI-2 ∆CD-loop and uPA:PAI-2 wild-type for VLDLR was found to be ~5
nM (Table 2.2) with these interactions both best fitting a 1:1 binding model. No interaction
was observed between VLDLR and either PAI-2 ∆CD-loop or PAI-2 wild-type alone
(Table 2.2).

Additionally, when complexed with uPA, both PAI-2 wild-type and PAI-2 ∆CD-loop lead to
an almost two-fold increase in the amount of uPA endocytosed by MCF-7 cells relative those
treated with uPA alone (Figure 2.7). Importantly, there was no significant difference between
cells treated with uPA:PAI-2 wild-type and uPA:PAI-2 ∆CD-loop. Pre-treatment of cells
with the LDLR antagonist RAP significantly reduced the amount of uPA internalised in all
treatments (Figure 2.7).
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Figure 2.6: Surface plasmon resonance analysis of the interaction between uPA:PAI-2
wild-type and uPA:PAI-2 ∆CD-loop and VLDLR. Samples were injected at a rate of 20
µL.min-1 at concentrations of 100 nM, 50 nM, 25 nM, 12,5 nM and 2.35 nM. Data is
representative of at least three experiments.
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Table 2.2: Kinetic parameters of the interaction between PAI-2 ∆CD-loop or PAI-2 wild-type and VLDLR, both alone and in complex
with uPA.
Analyte
PAI-2 wild-type

Binding

ka
-1 -1

kd

KD

-1

Model

(M s )

(s )

(nM)

No binding

-

-

-

3.75 × 105

1.44 × 10-3

4.81

(± 1.1 × 105)

(± 0.39 × 10-3)

(± 0.64)

-

-

-

4.16 × 105

1.36 × 10-3

4.34

uPA:PAI-2 wild-type

1:1

PAI-2 ∆CD-loop

No binding

uPA:PAI-2 ∆CD-loop

1:1

5

χ2
4.71

-

3.28

-3

(± 0.23 × 10 )
(± 0.56)
(± 1.8 × 10 )
Values were determined using surface plasmon resonance. Binding data was fitted using the BIAevaluation 4.0 software. The binding model
chosen represents that with the lowest χ2 value. (Values are the average ± SEM, n = 3).
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Figure 2.7: Cellular internalisation of uPA is equivalent between PAI-2 wild-type and
PAI-2 ∆CD-loop as determined by flow cytometry. MCF-7 cells were incubated with 10
nM uPA:Alexa488, either alone or in complex with PAI-2 wild-type or PAI-2 ∆CD-loop for 1
h at 37°C. Any surface bound uPA:Alexa488 remaining was quenched by incubation with
4 µg.mL-1 anti-Alexa488 polyclonal antibody for 30 min prior to analysis by dual colour flow
cytometry. Values shown are means ± SEM (n = 3) as a percentage of uPA only treatment. *
p < 0.005 compared to internalisation in the absence of RAP for each treatment.
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2.4 DISCUSSION
As introduced in Section 1, the 33 amino acid CD-loop of PAI-2 is the largest amongst
known serpins. Whilst seven other members of the clade B serpin family contain a CD-loop
(SerpinB3, SerpinB4, SerpinB7, SerpinB10, SerpinB11, SerpinB12 and SerpinB13), the only
described function of this domain (other than those proposed for PAI-2) is in SerpinB10,
where the CD-loop contains a nuclear import sequence (Chuang and Schleef 1999). Much of
the previous work describing the role of the CD-loop of PAI-2 in an intracellular context is
controversial, as discussed in Section 1.3.2.3. The CD-loop is involved in transglutaminase
mediated cross-linking to cellular and ECM proteins (Jensen et al. 1994; Jensen et al. 1996),
although the functional significance of this crosslinking is unknown. Interestingly, crosslinked PAI-2 maintains uPA inhibitory activity.

Lobov et al. (2004) and Wilczynska et al. (2003) found that, when purified, a fraction of histagged PAI-2 was always cleaved, with this cleavage occurring in the CD-loop at positions
Phe76-Thr77, Gly80- Phe81, Phe81-Met82 and Ala93-Ile94. This CD-loop cleaved conformation
accounts for the band observed at approximately 36 kDa in the purified sample (Figure 2.2A,
lane 3). Furthermore, Lobov et al. (2004) and Wilczynska et al. (2003) reported that this
cleavage of the CD-loop did not result in a loss of uPA inhibitory activity. Di Giusto et al.
(2005) previously showed that his-tagged PAI-2 ∆CD-loop had the same second order rate
constant for uPA (2.40 × 106 M-1 s-1) as the published wild-type non-tagged PAI-2 providing
further evidence that the CD-loop of PAI-2 plays no role in the inhibition of uPA in vitro.
The results presented here go further than previous studies, comparing not only the solutionphase uPA inhibitory properties of PAI-2 wild-type and PAI-2 ∆CD-loop directly, but
showing that the CD-loop of PAI-2 plays no role in uPA inhibition in the more
physiologically relevant setting of the cell surface. This is to be expected as the majority of
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serpin sequence deviation occurs in the loops joining secondary structures (Irving et al.
2000). Moreover, the intrahelical CD-loop is absent and hence not required for function in
inhibitory serpins of all other clades (Silverman et al. 2004). Intramolecular distance
measurements indicate that the CD-loop of PAI-2 in the monomeric form is folded to the side
of the molecule (Lobov et al. 2004) (Figure 2.8), away from the domains of the protein
involved in protease inhibition (namely the RCL, β-sheet A and other residues previously
deemed as important as reviewed by Gettins (2002)), further suggesting that the CD-loop
plays no role in substrate recognition or translocation of the protease with the RCL across the
helix-F face of PAI-2 to the base of the molecule.

Additionally, the findings presented here indicate that the use of PAI-2 ∆CD-loop is
advantageous compared to PAI-2 wild-type due to superior purity and yield of the
recombinant protein under identical conditions. A lower amount of contaminating proteins
were co-purified in the PAI-2 ∆CD-loop purification than PAI-2 wild-type. As western
blotting with a monoclonal antibody to PAI-2 (and previous experiments using a PAI-2
polyclonal antibody, data not shown) indicated that the additional protein bands co-purified
with PAI-2 wild-type did not contain breakdown products of PAI-2, they may be of bacterial
origin. Moreover, as these proteins are negligible in the PAI-2 ∆CD-loop sample, it is
feasible that these proteins may co-purify with PAI-2 wild-type via interactions with the CDloop.
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Figure 2.8: Hypothesised location of the CD-loop of PAI-2 based on intramolecular
distance measurements. In the stable monomeric form of PAI-2, the CD-loop is believed to
fold to the side of the molecule. The precise structure of the CD-loop has not been determine
by X-ray crystallography and the conformation shown here is a prediction. Numbers and
green spheres show locations of cysteine residues used in triangulation measurements. Figure
from Lobov et al. (2004).
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Previous studies expressing PAI-2 ∆CD-loop from E. coli have generally used the pET15b
plasmid in the BL21 Star (DE3) E. coli expression strain. Recloning of the cDNA encoding
for PAI-2 ∆CD-loop lacking the 3’ untranslated region, which has been shown to contain
mRNA instability regions (Maurer and Medcalf 1996), into pQE9 is one of the potential
reasons for the increased yield and purity of PAI-2 ∆CD-loop when purified under optimised
conditions from the pQE9 verses the pET15b vector system. A lower concentration of
imidizole was used in the binding and wash buffers during the purification of PAI-2 ∆CDloop from pQE9 relative to pET15 as pET15b/PAI-2 ∆CD-loop encodes for a thrombin
recognition sequence between the six histadine residues and the first amino acid of PAI-2
∆CD-loop which serves as a ‘linker’, extending the his-tag away from α- helix A PAI-2
∆CD-loop and leading to a slightly increased affinity for the TALON resin.

SDS-PAGE under non-reducing conditions and mass spectrometry of purified PAI-2 ∆CDloop indicated the presence of a dimeric form of PAI-2 ∆CD-loop. Whilst the CD-loop of
PAI-2 controls the ability of PAI-2 to polymerise, Lobov et al. (2004) showed that whilst less
polymergenic than PAI-2 wild-type, PAI-2 ∆CD-loop was still able to form dimers and
higher order aggregates. Serpins have been shown to polymerise via the insertion of a portion
of the RCL into β-sheet A or into β-sheet C of another serpin molecule (Chang et al. 1997).
As insertion of the RCL into β-sheet C requires the ‘recipient’ serpin to convert to the latent
conformation and PAI-2 is known not to convert to this state, formation of PAI-2 ∆CD-loop
dimmers cannot be explained via this mechanism. However, it is possible that PAI-2 may
form polymers via a CD-loop independent mechanism involving insertion of the RCL into βsheet A.
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Using a non-tagged, PAI-2 wild-type produced and purified in an alternative, mass
production scale procedure, Croucher et al. (2007) showed that PAI-2 wild-type did not
interact directly with VLDLR and that the interaction between uPA:PAI-2 wild-type and
VLDLR was mediated solely by the uPA moiety of the complex. As introduced in Section
1.4.1, LDLRs generally bind regions of basic charge on ligands. Whilst the CD-loop is
largely electroneutral, containing only one lysine and two glutamic acid residues, it may have
been possible that the CD-loop was able to block potential LDLR binding residues in PAI-2,
that would be revealed upon removal of the CD-loop. However, kinetic analysis of PAI-2
∆CD-loop both alone and in complex with uPA gave identical values to PAI-2 wild-type,
indicating that removal of the CD-loop had no impact on VLDLR binding. Furthermore,
removal of the CD-loop of PAI-2 had no impact on the internalisation of uPA:PAI-2 ∆CDloop relative to uPA:PAI-2 wild-type, suggesting that the CD-loop of PAI-2 plays no role in
the VLDLR mediated internalisation of these complexes.

PAI-2 ∆CD-loop represents a desirable starting material for the development of PAI-2 based
uPA targeted cancer therapies. Tumour uptake increases as protein size is decreased (Thomas
et al. 1989), suggesting that this shortened but fully active form of PAI-2 may not only be
simpler to express and purify than PAI-2 wild-type, but also exhibit a favourable
pharmacokinetic profile. Pharmacokinetic and bio-distribution studies have suggested that the
half life of PAI-2 wild-type in mice is quite short (< 2 min) (Hang et al. 1998) and this is not
significantly changed by removal of the CD-loop (Dr Kara Perrow, personal
communication), indicating that additional modifications are required to both PAI-2 species
to increase protein half life and increase tumour uptake. Nevertheless, the ease of purification
of PAI-2 ∆CD-loop makes it the preferential target upon which to optimise this property. The
ability of PAI-2 ∆CD-loop to target and clear uPA from the cell surface in a manner
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indistinguishable from PAI-2 wild-type combined with improved purification simplicity and
protein yield makes the use of PAI-2 ∆CD-loop favourable when studying the uPAdependent functions of PAI-2. Additionally, as the VLDLR binding profile of PAI-2 ∆CDloop is identical to PAI-2 wild-type, this protein form may also prove useful in the further
characterisation of the LDLR-dependent functionality of PAI-2.
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CHAPTER 3
CHARACTERATION OF THE DIFFERENTIAL
LDLR BINDING PROFILES OF PAI-1 AND PAI-2
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3.1 INTRODUCTION
PAI-1 and PAI-2 both efficiently inhibit uPA (Thorsen et al. 1988). As inhibitory members of
the serpin protein family, PAI-1 and PAI-2 exhibit an irreversible inhibitory mechanism and
conform to a strongly conserved structure (as discussed in Section 1.3.1) despite significant
variation in peptide sequence. Upon inhibition of uPAR-bound uPA, uPA:PAI complexes are
rapidly cleared via receptor mediated endocytosis mediated by LDLRs and delivered to
endosomes and lysosomes (Argraves et al. 1995; Al-Ejeh et al. 2004; Croucher et al. 2006).

Whilst PAI-1 has been shown to bind directly to LRP1, VLDLR, LRP2 and sorLA (Kounnas
et al. 1993; Nykjaer et al. 1994; Stefansson et al. 1995; Horn et al. 1997; Gliemann et al.
2004; Croucher et al. 2007), previous studies have shown that PAI-2 does not bind directly to
LDLRs, namely LRP1 (Croucher et al. 2006) and VLDLR (Croucher et al. 2007).
Additionally, the interaction between uPA:PAI-2 and these LDLRs is markedly different to
that of uPA:PAI-1 in terms of both affinity and mechanism (Croucher et al. 2006; Skeldal et
al. 2006; Croucher et al. 2007). Croucher et al. (2007) previously modelled the electrostatic
surface potential of both PAI-1 and PAI-2 in and around α-helix D, noting differences in the
alkalinity of the region surrounding R76 of PAI-1 and the corresponding residue in PAI-2
(R108). As LDLRs bind to target proteins via electrostatic interactions mediated by negatively
charged regions receptor and positive regions in the ligand (Lillis et al. 2005; Fisher et al.
2006), this may explain the differential LDLR binding of PAI-1 and PAI-2 to LDLRs.
Numerous studies have identified several positively charged residues within (R76, K80) and
nearby (K88, R118, K122) the α-helix D of PAI-1 that contribute to the high-affinity binding of
uPA:PAI-1 with LDLRs (Horn et al. 1998; Rodenburg et al. 1998; Stefansson et al. 1998;
Skeldal et al. 2006). In addition, the α-helix D of PAI-1 contains a proposed LDLR minimal
binding motif of two basic residues separated by two to five residues and N-terminally
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flanked by hydrophobic residues (Jensen et al. 2006) (Figure 3.1A). This motif facilitates the
high affinity interaction of a number of LDLR binding proteins, such as RAP (Figure 3.1B).
Previous analyses suggest that the decreased affinity of uPA:PAI-2 for LDLRs is likely due
to an incomplete LDLR binding motif within α-helix D of PAI-2, in which the first
hydrophobic/basic amino acid pair is conserved, whilst the second pair is replaced by serine
residues (Croucher et al. 2007) (Figure 3.1C, D and E). Indeed, previous studies using a
mutant form of PAI-1 with an incomplete LDLR binding motif (R76E) observed decreased
LRP1 and VLDLR binding affinity (Stefansson et al. 1998; Webb et al. 2001; Croucher et al.
2007). Whilst these differences in receptor binding may appear trivial, they underpin stark
differences in the biological actions of PAI-1 and PAI-2.

The lack of an LDLR binding site in PAI-2 facilitates the removal of cell surface uPA and
hence proteolytic activity, without activation of the pro-mitogenic/motogenic signalling
pathways associated with PAI-1 (Croucher et al. 2007; Croucher et al. 2008). As introduced
in Section 1.4.3, the binding of uPA:PAI-1 to VLDLR results in increased cell growth in
MFC-7 cells (Webb et al. 2001) and increased expression of MMP-2 and MMP-9 in
SGC7901 cells (Di et al. 2010) via sustained activation of the MAPK/ERK signalling
pathway. Webb et al. (2001) demonstrated that this activity was dependent on the interaction
between the PAI-1 moiety of the complex and VLDLR as both ERK signalling and cell
proliferation were reduced to levels similar to controls when treated with uPA:PAI-1 R76E.
Croucher et al. (2007) found that the affinity of uPA:PAI-1 R76E for VLDLR (9.95 nM) was
almost 10-fold lower than uPA:PAI-1 and was best described by a 1:1 binding model similar
to uPA:PAI-2.
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Figure 3.1: The LDLR minimal binding motif in PAI-1 is not conserved in PAI-2. The
proposed LDLR minimal binding motif consists of two basic amino acids N-terminal flanked
by hydrophobic residues and separated by 2-5 residues. These residues bind to acid residues
coordinated with tryptophan on the receptor. (B) The LDLR-binding interface of RAP
showing two lysine residues and the flanking hydrophobic residues. (C) Alignment of α-helix
D and adjacent residues of PAI-1 and PAI-2. The LDLR minimal binding motif in PAI-1 is
underlined and residues previously reported to mediate binding of PAI-1 to LDLRs coloured.
(D) Location of the LDLR binding motif in α-helix D of PAI-1 and (E) the corresponding
residues in PAI-2. Structure analysis performed using PyMol (DeLano 2002), and structural
coordinates for RAP (1LRE (Nielsen et al. 1997)), PAI-1 (9PAI (Aertgeerts et al. 1995)) and
PAI-2 (1JRR (Jankova et al. 2001)).
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The results described in this chapter show that by replacing residues of PAI-2 with those
corresponding to LDLR binding sites in PAI-1, LDLR binding can be introduced to PAI-2.
Interestingly, the mutations required to introduce binding differ for VLDLR and LRP1. This
provides important insights into the differences in the mechanisms of uPA:PAI-1 and
uPA:PAI-2 endocytosis (and downstream functionality, which will be discussed in Chapter
4), the proposed LDLR minimal binding motif and the differing binding specificities of LRP1
and VLDLR.

Whilst a robust, reproducible methodology for the production and purification of PAI-2
∆CD-loop was described in Chapter 2, the 6 × his-tag present at the N-terminus of PAI-2
∆CD-loop produced in this system cannot be removed. Whilst the presence of this tag has no
impact on the uPA and LDLR dependent function of PAI-2, the use of PAI-2 ∆CD-loop in
future applications (such as animal testing or crystallography) may require removal of the 6 ×
his-tag. To this end, PAI-2 ∆CD-loop cDNA was ligated into the TAGzyme pQE1 vector
(QIAGEN, Hilden, Germany). According to the manufacturer, this vector is optimised for the
removal of 6 × his-tags by a novel dipeptidase. The vector and expression system do not
differ significantly from pQE9, and as such the already optimised expression and purification
protocols used in the production of PAI-2 ∆CD-loop from this system (Section 2.2.5) may be
utilised.
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3.2 MATERIALS AND METHODS
3.2.1 MATERIALS
PCR MasterMix was from Promega (Madison, WI, USA). TAGzyme pQE1 vector,
TAGzyme enzyme kit and anti-pentahis antibody were from QIAGEN (Hilden, Germany).
Oligonucleotide

primers

were

from

Geneworks

(Adelaide,

Australia).

Lambda

DNA/EcoRI+HindIII molecular weight markers, HindIII and PvuII restriction enzymes were
from Fermentas (Vilnius, Lithuania). QuikChange site-directed mutagenesis kit was from
Stratagene. PAI-1 14-1B stable mutant was from Molecular Innovations (Novi, MI, USA).
The PAI-1 14-1B stable mutant contains four mutations (N150H/K154T/Q319L/M354I) that
increase the functional stability of PAI-1 without significantly altering the rate of inhibition
of uPA or tPA (Berkenpas et al. 1995). Human purified placental LRP1 was a kind gift from
Prof. Phillip Hogg (University of New South Wales, Sydney, Australia). SnakeSkin dialysis
tubing with a nominal 3.5 kDa molecular weight cut off was from Pierce (Rockford, IL,
USA).

3.2.2 AGAROSE GEL ELECTROPHORESIS
Agarose gel electrophoresis was conducted using a 1% agarose gel (Appendix I) in 1 × TAE
buffer (Appendix I) at 100 V for 1 h in a MiniSub Cell GT electrophoresis tank (BioRad,
Hercules, CA, USA). DNA in the gel was visualised using a UVP BioImaging System (UVP,
Upland, CA, USA) after staining with 0.5 mg.mL-1 ethidium bromide for 30 min. To allow
for size estimation of observed DNA bands, standard curves for each gel were constructed
using Lambda DNA/EcoRI+HindIII molecular weight markers (Appendix IV).
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3.2.3 CONSTRUCTION AND CHARACTERISATION OF TAGZYME pQE1/PAI-2 ∆CDLOOP

pQE9 does not encode a protease cleavage site for the removal of the his-tag from the Nterminus of PAI-2 ∆CD-loop. Whilst the presence of the 6 × his-tag has no impact on the
uPA-dependent and LDLR-dependent functionalities of PAI-2, future work may require
removal of this tag. To this end, PAI-2 ∆CD-loop cDNA was recloned into the vector
TAGzyme pQE1, which is similar to pQE9 but allows for the removal of the 6 × his-tag
using the TAGzyme system.

3.2.3.1 Amplification of PAI-2 cDNA
PAI-2 ∆CD-loop cDNA (type A) was amplified from pQE9/PAI-2 ∆CD-loop using Pfu HS
Fusion II DNA polymerase and the oligonucleotide primers ‘pQE1 PAI-2 Up’ and ‘pQE1
PAI-2 Down’ (Table 3.1). The PCR parameters used were: initial denaturing step 95ºC for 2
min, 30 cycles of denaturing at 95ºC for 10 s, annealing at 55ºC for 20 s, extension at 72ºC
for 1 min, followed by a final extension step of 72ºC for 3 min. Successful amplification was
assessed by agarose gel electrophoresis. To allow for ligation into TAGzyme pQE1, the
‘pQE1 PAI-2 Down’ primer contained a HindIII recognition sequence and the ‘pQE1 PAI-2
Up’ primer was 5’ phosphorylated. Purified PCR product was digested with HindIII (37°C
for 2 h) and TAGzyme pQE1 digested with HindIII and PvuII (37°C for 2 h), as advised by
the manufacturer. Ligation with T4 DNA ligase was conducted as per manufacturer’s
instructions and 1 µL from the ligation reaction used to transform electrocompletent E coli.
JM109.
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Table 3.1: Oligonucleotides used for vector construction, sequencing and mutagenesis.
P = phosphate group. Mutating codons are underlined.
Primer name

Sequence

Direction

pQE1 PAI-2 Up

5’-P-ATGGAGGATCTTTGTGTGGC-3’

Forward

pQE1 PAI-2 Down

5’-GCGCAAGCTTTTAGGGTGAGGAAAATCTGC-3’

Reverse

PAI-2 cDNA amplification primers

Colony PCR Screening Primers
pQE promoter

5’-CCCGAAAAGTGCCACCTG-3’

Forward

S2 reverse

5’-CCTTTGGTTTGAGTCTTGAC-3’

Reverse

N101K sense

5’-GAAGTGGGAGCCGCTGCAAAGAAAATCCATTCATCCTTCC-3’

Forward

N101K antisense

5’-GGAAGGATGAATGGATTTTCTTTGCAGCGGCTCCCACTTC-3’

Reverse

S112K sense

5’-CATCCTTCCGCTCTCTCAGCAAGGCAATCAATGCATCCACAGG-3’

Forward

S112K antisense

5’-CCTGTGGATGCATTGATTGCCTTGCTGAGAGAGCGGAAGGATG-3’

Reverse

5’-CATTCATCCTTCCGCTCTCTCTATAAGGCAATCAATGCATCCAC-3’

Forward

5’-GTGGATGCATTGATTGCCTTATAGAGAGAGCGGAAGGATGAATG-3’

Reverse

N120K sense

5’-CAATCAATGCATCCACAGGGAAGTATTTACTGGAAAGTGTCAATAAG-3’

Forward

N120K antisense

5’-CTTATTGACACTTTCCAGTAAATACTTCCCTGTGGATGCATTGATTG-3’

Reverse

Site-directed Mutagenesis Primers

S111Y/S112K
sense
S111Y/S112K
antisense
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3.2.3.2 Colony PCR
To determine if the PAI-2 ∆CD-loop cDNA had successfully ligated into TAGzyme pQE1,
bacterial colonies were screened via colony PCR. The PCR reaction was made as follows: 3.5
µL PCR Master Mix, 1 µM each of ‘pQE promoter’ primer and ‘S2 reverse’ primer (Table
3.1) and dH2O to a final volume of 7 µL. A single colony from the culture plate was added to
the reaction tube, resuspended and run at the following PCR parameters: intial denaturing
step, 95°C 2 min; 30 cycles, 95°C 30 s, 55°C 30 s, 72°C 1 min and a final extension step,
72°C 5 min. Reaction product was observed via agarose gel electrophoresis, with positive
vector construction indicated by amplification of a ~ 700 base pair band, corresponding to the
distance between the ‘pQE promoter’ and ‘S2 reverse’ primers. Plasmid DNA from these
colonies was extracted and the plasmid sequenced (as described in Section 2.2.3) to confirm
successful construction. PAI-2 ∆CD-loop was expressed and purified as described in Section
2.2.4.

3.2.4 SMALL-SCALE HIS-TAG REMOVAL
Optimisation of tag removal was carried out using 50 µg of PAI-2 ∆CD loop. As PAI-2
∆CD-loop does not contain an intrinsic DAPase stop point, Qcyclase was used so that the
DAPase would stop digestion at the glutamine residue directly before the PAI-2 ∆CD loop
sequence. PAI-2 ∆CD loop was buffer exchanged into 1 × TAGZyme buffer (20 mM sodium
phosphate, 150 mM NaCl, pH 7.0) using a PD-10 column immediately before the reaction.
50 µg of PAI-2 ∆CD loop was incubated with 2.5 mU DAPase, 150 mU Qcyclase and 80 µM
Cysteamine.HCl in a final volume of 50 µL. The reaction carried out at 37° C for 60 min.
Samples were taken from the reaction at 10 min time points and fractionated by SDS-PAGE,
western blotted to PVDF membrane and probed for the presence of histadine tagged protein
using a pentahis antibody.
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3.2.5 PROTEIN STRUCTURE MODELLING
Molecular modelling and figure preparation was performed using structural co-ordinates
obtained from X-ray crystal structures of the relaxed conformations of PAI-1 (Aertgeerts et
al. 1995) (PDB file 9PAI) and PAI-2 (Jankova et al. 2001) (PDB file 1JRR) and the PyMol
molecular graphics program.

3.2.6 SITE DIRECTED MUTAGENESIS
Residues of PAI-2 were replaced with the corresponding residues of PAI-1 on the pQE9/PAI2 ∆CD-loop backbone using the primers described in Table 3.1. The PAI-2 ∆CD-loop
backbone was used as removal of the CD-loop of PAI-2 allows for easier purification of
protein without compromising the inhibitory activity or LDLR binding affinity of PAI-2
(Chapter 2). Control PAI-2 ∆CD-loop protein will hence be referred to as PAI-2 in this study.
Initially, site directed mutagenesis was attempted using the Quickchange II kit to replace
specific residues of PAI-2 with the corresponding residues from PAI-1. However, after
numerous attempts, no mutagenesis product was produced in any of the reactions carried out.
As such, an alternative mutagenesis protocol was employed, based on a protocol described by
Higuchi et al. (1988) (Figure 3.2). This methodology involved the use of the primers
described in Table 3.1, but PCR of only the cDNA to be mutagenised, rather than
amplification of the entire plasmid. This methodology consisted of an initial step producing
two, overlapping DNA fragments, both containing the desired mutation. These fragments
were generated using separate reactions consisting of 100 ng template DNA, 0.2 µM of each
primer (one amplification primer and one mutagenesis primer), 25 mM dNTPs, 5 µL 10 ×
PfuUltra II reaction buffer, 1 µL PfuUltra II Fusion HS DNA polymerase in a 50 µL reaction.
Reactions were conducted in a PCR thermocycler (Eppendorf, Hamburg, Germany) using the
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pQE1 PAI-2 Up primer

Sense primer
cDNA to be mutated
pQE1 PAI-2 Down primer

Anti-sense primer

PCR

5’ fragment

3’ fragment

PCR with pQE1 PAI-2 Up and
pQE1 PAI-2 Down primers

Complete cDNA including mutations

Figure 3.2: Schematic diagram of modified site directed mutagenesis used to produce
PAI-2 mutants, based on the method of Higuchi et al. (1988). TAGzyme pQE1/PAI-2 ∆CDloop was used as the cDNA template, and the UP and DOWN primers were ‘pQE1 PAI-2
Up’ and ‘pQE1 PAI-2 Down’, respectively, as described in Table 3.1. Red sections denote
codon/s to be mutagenised.

following parameters: initial denaturing step 95ºC for 2 min, then 40 cycles of denaturing at
95ºC for 10 s, annealing at 55ºC for 20 s, extension at 72ºC for 1 min, followed by a final
extension step of 72ºC for 3 min. The overlapping PCR products were purified by agarose gel
electrophoresis using a WizardSV Gel and PCR Clean-Up System. In order to produce the
full length PAI-2 cDNA including the desired mutation, 1 µL of each of the purified PCR
products was added to a new reaction containing only the ‘pQE1 PAI-2 Up’ and ‘pQE1 PAI-
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2 Down’ primers and the PCR protocol repeated as previous. The resulting PCR product was
purified via agarose gel electrophoresis, digested with HindIII (5 U, 1 h at 37°C) and ligated
into TAGzyme pQE1 as described in section 3.2.3.1. Constructs were screened using colony
PCR (Section 3.2.3.2) and sequenced (Section 2.2.3) to confirm successful residue mutation.
As for PAI-2 ∆CD-loop, PAI-2 mutants were expressed and purified as described in Section
2.2.4.

3.2.7 SURFACE PLASMON RESONANCE
Surface plasmon resonance was performed essentially as previously described (Croucher et
al. 2006; Croucher et al. 2007). VLDLR or LRP1 were loaded onto CM5 BIAcore sensor
chips to a level of ~2000 response units (Appendix VI). Analytes were diluted into BIAcore
running buffer (Appendix I) and ran over the chip at 20 µL/min. Between samples, the sensor
surface was regenerated with 100 mM H3PO4. Data was analysed using BIAevaluation
software (Version 4), using a blank cell as the reference cell. Where multiple CM5 chips
were used, results were validated against control chips and samples to ensure reproducibility.

3.2.8 FAR-UV CIRCULAR DICHROISM SPECTROMETRY
The structural integrity of PAI-2 constructs was assessed using far UV circular dichroism
(CD) spectroscopy to determine if the replacement of residues of PAI-2 with those of PAI-1
resulted in significant secondary structural changes. Proteins were buffer exchanged into 10
mM sodium phosphate by dialysis and diluted to a concentration of 0.4 mg.mL-1. CD
spectroscopy was performed using a J-810 spectropolarimeter (Jasco, Tokyo, Japan)
equipped with a thermoelectric temperature control at 25°C. Spectra were collected from 190
nm to 240 nm at 1 nm intervals, with each spectrum representing the average of ten scans,
with a sample of 10 mM sodium phosphate serving as a reference.
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3.2.9 uPA ACTIVITY ASSAY
To ensure that mutagenesis of PAI-2 did not result in any changes in uPA inhibition, PAI-2
mutants were tested as described in Section 2.2.11.

3.3 RESULTS
3.3.1 CONSTRUCTION AND CHARACTERISATION OF TAGZYME PQE1/PAI-2 ∆CDLOOP

3.3.1.1 Construction of TAGzyme pQE1/PAI-2 ∆CD-loop
In order to generate TAGzyme pQE1/PAI-2 ∆CD-loop, PAI-2 ∆CD-loop cDNA was
amplified from pQE9/PAI-2 ∆CD-loop using the ‘pQE1 PAI-2 Up’ and ‘pQE1 PAI-2 Down’
primers as described in section 3.2.3.1. The reaction product was analysed by agarose gel
electrophoresis (Figure 3.3A) to determine if amplification was successful. A single band at
approximately 1100 base pairs corresponding to the expected size of PAI-2 ∆CD-loop cDNA
was observed. The band was purified from the gel and ligated into TAGzyme pQE1. The
ligation reaction was transformed into E coli. JM109. Colonies were screened for correct
ligation of PAI-2 ∆CD-loop cDNA into TAGzyme pQE1 by colony PCR using the ‘pQE
promoter’ and ‘PAI-2 S2R primers’. Potential successful construction of TAGzyme
pQE1/PAI-2 ∆CD-loop was observed in 10 of the 12 colonies analysed as indicated by the
presence of a ~ 700 base pair DNA band in these samples (Figure 3.3B). Sequence analysis
indicated that PAI-2 ∆CD-loop cDNA was correctly inserted in TAGzyme pQE1, contained
no mutations and was confirmed as type A (ie. with N120, N404 and S413) (Figure 3.4).
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Figure 3.3: Agarose gel electrophoresis indicating successful construction of TAGzyme
pQE1/PAI-2 ∆CD-loop. (A) PCR amplification of PAI-2 ∆CD-loop cDNA yielded a band
of ~ 1100 base pairs, corresponding to the molecular weight of PAI-2 ∆CD-loop cDNA. (B)
Colony PCR screen of E. coli colonies subsequent to transformation with TAGzyme
pQE1/PAI-2 ∆CD-loop ligation mix. Succesful insertion of PAI-2 ∆CD-loop cDNA into
TAGzyme pQE1 was observed in most colonies screened, as indicated by the presence of an
~700 base pair band. M = Lambda DNA/EcoRI+HindIII molecular weight markers.
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Figure 3.4: Sequence analysis of TAGzyme pQE1/PAI-2 ∆CD-loop (type A). Plasmid
sample was extracted from transformed E. coli and sequenced as described in section 2.2.3.
Sequence analysis performed using the BioEdit analysis program (Hall 1999). The predicted
translated product is shown beneath the DNA sequence.
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3.3.1.2 Purification of PAI-2 ∆CD-loop
As the general features of the pQE9 and TAGzyme pQE1 vectors are the same, PAI-2 ∆CDloop from TAGzyme pQE1/PAI-2 ∆CD-loop was expressed and purified as described in
Section 2.2.4. Throughout the purification process, samples were taken for subsequent
analysis by SDS-PAGE (Figure 3.5). All eluted fractions exhibited a major band at ~ 45 kDa,
correlating to the molecular weight of PAI-2 ∆CD-loop. Additional protein bands were also
present in the first elution fraction from the column, however the intensity of these bands was
significantly diminished in subsequent elution fractions whilst the total amount of protein
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Figure 3.5: Purification of PAI-2 ∆CD-loop by immobilised metal affinity
chromatography. PAI-2 ∆CD-loop was expressed in E. coli M15 [pREP4] and PAI-2 ∆CDloop purified using TALON resin. Samples from each stage of the purification process were
analysed by SDS-PAGE under reducing conditions to assess purification performance and
purity of eluted PAI-2 ∆CD-loop samples. Lane 1, crude cell lysate; lane 2, column loading
flow through; lane 3, wash buffer elution; lane 4-8, elution fractions.
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eluted remained relatively constant over the five fractions analysed by SDS-PAGE. Elution
fractions 2-5 (lanes 5-8 in Figure 3.5) were combined and buffer exchanged against PBS to
remove imidazole that may have impacted on further experiments. Yields of 10-15 mg of
protein per litre of culture were routinely achieved.

3.3.1.3 Small scale removal of 6 × his-tag
The vector TAGzyme pQE1 is designed to allow for the removal of the 6 × his-tag. Tag
removal was trialled on a small scale as suggested by the manufacturer over a period of 60
min. Western blot analysis of samples taken at 10 min time points indicated that the majority
of his-tag cleavage occurred in the first 10 min, as determined by a lack of reactivity to an
anti-pentahis antibody (Figure 3.6). After 60 min no reactivity to the anti-pentahis antibody
was observed, indicating that tag removal from PAI-2 ∆CD-loop was complete. Probing of
these same fractions with a monoclonal antibody for PAI-2 (3570, as described in section
2.2.6) indicated that no loss of protein from the fractions had occurred. However, attempts to
scale up this process did not result in successful tag removal.

Min

0
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20

30

40
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60

Antibody
pentahis

PAI-2

Figure 3.6: Small scale removal of the 6 × his-tag from PAI-2 ∆CD-loop expressed from
the TAGzyme pQE1 vector. PAI-2 ∆CD-loop was incubated with DAPase and Qcyclase for
the indicated time and probed with either an anti-pentahis or a PAI-2 antibody.
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As the presence of an N-terminus his-tag does not impact on the uPA and LDLR dependent
functions of PAI-2 (as demonstrated in Chapter 2 as PAI-2 proteins used retained N-terminal
his-tags), PAI-2 mutants generated to investigate the impact of complementing LDLR
binding to PAI-2 retained the 6 × his-tag. However, the option to subsequently remove the
his-tag was kept as future work may require generation of tag-less PAI-2.

3.3.2 STRUCTURAL COMPARISON INDICATES ABSENCE OF A CONSENSUS LDLRBINDING MOTIF IN PAI-2

The surface charge and topology of the region defining the consensus LDLR binding motif
on α-helix D of PAI-1 are clearly different to the corresponding region of PAI-2. Hence, the
differential binding to VLDLR and subsequent functional effects of PAI-1 and PAI-2 may be
due to an incomplete LDLR binding motif within PAI-2 (Croucher et al. 2008). To directly
investigate this residues of PAI-2 were substituted with those corresponding to the LDLR
binding motif within α-helix D of PAI-1, (Ehrlich et al. 1992; Horn et al. 1998; Stefansson et
al. 1998; Skeldal et al. 2006) (Figure 3.7A-C, Table 3.2). Specifically, S111 and S112 of PAI-2
were replaced with tyrosine and lysine respectively (corresponding to Y79 and K80 in PAI-1)

Table 3.2: PAI-2 mutants used to investigate the differential VLDLR and LRP1 binding
mechanisms of PAI-2 and PAI-1.
Protein
PAI-2 ∆CD-loop
PAI-2K1
PAI-2K2
PAI-2KK
PAI-2YK
PAI-2KYK
PAI-2YKK
PAI-1
1

Description
Amino acid residues 66-98 (CD-loop) deleted1
D101 in PAI-2 corresponds with K69 in PAI-1
S112 in PAI-2 corresponds with K80 in PAI-1
D101/S112 in PAI-2 corresponds with K69/K80 in PAI-1
S111/S112 in PAI-2 corresponds with Y79/K80 in PAI-1
D101/S111/S112 in PAI-2 corresponds with K69/Y79/K80 in PAI-1
S111/S112/N120 in PAI-2 corresponds with Y79/K80/K88 in PAI-1
Full length PAI-1

All PAI-2 mutants constructed on this backbone.
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Figure 3.7: Structural modelling of PAI-1 and PAI-2. (A) Amino acid sequence alignment
of the area in and adjacent to α-helix D of PAI-1 and PAI-2. Residues reported to be
important for the interaction between PAI-1 and LDLRs (Horn et al. 1998; Rodenburg et al.
1998; Stefansson et al. 1998; Skeldal et al. 2006) and the corresponding residues in PAI-2 are
coloured. The amino acid residues comprising the proposed LDLR minimal binding motif in
PAI-1 are underlined. (B,C) Ribbon representation and (D,E) surface representations of the
relative locations of PAI-1 residues implicated in LDLR binding and the corresponding
residues in PAI-2. Analysis performed using PyMol (DeLano 2002), PAI-1 (PDB file 9PAI
(Aertgeerts et al. 1995)) and PAI-2 (PDB file 1JRR (Jankova et al. 2001)).
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to generate PAI-2YK, completing an LDLR minimal binding motif (Figure 3.7A). To further
dissect the role of this LDLR minimal binding motif as well as other residues implicated in
the binding of PAI-1 to LDLRs, an panel of PAI-2 mutants were generated (Table 3.2, Figure
3.7A): PAI-2K1 (D101 of PAI-2 corresponds to K69 in PAI-1); PAI-2K2 (S112 of PAI-2
corresponds to K80 in PAI-1), PAI-2KK (D101K, S112K); PAI-2KYK (D101K, S111Y, S112K)
and PAI-2YKK (S111Y, S112K, N120K (N120 of PAI-2 corresponds to K88 of PAI-1). All PAI2 mutants were generated on the TAGzyme pQE1/PAI-2 ∆CD-loop backbone, sequenced to
ensure successful mutagenesis (Appendix V) and purified as described in Section 2.2.4 and
gave similar purification profiles to PAI-2 ∆CD-loop (Section 3.3.1.2).

3.3.3 LDLR BINDING CAN BE INTRODUCED TO PAI-2 BY COMPLEMENTATION OF
THE PAI-1 LDLR BINDING MOTIF

To investigate the molecular basis of the differential binding of PAI-1 and PAI-2 to LDLRs
residues of PAI-2 were substituted with those corresponding to PAI-1 previously identified as
important for LDLR binding. PAI-2 mutants (100 nM) were tested for the ability to bind to
VLDLR using surface plasmon resonance (Figure 3.8). Previous studies have demonstrated
that PAI-2 not in complex with uPA does not interact with either LRP1 of VLDLR (Croucher
et al. 2006; Croucher et al. 2007). Replacement of PAI-2 residues with the basic residues in
the α-helix D of PAI-1 important for LDLR binding, either in isolation (PAI-2K1, PAI-2K2) or
together (PAI-2KK) (Figure 3.7, Table 3.2) did not impact on binding to VLDLR (Figure 3.8,
Table 3.3). uPA-independent binding to VLDLR was only observed by PAI-2 mutants
containing a complete LDLR minimal binding motif (i.e. PAI-2YK and PAI-2KYK) (Figure
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Figure 3.8: Screening of PAI-2 mutants for VLDLR binding. Surface plasmon resonance
sensograms showing the interaction between 100 nM PAI-2 mutants and immobilised
VLDLR. Data shown is representative of at least three independent experiments.

3.8). Dose- dependent kinetic analysis gave affinity constants (KD) of 37.3 nM and 50.1 nM
for PAI-2YK and PAI-2KYK, respectively (Table 3.3). Kinetic analyses indicated that
interactions of uPA:PAI-2YK and uPA:PAI-2KYK with VLDLR were best described by a
heterogeneous analyte model with two independent, competing binding sites on the complex
with affinity constants (KD) of 1.35 nM and 70.1 nM for uPA:PAI-2YK; and 1.53 nM and 51.2
nM for uPA:PAI-2KYK (Figure 3.9C,D; Table 3.3). These values were similar to those
previously published for uPA:PAI-1 when analysed under comparable conditions (Skeldal et
al. 2006; Croucher et al. 2007). Kinetic analyses of uPA:PAI-2 binding to VLDLR confirmed
the single site binding model interaction (KD = 4.34 nM) (Figure 3.9B; Table 3.3). Croucher
et al. (2006) previously compared the differential binding interactions of uPA:PAI-1 and
uPA:PAI-2 with a related LDLR family member, LRP1. Interestingly, the interaction
between uPA:PAI-2YK complex and LRP1 displayed different kinetics to those observed for
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Table 3.3: Kinetic parameters of the interaction between PAI-2 forms used in this study and the endocytosis receptor VLDLR. Values
were determined using surface plasmon resonance. Binding data was fitted using BIAevaluation 4.0 software. The binding model chosen
represents that with the lowest χ2 value. (Values are the average ± SEM, n ≥ 3).

kd

KD

(M s )

-1

(s )
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-

-

-
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-

PAI-2K2
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-
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-

PAI-2KK

No binding

-
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-

-

PAI-2YK

1:1

6.77 × 104 (± 2.68 × 104)

1.99 × 10-3 (± 0.76 × 10-3)

37.3 (± 7.0)

0.97

PAI-2KYK

1:1

6.68 × 104 (± 2.91 × 104)

4.31 × 10-3 (± 2.22 × 10-3)

50.1 (± 10.2)

1.02

uPA:PAI-2

1:1

4.16 × 105 (± 1.80 × 105)

1.36 × 10-3 (± 0.23 × 10-3)

4.3 (± 0.56)

3.28

4.78 × 104 (± 0.38 × 104)

3.15 × 10-5 (± 1.07 × 10-5)

1.35 (± 0.41)

1.09 × 10 (± 0.51 × 10 )

5.69 × 10 (± 1.35 × 10 )

70.1 (± 24.9)

2.01 × 104 (± 0.22 × 104)

3.7 × 10-5 (± 2.11 × 10-5)

1.53 (± 0.43)

1.66 × 10 (± 0.33 × 10 )

3.35 × 10 (± 1.05 × 10 )

51.2 (± 12.9)

Analyte

Binding Model

PAI-2

uPA: PAI-2

YK

Heterogeneous analyte

ka
-1 -1

5

uPA: PAI-2

KYK

Heterogeneous analyte

5

5

5

-3

-3

-3

-3

χ2

7.6

4.3

100

uPA:PAI-1 (uPA:PAI-1 KD = 0.252 nM and 2.13 nM; uPA:PAI-2YK KD = 0.808 nM
and 57.8 nM) (Figure 3.10; Table 3.3). Since Skeldal et al. (2006) found that Lys88 of
PAI-1 (referred to as Lys90 in their study) is critical for the interaction between
uPA:PAI-1 and LRP1 (but not VLDLR), the PAI-2YKK mutant was generated by
replacing the asparagine at position 120 (corresponding to K88 of PAI-1) with lysine
(Figure 3.7A). uPA:PAI-2YKK complex displayed strikingly similar LRP1-binding
affinities to uPA:PAI-1, with the high and lower affinity interactions (KD = 0.128 nM
and 2.72 nM) not significantly different to those of uPA:PAI-1. However, it should be
noted that individual ka and kd values were significantly different (Figure 3.10C,D;
Table 3.3), indicating subtle differences in interaction mechanics that may reflect
variations in local surface potential and/or steric effects.
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Figure 3.9: Surface plasmon resonance analysis of the interaction between PAI-2
constructs and VLDLR. Surface plasmon resonance analysis of the dose dependant
interaction between uPA complexed PAI-2 mutants and VLDLR. The data presented
here is representative of at least three experiments with analyte concentrations from
100 to 6.25 nM.
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Binding Model

Heterogeneous analyte

1:1

Heterogeneous analyte

Heterogeneous analyte

Analyte

uPA:PAI-1

uPA:PAI-2

uPA:PAI-2YK

uPA:PAI-2YKK

(nM)

KD

57.8 (± 39.0)

1.97 × 105 (± 1.39 × 105)

1.10 × 10-2 (± 1.55 × 10-2)

2.72 (± 1.51)

3.68 × 10-5 (± 1.67 × 10-5) 0.128 (± 0.081)

-3

3.43 × 105 (± 1.34 × 105)

-3

8.06 × 10 (± 7.41 × 10 )

5

1.24 × 10 (± 0.44 × 10 )
5

1.9 × 10-5 (± 0.87 × 10-5) 0.808 (± 0.246)

1.38 × 105 (± 0.48 × 105)

1.02 (± 0.54)

(± 0.33 × 10 ) 2.13 (± 0.56 )
-3

6.71 × 10-4 (± 1.32 × 10-4)

-3

6.74 × 104 (± 4.53 × 104)

5

(s )

-1

kd

2.68 × 10-5 (± 0.84 × 10-5) 0.252 (± 0.087)

6.09 × 10 (± 1.56 × 10 ) 1.30 × 10
5

9.52 × 104 (± 2.89 × 104)

(M s )

-1 -1

ka
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7.32

3.35

3.41

8.31

χ2

Table 3.4: Kinetic parameters of the interaction between PAI forms used in this study and the endocytosis receptor LRP1. Values
were determined using surface plasmon resonance. Binding data was fitted using BIAevaluation 4.0 software. The binding model chosen
represents that with the lowest χ2 value. (Values are the average ± SEM, n ≥ 3).
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Figure 3.10: Surface plasmon resonance analysis of the interaction between uPA:PAI
complexes and LRP1. Surface plasmon resonance analysis of the dose dependant interaction
between LRP1 and uPA complexed PAI-2 mutants as indicated and uPA:PAI-1. The data
presented here is representative of at least three experiments with analyte concentrations from
100 to 6.25 nM.
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3.3.4 PAI-2 MUTANTS MAINTAIN GENERAL SECONDARY STRUCTURE AND
INHIBITORY ACTIVITY

To ensure that any observed changed in LDLR binding were a function of residue
replacement and not due to protein misfolding and exposure of alternative receptor binding
determinants, LDLR-binding PAI-2 mutants were tested for relative secondary structure
using far-UV circular dichroism spectroscopy. All PAI-2 species tested were found to have
similar ellipticity values to the control PAI-2 across the full range of wavelengths measured
(Figure 3.11). Additionally, PAI-2 mutants retained inhibitory activity indistinguishable from
control PAI-2, as assessed by the formation of SDS stable complexes with uPA (Figure
3.12A) and solution phase inhibitory assays (Figure 3.12B).
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Figure 3.11: PAI-2 forms maintained overall secondary structure. Far-UV circular
dichroism spectroscopy indicated that the relative secondary structure did not vary between
PAI-2, PAI-2YK, PAI-2KYK and PAI-2YKK. Each spectrum is the average of ten scans.
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Figure 3.12: PAI-2 forms maintained inhibitory activity. (A) LDLR-binding PAI-2
mutants were able to form SDS-stable complexes with uPA. PAI-2 mutants were incubated at
a 1:1 molar ratio with uPA for 30 min at 37°C and analysed by SDS-PAGE. (B) PAI-2
proteins showed similar solution phase uPA inhibitory activity (assessed as described in
Section 2.2.11.2). HMW-uPA was added at a concentration of 0.675 nM and fluorescence
emission measured at 37°C.
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3.4 DISCUSSION
Whilst numerous studies have utilised site directed mutagenesis of both PAI-1 and uPA to
characterise the LDLR binding of these proteins both alone and in complex, substantially less
is known about the interaction between uPA:PAI-2 and LDLRs, with the biological
importance of PAI-2 often underplayed in the literature. However, there is growing evidence
that PAI-2 is present in pericellular and extracellular environments and is clearly linked to
anti-tumourogenic activity suggesting that PAI-2 has an important role as a bona fide
inhibitor of uPA in vivo (Croucher et al. 2008).

As recently discussed by Dupont et al. (2009), understanding the receptor-ligand interaction
between uPA:PAI-1 and LDLRs is complicated by the increased affinity of the complex
compared to each moiety of the complex separately. This is also true for PAI-2 as, like PAI1, the uPA:PAI-2 complex has increased affinity for LDLRs compared to uPA alone
(Croucher et al. 2006; Croucher et al. 2007), despite no apparent interaction between the PAI2 moiety of the complex and the receptor. As such, it is reasonable to infer that this increase
in affinity is due to conformational changes in the protease. Whilst Dementiev et al. (2006)
showed that no major structural changes occur in porcine pancreatic elastase when in
complex with α1-proteinase inhibitor, there are major structural differences between uPA and
porcine pancreatic elastase and as such, the inferences that can be drawn between the
elastase:α1-proteinase inhibitor and uPA:PAI complexes is limited.

As previously reported, there are distinct differences in the interactions of uPA:PAI-2 and
uPA:PAI-1 with LDLRs (Croucher et al. 2006; Skeldal et al. 2006; Croucher et al. 2007). The
findings here further confirm this. The kinetic data for the interactions between uPA:PAI-1
and both VLDLR and LRP1 best fit a heterogeneous analyte model, whereby there are two
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competing binding sites in the complex, suggesting that the interaction between is dependant
on interactions in both the serpin and protease moieties of the complex. Interestingly,
reported affinity constants for uPA:PAI-1 with mutations in PAI-1 to reduce LRP1 and
VLRLR binding (Skeldal et al. 2006; Croucher et al. 2007) are similar to those of uPA:PAI-2
reported both here and previously (Croucher et al. 2007). In addition, the removal of these
basic residues in and around α-helix D of PAI-1 significantly reduced or eliminated the direct
binding of PAI-1 to LDLRs (Skeldal et al. 2006; Croucher et al. 2007).

As introduced previously, α-helix D of PAI-1 contains a proposed LDLR minimal binding
motif of two basic residues N-terminally flanked by hydrophobic residues and separated by
two to five residues (Jensen et al. 2006). This motif is not conserved in PAI-2 (Croucher et al.
2007; Croucher et al. 2008). This study demonstrates the robustness of the LDLR minimal
binding motif, as LDLR binding was introduced to PAI-2 via the mutation of PAI-2 residues
to corresponding residues in PAI-1 identified previously as important in the interaction of
PAI-1 and uPA:PAI-1 with LDLRs. As this motif is further validated, new, high affinity
LDLR ligands may be identified. Whilst the region in and around α-helix D of PAI-1 is
mostly positively charged (basic), the same region in PAI-2 is more neutral and surrounded
by multiple electronegative (acidic) regions (Croucher et al. 2007; Croucher et al. 2008).
Despite the generally accepted notion that LDLRs bind via interactions between acidic
residues in the receptor and basic regions in the ligand (Fisher et al. 2006), replacement of
D101 and S112 with lysine(s), PAI-2 still did not interact with VLDLR. However, VLDLR
binding could be introduced to PAI-2 through mutagenesis of S111, which corresponds to Y79
in PAI-1. Interestingly, despite uPA:PAI-2YK binding to VLDLR in an almost identical
manner to uPA:PAI-1 (reported affinity constants of 1.51 nM (Croucher et al. 2007) and 1.6
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Table 3.5: Summary of PAI-2 binding interactions with VLDR and LRP1.
KD (nM) (for uPA:PAI complexes)
uPA activity1/VLDLR
Protein
binding kinetics2
VLDLR
LRP1
3
4.34
1.02
PAI-2 ∆CD-loop
K1
Unchanged/Unchanged
ND
ND
PAI-2
K2
Unchanged/Unchanged
ND
ND
PAI-2
KK
Unchanged/Unchanged
ND
ND
PAI-2
YK
Unchanged/Similar to PAI-1
1.35
ND
PAI-2
KYK
Unchanged/Similar to PAI-1
1.53
0.808
PAI-2
YKK
Unchanged/ND
ND
0.128
PAI-2
PAI-1
1

-

1.514

0.252

2

& Compared to PAI-2 ∆CD-loop. Binding kinetics determined by SPR analysis of free PAI-2 (Section 3.3.3).
Section 2.3.4
5
Croucher et al. (2007).
ND: Not determined. As these constructs show no direct binding to VLDLR, the affinity of the uPA:PAI-2
construct complex for the receptor was not measured.
3

nM (Skeldal et al. 2006)) measured using surface plasmon resonance analysis), this was not
the case for LRP1. Skeldal et al. (2006) found that K88 (referred to as K90 due to differences
in residue numbering systems), whilst somewhat important in the interaction of PAI-1 with
VLDLR, was more critically implicated in the interaction of PAI-1 with LRP1 (Figure 3.13).
As such, an additional mutation was introduced in PAI-2, generating PAI-2YKK (N120
corresponds to K88 in PAI-1) which gave similar kinetics and mechanism of interaction with
LRP1 as uPA:PAI-1. This difference in the interaction surfaces highlights the distinct, whilst
overlapping, specificities of LDLRs (Strickland et al. 2002). Additionally, the binding of
uPA:PAI complexes to LRP1 is complicated by the involvement of both CTR (C-terminal
repeat) clusters II and IV (Strickland et al. 2002; Croucher 2006).

The mutations made to complement LDLR binding in PAI-2 were found to have no impact
on the general level of secondary structure or inhibitory activity of these proteins. Despite
significant differences in primary sequence, there are 51 core residues conserved in
approximately 70% of serpins (Irving et al. 2000). However, none of the mutations made here
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correspond to these residues. As no difference in inhibitory activity was detected between the
control PAI-2 and the PAI-2 mutants used in this study, any downstream functional
differences observed are not a function of uPA inhibitory activity, suggesting that the
differential extracellular functionalities in terms of protease clearance and degradation
ascribed to PAI-1 and PAI-2 lies primarily in differential interactions with LDLRs.

The results presented here provides evidence that the high affinity interaction between
uPA:PAI-1 and LDLRs is mediated by an avidity effect due to the combination of two
binding sites on the same ligand. Furthermore, as mutations can easily modify the LDLR
binding properties of PAI-1 and PAI-2 to act essentially like one another, it can be inferred
that upon inhibition, conformational changes occur in uPA which, in turn, leads to an
increase in affinity for LDLRs. Modification of the LDLR binding affinity/mechanism of
uPA:PAI complexes may be further implicated in the contrasting non-proteolytic activities of
PAI-1 and PAI-2, namely cell growth, adhesion and activation of pro-mitogenic cell
signalling pathways.
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Figure 3.13: The receptor binding surface of the uPA:PAI-1 complex showing the
difference in the importance of K90 (equivalent to K88 in this study due to differences
in the numbering system used) of PAI-1 in the interaction of uPA:PAI-1 with VLDLR
and LRP1 as determined by Skeldal et al. (2006). Alanine substitution of residues
coloured red led to a greater than 5-fold reduction in binding of the uPA:PAI-1
complex to the appropriate receptor, residues coloured pink led to a 1.5 to 5-fold
reduction. Alanine substitution of residues coloured blue led to a less than 1.5-fold
reduction in binding. Reproduced from Skeldal et al. (2006).
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CHAPTER 4
CELLULAR EFFECTS MEDIATED BY
COMPLEMENTATION OF THE LDLR
BINDING MOTIF IN PAI-2
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4.1 INTRODUCTION
PAI-1 (SerpinE1) and PAI-2 (SerpinB2) are both efficient inhibitors of the urokinasetype plasminogen activator (uPA), a key enzyme in the tissue remodelling process.
Combined tumour overexpression of uPA, its receptor (uPAR) and PAI-1 is strongly
correlated with poor patient prognosis (Foekens et al. 2000; Choong and Nadesapillai
2003; Duffy 2004) and metastatic potential (Duffy et al. 1999; Scherrer et al. 1999;
Schmitt et al. 2000; Look et al. 2002; Weigelt et al. 2005) and uPA/PAI-1 expression
has been recommended as an independent prognostic indicator in node-negative
breast cancer (Harris et al. 2007). On the contrary, tumour expression of PAI-2 is
correlated with increased relapse-free survival in breast cancer (and possibly other
cancer types) (Croucher et al. 2008). Further, the relationship between outcome and
high PAI-2 levels in node negative breast cancer is only statistically relevant if uPA
levels are also elevated (Bouchet et al. 1999; Foekens et al. 2000), suggesting that the
inhibitory relationship between uPA and PAI-2 mediates this functionality.

Binding of uPA to uPAR induces the activation of numerous cell-type specific
signalling pathways, such as MAPK/ERK, Jak/Stat, Src, FAK and Rac, thereby
affecting cell adhesion, migration, differentiation and apoptosis (D'Alessio and Blasi
2009). As uPAR is not a transmembrane protein, but is rather linked to the cell
surface by a glycosylphosphatidylinositol-anchor, uPA/uPAR signalling is mediated
by integrins and several other adaptor molecules, including members of the lowdensity lipoprotein receptor (LDLR) superfamily (Preissner et al. 2000; Resnati et al.
2002; Strickland and Ranganathan 2003; D'Alessio and Blasi 2009). Both PAI-1 and
PAI-2 efficiently inhibit uPA in solution and at the cell surface (Astedt et al. 1987;
Ellis et al. 1990; Al-Ejeh et al. 2004) through the formation of covalent, irreversible
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enzyme:substrate complexes. Following the formation of an inhibitory complex at the
cell surface, uPA:PAI complexes are rapidly cleared via LDLR mediated endocytosis
(Argraves et al. 1995; Al-Ejeh et al. 2004; Croucher et al. 2006; Croucher et al. 2007).
Inhibition of uPA by PAI-1 has previously been shown to modulate uPA/uPAR
signalling, resulting in sustained activation of the MAPK/ERK signalling pathway in
both MCF-7 and SGC7901 cells (Webb et al. 2001; Di et al. 2010) leading to
increased cell growth (Webb et al. 2001) and expression of MMP-2 and MMP-9 (Di
et al. 2010) in these cell lines, respectively. Webb et al. (2001) demonstrated that this
pro-mitogenic activity was dependent on the direct, high affinity interaction between
the PAI-1 moiety of the uPA:PAI-1 complex and the very low-density lipoprotein
receptor (VLDLR). Further, previous work has demonstrated that PAI-2 does not
initiate these signalling events following uPA inhibition and VLDLR mediated
endocytosis (Croucher et al. 2007) and PAI-2 (unlike PAI-1) does not bind directly to
LDLRs (Croucher et al. 2006; Croucher et al. 2007). Additionally, the interaction
between the uPA:PAI-2 complex and these LDLRs is markedly different to that of
uPA:PAI-1 in terms of both affinity and mechanism (Croucher et al. 2006; Skeldal et
al. 2006; Croucher et al. 2007). As detailed in Chapter 3, numerous studies have
identified several positively charged residues within (Lys69, Arg76, Lys80) and nearby
(Lys88, Arg118, Lys122) the α-helix D of PAI-1 that contribute to the high-affinity
binding of uPA:PAI-1 with LDLRs (see Figure 3.7) (Horn et al. 1998; Rodenburg et
al. 1998; Stefansson et al. 1998; Skeldal et al. 2006). In addition, the α-helix D of
PAI-1 contains a proposed LDLR minimal binding motif

(75-LRHLYK-80),

consisting of two basic residues (Arg76 and Lys80) separated by two to five residues
and N-terminally flanked by hydrophobic residues (Leu75 and Tyr79) (Jensen et al.
2006). Analysis by Croucher et al. (2007) suggested that the decreased affinity of
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uPA:PAI-2 is likely due to an incomplete LDLR binding motif within α-helix D of
PAI-2 (107-FRSLSS-112), in which the first hydrophobic/basic amino acid pair is
conserved, whilst the second pair is replaced by serine residues (Figure 3.7). Indeed,
previous studies using a mutant form of PAI-1 with an incomplete LDLR binding
motif (R76E) observed decreased LRP1 and VLDLR binding affinity and hence
functional outcomes (Stefansson et al. 1998; Webb et al. 2001; Croucher et al. 2007).
PAI-2 may inhibit and clear cell surface uPA (and hence proteolytic activity) without
influencing pro-mitogenic signalling pathways that are activated via PAI-1 and this
may account for the differential prognosis seen between these two serpins (Croucher
et al. 2007; Croucher et al. 2008).

Using the LDLR-binding PAI-2 mutants generated in Chapter 3 (see Table 3.2), the
results presented here show that introduction of LDLR binding to PAI-2 has a
profound impact on the functionality of PAI-2 in the clearance of uPA from the cell
surface and initiates sustained cell signalling events similar to PAI-1 resulting in
increased cell proliferation. These findings agree with the hypothesis of Croucher et
al. (2007) that LDLR binding may be the biochemical basis underlying the functional
disparity between PAI-1 and PAI-2 in cancer prognosis.
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4.2 MATERIALS AND METHODS
4.2.1 MATERIALS
Protease inhibitor cocktail, glutamine, transferrin, selenium, rabbit IgG and peroxidise
conjugated anti-rabbit IgG were from Sigma-Aldrich (St Louis, MO, USA). Purified
human receptor associated protein (RAP) were from Molecular Innovations (Novi,
MI, USA). Rabbit antibodies to ERK and phosphorylated ERK from Cell Signaling
Technology (Danvers, MA, USA). VLDLR polyclonal antibody from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Monoclonal antibodies to human LRP1
(3402), uPA (390) and uPAR (3936) were from American Diagnostica Inc. (Stamford,
CT, USA). Matched isotype control antibodies IgG2a and IgG1 were from Millipore
(Billerica, MA, USA). Goat anti-rabbit FITC- IgG and sheep antimouse FITC-IgG
were from BioRad (Hercules, CA, USA).

4.2.2 CELL LINES
The human breast adenocarcinoma (MCF-7), human prostate carcinoma (PC-3),
human fibrosarcoma (HT1080) and human cervical cancer carcinoma (HeLa) cell
lines were obtained from American Type Culture Collection distributed by Cryosite
(Sydney, Australia). All cell lines were routinely cultured as described in Section
2.2.9.

4.2.3 ANALYSIS OF CELL SURFACE ANTIGEN EXPRESSION BY FLOW
CYTOMETRY
Prior to analysis, cells were grown to ~ 80 % confluency over a period of at least 48 h.
Cells were detached using PBS with 5 mM EDTA, collected by centrifugation at 200
g for 5 min at 4°C and washed twice with ice cold binding buffer (Appendix I). The
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cells were resuspended at 1 × 106 cells.mL-1 in ice cold binding buffer containing
primary antibody or matched isotype control (5 µg.mL-1) and incubated on ice for 45
min. Cells were washed three times with ice cold binding buffer and incubated with
FITC-labelled secondary antibody (1:50 dilution) for 45 min on ice. After three
further washes with ice cold binding buffer, cells were analysed by flow cytometry,
with non-viable cells excluded from measurements by gating for positive propidum
idiode flourecence as described previously in Section 2.2.13

4.2.4 ANALYSIS OF UPAR SATURATION AT THE CELL SURFACE
The level of uPAR saturation in cell lines expressing significant levels of uPA was
analysed to determine if these cell lines were suitable for downstream characterisation
of uPA:PAI complexes. Cells, grown to ~ 80 % confluency were prepared as
described in section 4.2.2. Cells were resuspended in either binding buffer (Appendix
I), or Cell Acid Elution buffer (Appendix I) for 3 min at room temperature to remove
surface bound uPA. Cells were neutralised with 1/5 volumes of Cell Neutralisation
buffer (Appendix I) and immediately collected by centrifugation at 200 g for 5 min at
4°C and washed twice in ice cold binding buffer. Cells were incubated with 0, 5, 10,
25, 50, 75 or 100 nM Alexa488 labelled uPA for 30 min on ice. Cells were again
washed twice to remove unbound uPA and analysed by flow cytometry as described
above.

4.2.5 ENDOCYTOSIS ASSAY
Cell internalisation of Alexa488-labelled uPA alone or in complex with either PAI-1 or
PAI-2 forms was conducted in the absence or presence of the LDLR antagonist RAP
(to confirm the involvement of LDLRs in this process) essentially as described in
Section 2.2.13.
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4.2.6 ANALYSIS OF ERK ACTIVATION
Activation of ERK was analysed as described previously (Webb et al. 2001). Briefly,
MCF-7 cells were grown in 12 well plates to ~ 60% confluency and then serum
starved (in RPMI) for 12 h. Cells were then incubated with 10 nM uPA or uPA:PAI
complexes (in RPMI) for the time periods indicated. After washing twice in ice cold
RIPA buffer (Appendix I), wells were incubated for 5 min on ice in RIPA buffer,
collected and insoluble inclusions removed by centrigufation at 14,000 g for 5 min at
4ºC. Supernatants were electrophoresed on 12% SDS-PAGE gels under reducing
conditions, transferred to PVDF membranes and probed with antibodies that detect
phosphorylated and total ERK. Bound phosphorylated and total ERK were detected
using peroxidise conjugated anti-rabbit IgG secondary antibodies and visualised via
ECL.

4.2.7 CELL PROLIFERATION ASSAY
Cell proliferation was examined in real-time using the xCELLigence RTCA DP
System (Roche, Basel, Switzerland). The xCELLigence system allows continuous
quantitative monitoring of cellular behaviour including proliferation by measuring
electrical impedance. MCF-7 cells were seeded at 5000 cells per well into E-Plate 16
wells (cell number per well was previously optimised for this cell line, Appendix VII)
and cultured for 24 h. The media was replaced with 100 µL of serum free RPMI
containing 300 µg.mL-1 glutamine, 5 µg.mL-1 transferrin and 38 nM selenium in the
presence of 10 nM uPA, uPA:PAI complexes or media alone. Proliferation was
continuously monitored every 15 min over a time period of 72 h. Data analysis was
carried out using RTCA Software 1.2.1 supplied with the instrument.
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4.2.8 STATISTICAL ANALYSES
Statistical significance of treatment groups as compared to control groups was
determined using an unpaired Student’s t-test or one-way ANOVA with a Tukey posttest (GraphPad Prism V 5.1). p values < 0.05 were considered statistically significant.
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4.3 RESULTS
4.3.1 COMPONENTS OF THE PLASMINOGEN ACTIVATION SYSTEM ARE
DIFFERENTIALLY EXPRESSED ON CANCER CELL LINES
Prior to analysing the cellular functional consequences of complementing LDLR
binding in PAI-2, a panel of cancer cells lines were screened for expression of
receptors involved in the endocytosis of uPA:PAI complexes. As there are differences
in the determinants required to increase the affinity of uPA:PAI-2 for LRP1 and
VLDLR to a level similar to that of uPA:PAI-1 binding (Chapter 3), cell lines that
express either LRP1 or VLDLR and not both receptors were desirable to allow for
non-confounding characterisation. HT1080 cells have previously been shown to
express LRP1 (Webb et al. 2000; Degryse et al. 2004) and this was confirmed (Figure
4.1). These cells also expressed considerable amounts of uPA and uPAR, but did not
express any detectable VLDLR (Figure 4.1). The HeLa human cervical cancer cell
line was found to express uPA, uPAR and both LRP1 and VLDLR (Figure 4.2). As
such, HeLa cells were deemed unsuitable for further use due to the dual expression of
LRP1 and VLDLR. Al-Ejeh et al. (2004) and Croucher et al. (2006) previously
characterised the internalisation of PAI-2 on PC-3 cells, noting that these cells
expressed uPA, uPAR and LRP1. Analysis here confirms expression of these
antigens, and very low to negligible levels of VLDLR (Figure 4.3). The level of uPA
expressed by PC-3 cells was significantly less than that of HeLa cells (p < 0.05).
MCF-7 cells were used in Chapter 2 and previously (Webb et al. 2001; Croucher et al.
2007) to characterise uPA:PAI internalisation in a VLDLR dependent manner. As
anticipated, these cells expressed significant levels of uPAR, VLDLR, a small but
significant level of uPA and negligible levels of LRP1 (Figure 4.4).
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uPA

90.8 ± 6.7

uPAR

LRP1

52.1 ± 4.1

VLDLR

68.6 ± 9.6

2.1 ± 1.8

Figure 4.1: Cell surface antigen profiling of the HT1080 human fibrosarcoma
cell line. HT1080 cells were incubated with 5 µg.mL-1 primary antibody against either
uPA, uPAR, LRP or VLDLR, washed, incubated with a secondary FITC labelled
antibody and cell surface fluorescence on intact cells measured by flow cytometry.
Representative histograms are shown. Values in top right corner of each panel are the
difference between means of treatment and matched isotype control ± standard
deviations (n = 3).
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uPA

LRP1

11.0 ± 0.3

23.4 ± 3.6

uPAR

VLDLR

107.8 ± 13.1

6.1 ± 1.8

Figure 4.2: Cell surface antigen profiling of the HeLa human cervical carcinoma
cell line. HeLa cells were incubated with 5 µg.mL-1 primary antibody against either
uPA, uPAR, LRP or VLDLR, washed, incubated with a secondary FITC labelled
antibody and cell surface fluorescence on intact cells measured by flow cytometry.
Representative histograms are shown. Values in top right corner of each panel are the
difference between means of treatment and matched isotype control ± standard
deviations (n = 3).
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uPA

LRP1

7.2 ± 1.8

18.1 ± 2.9

uPAR

VLDLR

49.2 ± 4.5

1.2 ± 0.9

Figure 4.3: Cell surface antigen profiling of the PC-3 human prostate carcinoma
cell line. PC-3 cells were incubated with 5 µg.mL-1 primary antibody against either
uPA, uPAR, LRP or VLDLR, washed, incubated with a secondary FITC labelled
antibody and cell surface fluorescence on intact cells measured by flow cytometry.
Representative histograms are shown. Values in top right corner of each panel are the
difference between means of treatment and matched isotype control ± standard
deviations (n = 3).
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uPA

5.1 ± 2.8

uPAR

LRP1

2.9 ± 2.0

VLDLR

69.2 ± 8.3

52 ± 5.9

Figure 4.4: Cell surface antigen profiling of the MCF-7 human breast epithelial
carcinoma cell line. MCF-7 were incubated with 5 µg.mL-1 primary antibody against
either uPA, uPAR, LRP or VLDLR, washed, incubated with a secondary FITC
labelled antibody and cell surface fluorescence on intact cells measured by flow
cytometry. Representative histograms are shown. Values in top right corner of each
panel are the difference between means of treatment and matched isotype control ±
standard deviations (n = 3).
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4.3.2 CHARACTERISATION OF UPAR SATURATION
As the focus of this study was on the role of uPA:PAI complexes (as explained in
Section 4.1, the prognostic value of PAI-1 and PAI-2 in cancer is only significant
when

co-expressed

with

uPA),

internalisation

and

downstream

functional

consequences of introducing LDLR binding to PAI-2 was examined using preprepared uPA:PAI complexes. This allows for the assumption that any changes in cell
behaviour upon treatment with uPA:PAI complexes is due to differences in complex
affinity and not dependent on the differing inhibition rates of PAI-1 and PAI-2.
Additionally, whilst PAI-1 can moderate cell adhesion/deadhesion via interactions
with vitronectin, the uPA:PAI-1 complex does not readily bind vitronectin. This is
particularly relevant given that PAI-1 alone, but not PAI-2, interacts with vitronectin
and causes considerable cell detachment (Lobov and Ranson, Cancer Letters, in
press), which confounds endocytosis analysis. Further, cell lines used to examine the
link between LDLR affinity and uPA:PAI complex endocytosis were required to bind
exogenous uPA. The level of uPAR saturation of MCF-7 cells was not examined as
these cells have previously been demonstrated to internalise uPA:PAI complexes in an
LDLR-affinity dependent manner represent a suitable model (Section 2.3.4 and
Croucher et al. (2007)). HT1080 cells did not readily bind exogenous uPA (at
concentrations up to 100 nM) (Figure 4.5A). However, after acid stripping to elute
non-covalently associated surface proteins, HT1080 cells showed a dose dependent
uPA binding response, suggesting that under native conditions, uPAR is fully
saturated with uPA. As such, these cells do not present an ideal model to test uPA:PAI
internalisation as endogenous uPA would first need to be stripped from the cell
surface and this may cause other confounding effects. In contrast, PC-3 cells readily
bound exogenous uPA (Figure 4.5B). As such,
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Figure 4.5: uPA binding profile of cancer cell lines. Any endogenous uPAR bound
uPA was either removed by acid stripping (red lines) or not (black lines) from (A)
HT1080 and (B) PC-3 cells. Cells were then incubated with increasing concentrations
of Alexa488 labelled uPA. Excess uPA was removed via centrifugation and cell surface
associated fluorescence measured by flow cytometry. Values are means ± standard
deviation (n = 3).
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PC-3 cells were further used to characterise the internalisation of uPA:PAI complexes
in an LRP1 dependent system.

4.3.3 INTRODUCTION OF LDLR BINDING TO PAI-2 INCREASED UPARMEDIATED ENDOCYTOSIS
Croucher et al. (2007) previously demonstrated that the affinity of uPA or uPA:PAI
complex for LDLRs is a key determinant of its rate of endocytosis. This was
confirmed here with significantly more uPA:PAI-2 endocytosis (~4 fold, relative to
uPA alone) by MCF-7 cells in an LDLR antagonist (RAP)-sensitive manner over a 30
min time period (Figure 4.6A). Given that VLDLR is the only LDLR family member
expressed by MCF-7 cells (Figure 4.4), these data reflect the increased affinity of the
complex for VLDLR (see Table 3.3). Accordingly, the RAP-sensitive endocytosis of
uPA:PAI-2YK was increased to a level comparable with uPA:PAI-1 (~7 fold compared
to uPA alone) (Figure 4.6A). The uPA:PAI-2KYK complex had no significant impact
on endocytosis over and above that of uPA:PAI-2YK (Figure 4.6A). This result
reflected the similar VLDLR binding affinities of the PAI-2 mutants and PAI-1 (Table
3.2) and further confirms that completion of the LDLR binding motif is sufficient for
enhanced endocytosis via VLDLR.

Further investigation of endocytosis in an LRP1-dependent cell model (PC-3) showed
that the LDLR-binding motif alone was not sufficient for enhanced endocytosis via
LRP1. Although a small but significant increase in RAP-sensitive uPA:PAI-2
endocytosis was observed compared to uPA alone, no significant difference in
internalisation was observed between uPA:PAI-2 and uPA:PAI-2YK (Figure 4.6B).
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Figure 4.6: Increased LDLR affinity leads to increased internalisation of
uPA:PAI complexes by cancer cells. (A) MCF-7 cells or (B) PC-3 cells were
incubated in the presence or absence of RAP (200 nM) for 15 min at 37°C, prior to
analysis of endocytosis of Alexa488-labelled uPA. Values are means ± SEM (n = 3).
p < 0.005 compared to relative uPA treatment,
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uPA:PAI-2 treatment, n.s., no significant difference between these values.
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However, the level of uPA:PAI-2YKK and uPA:PAI-1 endocytosis were similarly
significantly enhanced ~2.5 fold compared with uPA alone; and ~1.6 fold compared
with uPA:PAI-2 (Figure 4.6B). These functional data are entirely consistent with the
biochemical data describing the differential interactions of uPA:PAI-2YK versus
uPA:PAI-2YKK with LRP1 (Table 3.3).

4.3.4 INTRODUCTION OF VLDLR BINDING TO PAI-2 INDUCES MITOGENIC
SIGNALLING IN MCF-7 CELLS
The sustained ERK phosphorylation that is initiated in breast cancer cells via a highaffinity LDLR minimal binding motif in PAI-1 is not observed in cells treated with
uPA:PAI-2 (Webb et al. 2001; Croucher et al. 2007). This was confirmed in this study
as the effect of uPA:PAI-2 being indistinguishable from uPA (Figure 4.7). The
importance of an intact LDLR minimal binding motif in facilitating this activity was
confirmed, as stimulation of MCF-7 cells with uPA:PAI-2YK initiated a significant
increase in both acute and sustained ERK phosphorylation (~3.5 fold within 3 min,
relative to uPA alone) (Figure 4.7B). The kinetics of ERK phosphorylation by
uPA:PAI-2 was similar to that observed for uPA:PAI-1.

A downstream functional outcome of sustained ERK phosphorylation in MCF-7 cells
stimulated by uPA:PAI-1 is induction of proliferation (Webb et al. 2001; Croucher et
al. 2007). Thus, the effect of uPA:PAI-2YK on MCF-7 cell proliferation was measured
in real time using the xCELLigence system (Figure 4.8A). Cell indices for uPA:PAI2YK and uPA:PAI-1 treatments were distinct from those observed for cells incubated
with uPA or uPA:PAI-2 (Figure 4.8A). Clear proliferative effects were evident over
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A

B

Figure 4.7: uPA:PAI-2YK induces promitogenic signalling pathways in MCF-7
cells similar to those of uPA:PAI-1. MCF-7 cells were cultured in serum-free
medium for 12 h and then exposed to 5 nM uPA, uPA:PAI-2, uPA:PAI-2YK or
uPA:PAI-1 for the indicated times. (A) Cell lysates were analysed for phosphorylated
and total ERK by western blotting. (B) Analysis of phoshorylated ERK levels using
densitometry was performed using the Quantitiy One software package (BioRad).
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Figure 4.8: uPA:PAI-2YK increased cell proliferation in MCF-7 cells similar to
uPA:PAI-1. (A) MCF-7 cells were cultivated in E-plates with RPMI/5% FCS for 24
h, before changing to serum free media containing 10 nM uPA, uPA:PAI-2, uPA:PAI2YK, uPA:PAI-1 or media only and cell proliferation monitored over 72 h in real-time
using an xCELLigence RTCA DP System. The electronic readout of cell sensor
impedance is displayed continuously as the Cell Index (CI) normalised to the
compound addition timepoint (indicated by vertical dotted line). The CI value at each
time point is defined as (Rn–Rb)/Rb, where Rn is the electrode impedance of wells with
cells and Rb is the background of wells with media alone. Curves are means of 4
replicates. (B) Bar graphs showing CI values 24, 48 and 72 h after addition of proteins
as percentage of media only treatment (time points are indicated on electronic readout
by arrows). Values are means ± SEM (n = 4). * p < 0.005 as determined by one-way
ANOVA with a Tukey post-test; n.s., no significant difference between treatments.
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an extended time-frame following addition of either uPA:PAI-2YK or uPA:PAI-1, as
reflected in an apparent logarithmic phase growth pattern (Figure 4.8A). This resulted
in a significant (~1.6 fold) increase in cell index relative to controls (media, uPA or
uPA:PAI-2) after 72 h (Figure 4.8B). Interestingly, cell indices following uPA:PAI2YK or uPA:PAI-1 treatment were initially slightly lower than those obtained
following treatment with uPA or uPA:PAI-2. The reason for this is unclear. No
difference was observed between cells incubated with uPA or uPA:PAI-2 (Figure
4.8B), with both reaching a plateau between 12 and 36 h post-treatment before
declining, suggesting a decrease in cell number.
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4.4 DISCUSSION
Together with the results presented in Chapter 3, this study provides the first
definitive molecular characterisation of the key structural elements that underlie the
differential interactions of PAI-1 and PAI-2 with LDLR receptors and how these are
associated with VLDLR-mediated downstream mitogenic signalling and cell
proliferation. By completing the LDLR binding motif in PAI-2 with residues
corresponding to those in PAI-1, PAI-2 displayed the pro-mitogenic functionalities of
PAI-1 when complexed with uPA. This suggests that the high LDLR binding affinity
and endocytosis rate of uPA:PAI-1 are part of the repertoire of effects attributable to
the pro-mitogenic function of PAI-1. This helps to explain why, despite a shared
serpin inhibitory function, high tumour levels of uPA and PAI-1 promote tumour
progression, whereas high levels of PAI-2 are protective (Croucher et al. 2008).

The existence of a strong correlation between the affinity of uPA:PAI complexes for
VLDLR and uPA:PAI endocytosis has been previously reported (Webb et al. 2001;
Croucher et al. 2007), suggesting that VLDLR affinity may be the rate limiting
determinant of uPA/uPAR clearance from the cell surface (Croucher et al. 2007). By
comparison to uPA:PAI-1, the uPA:PAI-2YK complex displayed similar binding
affinity to VLDLR (Section 3.3.3), and was internalised via this endocytosis receptor
to the same extent. The importance of the LDLR binding motif for high affinity
VLDLR binding and enhanced endocytosis was confirmed by the lack of a significant
impact of uPA:PAI-2KYK over and above that of uPA:PAI-2YK. As members of the
LDLR family have overlapping, yet distinct ligand specificities (Strickland et al.
2002), presence of the LDLR minimal binding motif alone was not sufficient to
introduce binding to LRP1 (as discussed in Chapter 3). Skeldal et al. (2006) reported
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that Lys88 was critically implicated in the interaction of PAI-1 with LRP1. In
agreement with this, modification of the residue Asn120 in PAI-2 (Asn120 corresponds
to Lys88 in PAI-1) was also required in conjunction with a complete LDLR minimal
binding motif (PAI-2YKK) to result in LRP1 binding kinetics and LRP1-mediated
endocytosis similar to that of uPA:PAI-1. This thus confirms that LDLR affinity is
the rate-limiting step of uPA:PAI endocytosis.

Webb et al. (2001) demonstrated that affinity of uPA:PAI-1 complexes for VLDLR
correlates to the sustained activation of ERK and increased cell proliferation in MCF7 cells. The VLDLR binding and downstream functional activity associated with PAI1 was also introduced into PAI-2 via completion of the LDLR minimal binding motif
within the α-helix D of PAI-2. As such, it is clear that VLDLR affinity is the key
property underlying the differences in sustained ERK activation and subsequent
effects on cell proliferation between uPA:PAI-1 and uPA:PAI-2. Given this, it was
unnecessary to investigate the impact of uPA:PAI-2KYK (or other PAI-2 mutants
generated with incomplete LDLR binding motifs) on mitogenic signalling as the
VLDLR binding affinity of this complex was indistinguishable from that of uPA:PAI2YK. Direct binding of PAI-1 to LRP1 has also been demonstrated to activate the
Jak/Stat pathway, leading to increased cell motility (Degryse et al. 2004). However, as
the prognostic data for PAI-1 is only significant in tumours also expressing uPA
(Foekens et al. 2000; Choong and Nadesapillai 2003; Duffy 2004; Ohba et al. 2005),
the impact of introducing PAI-2 LRP1 binding on the activation of this pathway was
also not investigated in this study. Furthermore, PAI-1 alone causes significant
cellular detachment (Lobov and Ranson, Cancer Letters in press) which complicates
analysis of endocytosis and cell signalling.
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Whilst high affinity binding of uPA:PAI complexes to VLDLR is clearly vital for the
induction of downstream ERK activation, it is important to note that high affinity
binding of any ligand to VLDLR will not necessarily induce the same response. This
is particularly highlighted by the high affinity interaction of RAP with VLDLR (KD =
0.7 nM) (Battey et al. 1994), which fails to induce downstream ERK activation and
cell proliferation (Webb et al. 2001; Croucher et al. 2007). Therefore, the rapid
formation of a multi-molecular complex consisting of VLDLR, a uPA:PAI complex,
uPAR and any associated integrins or co-receptors is likely implicated in the
induction of this signal, not merely the recognition of a high affinity ligand by
VLDLR

Other factors that would impact on the prognostic differences between overexpression of PAI-1 versus PAI-2 in cancer include the complex interplay of
interactions between uPA/uPAR, PAI-1 and other ligands and co-receptors, by which
PAI-1 modulates adhesion and migration. For example, PAI-1 competes with uPAR
and integrins for vitronectin binding which has further implications on cell
adhesion/deadhesion (Deng et al. 1996; Stefansson et al. 2003; Croucher et al. 2008).
PAI-2 does not bind vitronectin (Mikus et al. 1993). Furthermore, the vitronectin
binding site/s in PAI-1 are distinct from the LDLR minimal binding motif (Jensen et
al. 2002) and in agreement with this, the PAI-2 constructs used in this study did not
bind to vitronectin or impact on cell adhesion (Dr Sergei Lobov, personal
communication). This indicated that the proliferative effects seen with PAI-2YK with a
VLDLR-dependent cell line (Figure 4.8) were not due to modulation of cellular
adhesion/deadhesion, but solely reliant on the increased affinity for VLDLR.
Regardless, the absence of an LDLR minimal binding motif in the PAI-2 moiety of
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the uPA:PAI-2 complex indicates how, unlike PAI-1, extracellular PAI-2 would
inhibit and clear uPA from the cell surface, thereby preventing plasmin-mediated
ECM degradation, without impacting on cell proliferation.

In conclusion, this study clearly demonstrates that VLDLR affinity is the critical
determinant underlying the disparate roles of PAI-1 and PAI-2 in mitogenic signalling
and cell proliferation. Understanding the molecular basis of such physiological roles
increases the understanding of the association of these proteins with their respective
roles in predicting disease severity and outcome.
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CHAPTER 5
CONCLUSIONS AND FUTURE
DIRECTIONS
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The findings described in this thesis define the relationship between LDLR affinity
and the physiological roles of PAI-2 verses PAI-1. Generally, as PAI-1 is considered
the primary physiological mediator of thrombosis and fibrinolysis, PAI-1 has attracted
significantly more attention than PAI-2. Numerous studies have analysed the links
between the molecular biology and physiological function in PAI-1 (De Taeye et al.
2004) whilst irrefutable proof of PAI-2 internalisation and the mechanisms facilitating
this endocytosis, at least in vitro, have only been described more recently (Al-Ejeh et
al. 2004; Croucher et al. 2006; Croucher et al. 2007). Significant resistance exists in
the acceptance of the role of PAI-2 in inhibiting plasminogen activation due to the
majority of expressed PAI-2 being unsecreted. Whilst there has been no definitive
identification of uPA:PAI-2 complexes in vivo, a number of studies have detected
PAI-2 co-localised with a plasminogen activator(s) (Nakashima et al. 1996; Kinnby et
al. 1999) or in forms likely to have reacted with uPA or tPA (Kiso et al. 1991; Brown
et al. 1995). Furthermore, expression of PAI-2 in predicting outcomes in node
negative breast cancer is only significant when combined with increased uPA
expression (Foekens et al. 2000), suggesting that this relationship is due to the
inhibitory action of PAI-2. Future studies will aim to isolate intact PA:PAI-2
complexes to definitivly confirm the role of PAI-2 as a protease inhibitor in vivo. The
2H5 monoclonal antibody has been been demonstrated to recognise PAI-2 in the
‘relaxed’ conformation (Saunders et al. 1998) and could be used to isolate PAI-2 in
complex with plasminogen activators from PAI-2 rich tissues such as placenta,
gingivia or plasma from women in the third trimester of pregnancy. Further validation
of the role of PAI-2 in the inhibition of cancer progression should involve an animal
model. For example, SERPINB2-/- mice would be engineered to express human PAI-2
using the Cre/lox system (Sauer and Henderson 1988) with Cre under the control of a
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fibroblast specific promoter. These mice, which would express human PAI-2 only in
fibroblast cells, would then be utilised in xenograft models using human cancer cell
lines. The rationale behind the transfection of only fibroblast cells is that in doing so,
the ECM surrounding the xenograft would contain PAI-2, with the PAI-2 inhibiting
the intravasation, presenting a ‘barrier’ which the invading cells must pass. The
impact of enhancing the secretion of PAI-2 from the fibroblasts could also be assessed
with the use of a PAI-2 construct fused to the signal peptide of PAI-1 which has
previously been reported to increase the secretion efficiency of PAI-2 (von Heijne et
al. 1991).

Understanding the interactions between PAI-2 and members of the LDLR family is
important in providing rationale for the continued development of PAI-2 as a targeted
cancer therapeutic. The ability of PAI-2 to target, inhibit and clear uPA without
influencing additional biochemical pathways is an important characteristic in the
choice to develop PAI-2 rather than PAI-1 as a therapeutic. Previous work defining
the interactions of PAI-2 with VLDLR and LRP1 could not definitively rule out the
CD-loop blocking an interaction between the PAI-2 moiety of the uPA:PAI-2
complex and LDLRs (Croucher et al. 2006; Croucher et al. 2007) and as such, it could
not be assumed that removal of the CD-loop would not alter the binding of uPA:PAI2 to LDLRs and thereby activate promitogenic signalling pathways. The findings
described in this thesis showed that removal of the CD-loop had no impact on the uPA
targeting function of PAI-2, nor does the CD-loop block an LDLR binding site in
PAI-2. As removal of the CD-loop enabled easier purification from a prokaryotic
system, PAI-2 ∆CD-loop is currently being utilised as the starting material to further
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the development of PAI-2 as a targeted cancer therapeutic (Vine et al. 2010 and Dr
Kara Perrow, University of Wollongong, manuscript submitted).

The strong prognostic value of tumour expression of uPA and PAI-1 in predicting
poor patient outcome is well established and is gaining traction as a diagnostic clinical
tool in node negative breast cancer. In contrast, there is a growing body of evidence
linking tumour expression of PAI-2 and favourable patient outcome. The biochemical
basis underlying this disparate role in disease outcome is poorly understood and
represents a fundamental shortfall in basic tumour pathobiology. This thesis directly
addresses this shortfall and provides a definitive mechanistic basis for the apparently
paradoxical relationship of PAI-1 and PAI-2 with disease outcome.

Previous work demonstrated clear differences in the interactions of PAI-2 and PAI-1
with LDLR endocytosis receptors (Croucher et al. 2006; Croucher et al. 2007). By
introducing the LDLR minimal binding motif in PAI-2, the findings presented here
demonstrate that these biochemical differences define the disparate cellular functions
of PAI-1 and PAI-2 in cancer. The sustained activation of ERK initiated in MCF-7
and SGC7901 cells by uPA:PAI-1 is clearly mediated via the high affinity interaction
between the complex and VLDLR. However, the precise mechanism by which this
occurs remains undefined. Strickland et al. (2002) outlined three possible, nonmutually exclusive mechanisms by which uPA:PAI-1 may initiate this signalling
(Figure 5.1). Transient phosporylation of ERK due to the binding of uPA to uPAR
occurs via interactions of the uPA:uPAR complex with integrins (Ossowski and
Aguirre-Ghiso 2000) (Figure 5.1A). All of the proposed mechanisms by which
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Figure 5.1: Proposed models by which uPA:PAI complexes mediate ERK activation via
VLDLR-mediated endocytosis. (A) The binding of uPA to uPAR induces a transient
phosphorylation of ERK which is mediated via adapter proteins such as integrins. Strickland
et al. (2002) proposed three models (B-D) by which uPA:PAI-1 may sustain ERK
phosphorylation. (B) After internalisation of the uPAR:uPA:PAI-1:VLDLR complex, uPAR
is recycled to the cell surface where it can potentiate further cell signalling resulting in a
sustained ERK phosphorylation that is the sum of many transient responses. (C) Subsequent
to internalisation, the complex is delivered to endosomes where pH changes result in
structural changes in uPAR which activates signalling proteins associated with uPAR and
thereby sustaining activation of ERK. (D) In the final model, the high affinity of the
uPA:PAI-1 complex results in the colocalisation of integrins and VLDLR resulting in
bridging of proteins associated with the intracellular domains of integrins and signalling
motifs in VLDLR. This thesis further characterises the internalisation of uPA:PAI-2, building
upon previous studies (Al-Ejeh et al. 2004; Croucher et al. 2006; Croucher et al. 2007) and
shows that the differential mechanisms by which uPA:PAI-1 and uPA:PAI-2 differentially
modulate ERK activity in MCF-7 cells upon complex internalisation is due to differences in
the affinity of the complex for the receptor. (E) Internalisation of uPA:PAI-2 results in uPAR
recycling (Al-Ejeh et al. 2004), but only transient phosphorylation of ERK. (F) Like PAI-1,
upon internalisation the uPAR:uPA:PAI-2 complex is delivered to endosomes. As such, it
appears unlikely that the difference in ERK phosphorylation mediated by uPA:PAI-1 and
uPA:PAI-2 is due to signalling through uPAR associated changes that occur in the endosome.
(G) The lower affinity of the uPA:PAI-2 complex for VLDLR is not sufficient to bridge the
intracellular domains of VLDLR and integrins/uPAR coreceptors and as such, the proteins
associated with these intracellular domains are not able to sustain ERK phosphorylation. (H)
Introducing VLDLR binding to PAI-2 in uPA:PAI-2YK results in sustained phosphorylation
of ERK similar to uPA:PAI-1 with this likely occurring via the increased receptor affinity
allowing for interactions between the cytoplasmic domains of integrins and VLDLR or by
altering the uPAR recycling profile. A-D adapted from Strickland et al. (2002).
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uPA:PAI-1 require interplay between the uPA:uPAR:integrin complex and VLDLR
(Figure 5.1B-D), as high affinity binding to VLDLR is not, in itself, able to induce
sustained ERK activation – as evidenced by the lack of signal transduction induced
upon treatment of cells with RAP (KD = 0.7 nM). Additionally, the general colocalisation of VLDLR and integrins mediated by uPA:PAI-2 does not sustain
phosphorylation of ERK (Figure 5.1E-G), suggesting that there may be some
threshold in the affinity of the integrin:uPAR:uPA:PAI complex for VLDLR at which
point ERK phosphorylation is sustained. If the sustained ERK phosphorylation
observed in cells treated with uPA:PAI-1 was solely due to receptor recycling of
uPAR (Figure 5.1B) a similar signalling response would be expected in cells treated
with uPA:PAI-2, rather than just a transient phosphorylation of ERK (Figure 5.1E).
Furthermore, as both uPA:PAI-1 and uPA:PAI-2 mediated endocytosis of the
integrin:uPAR:uPA:PAI complex results in delivery of the complex to endosomes
(Figure 5.1C,F), both uPA:PAI-1 and uPA:PAI-2 would be expected to sustain ERK
phosphorylation if this was mediated via structural changes in uPAR initiated by a
change in pH. As such, it appears most likely that it is the bridging of the intracellular
domains of integrins and VLDLR facilitated by uPA:PAI-1 that results in sustained
phosphorylation of ERK (Figure 5.1D). The affinity of uPA:PAI-2 for VLDLR is
insufficient to bridge the intracellular domains of integrins and VLDLR and results
only in the transient activation mediated by the integrin:uPAR interaction (Figure
5.1G). The results presented in this thesis lend weight to this hypothesis as increasing
the affinity of PAI-2 for VLDLR (in PAI-2YK) to a level indistinguishable from that of
PAI-1 led to sustained ERK phosphorylation in MFC-7 cells (Figure 5.1H). As the
rate of co-localisation of uPAR and VLDLR following ligand stimulation may
underpin the activation of signalling events, the kinetics of uPAR and VLDLR co-
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localisation could be measured in real time following ligand stimulation via
bimolecular fluorescence complementation (Kerppola 2006). Identification of the
protein/s that associate with the intracellular domain of VLDLR and mediate
sustained ERK phosphorylation could also be analysed by combining bimolecular
fluorescence complementation with a high through-put screen using a human
ORFeome set. Previous studies have shown that reelin, which is involved in brain
development and neuroplasticity, contains two LDLR binding sites, is able to initiate
cell signalling events via clustering of VLDLR and Dab-1, a tyrosine kinase
associated with the interacellular domain of VLDLR but expressed only in neural
cells (Strasser et al. 2004). Whilst uPA:PAI-1 and uPA:PAI-2YK do contain two
independent binding sites for VLDLR, the low affinity interaction (KD values of 84.8
nM and 70.1 nM for uPA:PAI-1 and uPA:PAI-2YK) is less than that of uPA alone (KD
31.2 nM) and would likely not result in clustering of VLDLR.

A recent study by Di et al. (2010) found that treatment of SGC7901 cells with
uPA:PAI-1 led to an increased ratio of type II VLDLR to type I VLDLR. These forms
of VLDLR differ in the presence (type I) or absence (type II) of the O-linked sugar
domain (Iijima et al. 1998) with type I VLDLR primarily found in heart and skeletal
muscle whilst type II VLDLR is predominant in non-muscle tissue. Previous studies
have found that the ratio of type II to type I VLDLR in breast cancer,
gastroinintestinal adenocarcinoma and hepatocellular carcinoma tissues and cell lines
in significantly higher compared to control tissues or cells (Chen et al. 2005; He et al.
2010; Luo et al. 2010). Luo et al. (2010) found that silencing expression of type II
VLDLR in hepatocellular carcinoma cell lines decreased cell proliferation suggesting
perhaps the expression of type II VLDLR is not merely an indicator of cell
proliferation but facilitates proliferation by an as yet identified mechanism. The
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impact of incubating cells with uPA or uPA:PAI-2 on the expression pattern of
VLDLR has not been investigated. Upregulation of VLDLR expression via the ERK
signalling pathway in cells treated with VLDL and β-VLDL has been reported (Liu et
al. 2009); the increased expression of type II VLDLR could be a function of the
sustained ERK activation mediated by uPA:PAI-1.

The results of this thesis further the understanding of the relationship between the
biochemical properties and cellular function of PAI-2. Whilst both PAI-1 and PAI-2
efficiently inhibit and clear uPA from the cell surface, the high affinity interaction
between uPA:PAI-1 and VLDLR mediates promitogenic signalling effects, resulting
in increased metastatic potential (Figure 5.2). The lack of an LDLR minimal binding
motif in PAI-2 lowers the affinity of uPA:PAI-2 for VLDLR to a level below that
required

to

initiate

promitogenic

signalling.

Furthermore,

differences

in

adhesion/deadhesion effects further underlie the disparate roles of PAI-1 and PAI-2 in
cancer pathobiology. The relationships between these biochemical function and
physiological roles provides rationale for the use of PAI-1 and PAI-2 as markers of
disease progression and the continued development of PAI-2 as a targeted cancer
therapeutic. More generally, these findings also further validate the importance of the
LDLR minimal binding motif in endocytosis and downstream function.
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Figure 5.2: Physiological actions of PAI-1 and PAI-2 upon inhibition and
clearance of uPA. PAI-1 is able to promote metastasis via the activation of
promitogenic signalling pathways that are dependent on the high affinity uPA:PAI1:VLDLR interaction. Additionally, PAI-1 can influence cell adhesion/deadhesion via
completion for vitronectin. Whilst PAI-2 also rapidly clears uPA from the cell
surface, the uPA:PAI-2 complex lacks sufficient affinity for VLDLR to activate
promitogenic signalling and PAI-2 does not compete for vitronectin (Lobov and
Ranson, Cancer Letters, in press) defining the protective role of PAI-2 in cancer.
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Appendix I: Buffers and solutions
TAE buffer, pH 8
40 mM Tris
1 mM EDTA
0.142% (v/v) glacial acetic acid
1% TAE agarose gel
1% (w/v) agarose
40 mM Tris
1 mM EDTA
0.142% (v/v) glacial acetic acid
Phosphate buffered saline (PBS), pH 7.4
12 mM Na2HPO4
2 mM NaH2PO4
2.7 mM KCl
137 mM NaCl
BIAcore running buffer, pH 7.4
10 mM HEPES
140 mM NaCl
1 mM CaCl2
0.05% (v/v) Tween-20
Binding buffer, pH 7.4
0.98% (w/v) Hanks balanced salts
20 mM HEPES
1 mM CaCl2
1 mM MgCl2
0.1% (w/v) BSA
RIPA buffer, pH 7.4
50 mM HEPES
100 mM NaCl
1% (v/v) Nonidet P-40
2 mM EDTA
0.4 mg.mL-1 sodium orthovanadate
5 mg.mL-1 dithiothreitol
1 mL.L-1 protease inhibitor cocktail
BIAcore running buffer, pH 7.4
10 mM HEPES
150 mM NaCl
1 mM CaCl2
0.005% Tween-20
Cell Acid Elution buffer, pH 3.0
50 mM glycine
0.15 M NaCl
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Cell Neutralising buffer, pH 7.5
0.5 M HEPES
0.1 M NaCl
uPA activity assay reaction buffer, pH 7.6
20 mM HEPES
100 mM NaCl
0.5 mM EDTA
0.01% (v/v) Tween 20
Bacterial Culture Media
Lauria-Bertani (LB) broth
1% (w/v) tryptone
0.5% (w/v) yeast extract
170 mM NaCl
LB agar
1% (w/v) tryptone
0.5% (w/v) yeast extract
170 mM NaCl
1.5% (w/v) agar
Z-broth
1% (w/v) tryptone
0.5% (w/v) yeast extract
170 mM NaCl
5.5 mM glucose
4.5 mM CaCl2
YENB medium
0.75% (w/v) yeast extract
0.8% (w/v) tryptone
SOC medium
0.5% (w/v) yeast extract
2% (w/v) tryptone
10 mM NaCl
2.5 mM KCl
10 mM MgCl2
10 mM MgSO4
20 mM glucose
Wizard Plus SV Minipreps DNA Purification
Cell resuspension solution
50 mM Tris-HCl (pH 7.5)
10 mM EDTA
100 µg.mL-1 RNase A
Cell lysis solution
0.2 M NaOH
1% (w/v) SDS
184

Neutralisation solution
4.09 M guanidine hydrochloride
0.759 M potassium acetate
2.12 M glacial acetic acid
Column wash solution
60 mM potassium acetate
8.3 mM Tris-HCl (pH 7.5)
0.04 mM EDTA (pH 8.0)
60% (v/v) ethanol
SDS-PAGE
5 × non-reducing sample buffer
225 mM Tris-Cl
20% (v/v) glycerol
2 mM SDS
0.02% (w/v) bromophenol blue
5 × reducing sample buffer
225 mM Tris-Cl
20% (v/v) glycerol
2 mM SDS
0.02% (w/v) bromophenol blue
250 mM DTT
4% stacking acrylamide gel
9% (v/v) 37.5:1 Bis:acrylamide
24.3% (v/v) 0.5 M tris-HCl (pH 6.8)
0.097% (w/v) SDS
0.0485% (w/v) APS
0.485% (v/v) TEMED
12% resolving acrylamide gel
30% (v/v) 37.5:1 Bis:acrylamide
24.3% (v/v) 1.5 M tris-HCl (pH 8.8)
0.097% (w/v) SDS
0.0485% (w/v) APS
0.485% (v/v) TEMED
SDS-PAGE running buffer
25 mM Tris
120 mM glycine
2 mM SDS
pH 8.3
Coomassie staining solution
0.2% (w/v) coomassie blue R-250
40% (v/v) methanol
10% (v/v) glacial acetic acid

185

Rapid destain
40% (v/v) methanol
10% (v/v) glacial acetic acid

Final destain
10% (v/v) glacial acetic acid
4% (v/v) glycerol
Western blotting
Transfer buffer
25 mM Tris base
200 mM glycine
20% (v/v) methanol
TBS
50 mM Tris base
150 mM NaCl
TBST
50 mM Tris base
150 mM NaCl
0.05% (v/v) Tween 20
Immobilised metal affinity chromatography
Loading buffer, pH 7.0
50 mM sodium phosphate
0.3 M NaCl
5 mM imidazole
Washing buffer, pH 7.0
50 mM sodium phosphate,
0.3 mM NaCl,
10 mM imidazole
Elution buffer, pH 7.0
50 mM sodium phosphate
0.3 mM NaCl
150 mM imidazole
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Appendix II: Plasmid maps
pET15b/PAI-2 wild-type and pET15b/PAI-2 ∆CD-loop

Source: Novagen
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BamHI - 319 - G'GATC_C

ApR
PAI-2 wild-type (1808 bp)

pET15b/PAI-2 wild-type
7556 bp
XhoI - 2172 - C'TCGA_G

lacI

ApR

PAI-2 ∆CD-loop (1754 bp)

∆

lacI
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pQE9/PAI-2 wildtype and pQE9/PAI-2 ∆CD-loop

Source: Qiagen
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ApR

PAI-2 wild-type (1251 bp)

Col E1

ApR

PAI-2 ∆CD-loop (1152 bp)

∆

Col E1

190

TAGzyme pQE1/PAI-2 ∆CD-loop

Source: Qiagen

191

PvuII site lost

PAI-2 ∆CD-loop (1152 bp)

ApR

∆

Col E1
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Appendix III: Construction of protein standard curve
Using molecular weight markers, standard curves were constructed to allow for the
estimation of the size of proteins observed on SDS-PAGE gels. The standard curve
constructed using the markers in Figure 3.5 is shown below (Table A.1 and Figure
A.1).

Table A.1: Mobility of protein markers used for construction of a standard curve
(Figure A.1). The data here is based on the markers present on the gel in Figure 3.5
Size (kDa)

log10size

Mobility (mm)

150

2.176091

11

100

2

19

75

1.875061

26

50

1.69897

32

37

1.568202

44

25

1.39794

56

20

1.30103

70

15

1.176091

84

2.5

log10MW (kDa)

y = -0.0135x + 2.2249
2.0

R2 = 0.9581

1.5
1.0
0.5
0.0
0

20

40

60

80

100

Mobility (mm)

Figure A.1: Standard curve constructed using protein markers from the SDSPAGE gel in Figure 3.5
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Appendix IV: Construction of DNA standard curve
Using molecular weight markers, standard curves were constructed to allow for the
estimation of the size of DNA bands observed on agarose gels. The standard curve
constructed based on the markers in Figure 3.3 is shown below (Table A.2 and Figure
A.2).

Table A.2: Mobility of EcoRI + HindIIII λ DNA markers used for construction of
a standard curve (Figure A.2). The data here is based on the markers present on the
gel in Figure 3.3
Size (bp)

log10size

Mobility

5148

0.711639

31

4268

0.630224

34

2027

0.306854

50

1904

0.279667

52

1584

0.199755

56

1375

0.138303

59

947

-0.02365

68

831

-0.0804

74

564

-0.24872

81

4.0

log10MW (kDa)

y = -0.0188x + 4.2272
R2 = 0.9982

3.5

3.0

2.5
0

20

40

60

80

100

Mobility (mm)
Figure A.2: Standard curve constructed using EcoRI + HinIII λ DNA markers
from the gel in Figure 3.3
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Appendix V: Sequencing of PAI-2 mutants
To ensure successful mutagenesis of PAI-2 cDNA to generate the intended PAI-2
mutants, the full cDNA of all inserts generated was sequenced. The α-helix D and
adjacent area of PAI-2 mutants is shown in Figure A.3.

PAI-2
PAI-2K1
PAI-2K2
PAI-2KK
PAI-2YK
PAI-2KYK
PAI-2YKK

360
295
....|....|....|....|....|....|....|....|....|....|....|....|....|.
GCTGCAGATAAAATCCATTCATCCTTCCGCTCTCTCAGCTCTGCAATCAATGCATCCACAGGGAAT
A A D K I H S S F R S L S S A I N A S T G N
......A.G.........................................................
A A K K I H S S F R S L S S A I N A S T G N
.......................................AAG........................
A A D K I H S S F R S L S K A I N A S T G N
......A.G..............................AAG........................
A A K K I H S S F R S L S K A I N A S T G N
....................................TATAAG........................
A A D K I H S S F R S L Y K A I N A S T G N
......A.G...........................TATAAG........................
A A K K I H S S F R S L Y K A I N A S T G N
....................................TATAAG.......................G
A A D K I H S S F R S L Y K A I N A S T G K
99
120

Figure A.3: Alignment of mutagenised regions of PAI-2 α-helix D and adjacent
residues used in this study. The full cDNAs of all mutants were sequenced to ensure
that only the desired mutations were present. Region underlined denotes complete
LDLR minimal binding motif.
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Appendix VI: Preparation of BIAcore analysis surface
In order to analyse the kinetics of the interactions between proteins used in this study,
VLDLR or LRP1 were immobilised to BIAcore CM5 chips. The example shown here
is for a VLDLR chip. The chip was activated with a 1:1 mixture of 0.2 M N-ethyl-N’(3-dimethylaminopropyl)carbodi-imide and 0.05 M N-hydroxysuccimide. For kinetic
analysis a blank cell (Figure A.4A) and a VLDLR cell (Figure A.4B) were created.
VLDLR was coated onto the chip at 40 µg/mL in 10 mM sodium acetate (pH 3) for 7
min at 5 µg/min. Un-occupied binding sites on both cells were blocked using 1 M
ethanolamine, pH 8.5. Chips containing LRP1 were generated in a smiliar manner.

A

Response (RU)

30000

Ethanolamine blocking

20000

NHS Activation

10000

0
0

500

1000

1500

Time (s)

B

40000

Response (RU)

Ethanolamine blocking

30000
NHS Activation

20000
VLDLR test
binding

10000

VLDLR binding

0
0

500

1000

1500

2000

2500

Time (s)
Figure A.4: Construction of VLDLR chip for use in surface plasmon resonance. A blank
flow cell to serve as a control (A) and a flow cell containing immobilised VLDLR (B) were
generated for kinetic analysis.
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Apendix VII: Optimsation of cell seeding density using the
xCELLigenge system

Cells/well
Relative Cell Index (CI)

8

5000
2500
1250
625
312
156
78

6
4
2
0
0

10

20

30

40

Time (h)

Figure A.5: Optimisation of initial seeding cell density for examination of
proliferative effects in MCF-7 cells. MCF-7 cells were seeded in E-plates at 5000,
2500, 1250, 625, 312, 156 or 78 cells per well and cultivated with RPMI/5% FCS
over a 48 h period. Cell proliferation was monitored in real-time using an
xCELLigence RTCA DP System. The electronic readout of cell sensor impedance is
displayed continuously as the Cell Index (CI) normalised to the compound addition
timepoint (indicated by vertical dotted line). The CI value at each time point is
defined as (Rn–Rb)/Rb, where Rn is the electrode impedance of wells with cells and Rb
is the background of wells with media alone. Curves are means of 4 replicates. Cell
seeding at 5000 cells/well gave optimal logarithmic growth curves over an extended
time frame and was chosen for further experiments.
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Appendix VIII: Publications
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